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Abstract 
Heart failure (HF) is a complex clinical syndrome associated with significant mortality and 
morbidity, which leads to a significant burden for patients and healthcare systems1,2.There is a 
well-established association between diabetes and HF that is partly but not entirely linked to 
coronary heart disease and hypertension. The Framingham Study firmly established the 
epidemiologic link between diabetes and HF3, 4. This study showed the risk of HF was increased 
2.4-fold in men and 5-fold in women5, 6, and 12% diabetes already have established HF7. The 
frequency of HF in diabetic patients is even higher among elderly adults with a 3.3% annual 
incidence rate7. 
HF is usually a progressive condition. In recognition of the importance of this concept, 
American College of Cardiology (ACC) and the American Heart Association (AHA) have 
identified four stages of HF8. Stage A HF (SAHF) comprises patients with any of the HF risk 
factors (diabetes, hypertension, coronary artery disease, metabolic syndrome and obesity) 
without evidence of left ventricular (LV) remodelling or low ejection fraction (EF). LV 
hypertrophy and reduced LVEF is associated with even greater risk of incident HF, hence, 
asymptomatic patients with these structural changes are categorized as having stage B HF 
(SBHF). Stage C and Stage D HF is clinical symptomatic HF while stage D is the end stage of 
HF. Patients may only move forward through the stages and not regress. The AHA and ACC 
recommend that an angiotensin converting enzyme inhibitor (ACEi) or angiotensin II receptor 
blocker (ARB) and a beta-blocker (BB) should be prescribed in the presence of Stage B HF 
(SBHF), to reduce the risk of developing symptomatic HF9. Two considerations are important. 
First, the recommendation is based on the assumption that patients with non-ischaemic HF 
respond in the same way as the evidence involving patients with ischemic heart disease.  
Second, a large number of patients are classifiable as Stage B HF, but currently unrecognised. 
X 
If there is a benefit in HF prevention, screening programs may need to be implemented to detect 
these individuals, but the optimal tools for doing so are unclear. The most commonly used 
measure of systolic function in clinical practice, LVEF, is not a robust index of myocardial or 
chamber contractility for this purpose because of its load dependence and sensitivity to 
chamber size. A more robust echo marker is desired. Global longitudinal strain (GLS) by 
speckle tracking imaging is potentially a useful marker as it measures longitudinal function 
being an early marker of disease and conveys more detailed information about LV systolic 
function than EF can provide. However, the usefulness of GLS in clinical decision-making still 
needs to be tested. 
T2DM is an important HF risk factor, and provides a readily-recognised group for screening 
for SBHF. This thesis investigates the clinical role and implication of early detection of HF by 
echocardiography in elderly asymptomatic patients with T2DM.The work in this thesis is 
divided into four parts: 
The first part (chapter 2) sought to improve the assessment of HF risk in patients with T2DM 
– a step that would be critical for effective HF screening. A systematic literature search and
meta-analysis was performed to determine the effect size of each risk factor for incident HF in 
T2DM. Among elderly patients with T2DM, five common clinical variables are associated with 
significantly increased risk of incident HF and T2DM patients with these risks represent a 
target group for HF screening. 
The next part (chapter 4-8), pertains to the Tasmanian Study of Echocardiographic detection 
of Left ventricular dysfunction (Tas-ELF study), which sought to determine the role of early 
detection of HF by GLS in patients with T2DM in the Tasmanian community. Several studies 
were carried out to understand this. First, we assessed the association between insulin resistance 
(IR) and impaired exercise capacity to better understand the cause of exercise intolerance in 
X 
T2DM, which is associated with LV dysfunction and adverse cardiac outcome including HF. 
In addition, this study supports the contribution of diabetic myocardial disease that contributes 
to the development of HF in diabetes10. Second, longitudinal community studies were carried 
out to clarify the rate of progression through asymptomatic stage A to stage B HF in both 
diabetes and non-diabetes, in order to addresses the incidence and predictors of HF and all-
cause mortality in this cohort, and define strategies for prevention of HF progression in T2DM. 
The result suggested the predictors of prognosis in SAHF patients due to T2DM and other 
causes of SAHF were different. SAHF due to T2DM had worse subclinical LV function, 
functional capacity and adverse outcome than other causes of SAHF. Impaired GLS was 
independently associated with prognosis in T2DM-SAHF, whereas not for other-SAHF 
patients. This study emphasised that not all types of SAHF are the same, and better targeting 
of interventions at the most vulnerable SAHF group – those with T2DM – seems appropriate.  
Third, we evaluated different echocardiographic markers including increased LV mass index, 
left atrial enlargement, LV diastolic dysfunction and impaired GLS as potential 
echocardiographic features of stage B HF in T2DM.  The result suggested that GLS would be 
the optimal echocardiographic feature of stage B HF in T2DM for community screening. 
Fourth, the features associated with incident HF risk in T2DM are incompletely understood. In 
addition to myocardial disease, a number of other factors including mental factors are likely to 
influence the process. Therefore, we explored the association of depression and incident HF in 
elderly T2DM without any baseline cardiovascular symptoms. The result suggested that 
depression is prevalent in asymptomatic elderly patients with T2DM, and its role as an 
independent and incremental association with incident HF is an important confounder to the 
effect of myocardial disease. Finally, we observed the evolution of longitudinal changes of 
GLS among elderly T2DM patients, as little is known about the natural history of GLS over 
time. During our 2-year observation, the change of GLS in asymptomatic T2DM with 
X 
preserved EF was only mild, but mental status had an independent association with worsening 
GLS. 
The last part (chapter 9) was a study that used a Markov model to assess the cost-effectiveness 
among different strategies for HF prevention from a healthcare payer perspective. The three 
strategies were elderly asymptomatic patients with T2DM receiving; 1) usual care; 2) primary 
prevention without screening; 3) screening of LVD and GLS guided prevention.  The results 
showed that based on this Markov model, screening for asymptomatic LV dysfunction 
(evidenced by abnormal GLS) in elderly patients with T2DM appears cost-saving. These 
results could be used to inform clinical trials aimed at the early detection and treatment of LV 
dysfunction, with the intent of preventing the development of HF in T2DM. 
Conclusions. The results of the studies contained within this thesis suggest that subgroups of 
patients with diabetes are at the highest risk, and suitable for screening. Detection of LV 
dysfunction by strain imaging can predict the development of HF and all-cause of mortality 
in elderly asymptomatic patients with T2DM. Preventive treatment guided by GLS for HF 
prevention in elderly patients T2DM appears to be cost-saving.  
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1.1 Epidemiology of Heart Failure in Type 2 Diabetes Mellitus 
1.1.1 Epidemiology of Heart Failure 
Heart failure (HF) is a common clinical syndrome associated with high morbidity and mortality. 
It has become a major public health problem, affecting at least 26 million worldwide12.  This 
epidemic is one of increased prevalence, largely due to increased survival, and may be 
attributable to increased incidence – although we have not yet witnessed this. In Australia, a 
recent systematic review reported that the overall prevalence of HF ranges between 1-2 %, and 
is similar to western countries 1. (Figure 1.1) HF incidence varies from studies and countries. 
Currently in US, there are 915,000 incident HF presentations annually, giving an event rate 
approaching 10/1,000 person-years among individuals ≥65 years2. HF incidence is higher in 
the aging population, particularly in patients aged ≥65 years. The majority of prevalent HF is 
due to heart failure with preserved ejection fraction (HFpEF) 2.  
 
Figure 1.1Prevalence and Incidence of Heart Failure Worldwide 
Savarese G and Lund LH. Cardiac Failure Review. 2017; 3 (7-11) 
The cost of HF continues to increase and has become a heavy burden to the economy and 
healthcare system. In United States (US), more than 10% of the total health expenditure was 
attributed to cardiovascular diseases in 2012 (approximately $31 billion), and between 2012 to 
2030, the total costs are expected to increase by 127% 13.  
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1.1.2 Definition and Classification of Heart Failure 
According to American Heart Association/American College of Cardiology (AHA/ACC) 
guidelines, the definition of HF is “a complex clinical syndrome that can result from any 
structural or functional cardiac disorder that impairs the ability of the ventricle to fill or eject 
blood” 14, 15. Chronic heart failure (CHF) is a chronic progressive condition that is often referred 
to simply as “Heart Failure”. As HF is a complex clinical syndrome but not a disease, the 
aetiology of the problem should always be considered. The diagnosis of HF is mainly based on 
clinical examination including history and physical examination, chest radiography, 
electrocardiogram, laboratory assessment and echocardiogram. There are several instruments 
have been proposed to diagnose HF in particular including the Framingham criteria16, the 
Gothenburg criteria17, the Boston criteria18 and the European Society of Cardiology criteria19. 
These criteria all rely on similar indicators from the clinical examination, and the most widely 
used are the Framingham criteria (Table 1.1). Compared  with other criteria, the Framingham 
criteria can capture more possible HF providing 100% sensitivity and is less influenced by time 
and diagnostic tests 12. The Framingham criteria is well suited for research and long-term trends. 
Table 1.1 Framingham CHF clinical diagnosis criteria (requiring the simultaneous presence of at least 
2 major or 1 major with 2 minor criteria).
MAJOR CRITERIA 
 Paroxysmal nocturnal dyspnea or 
orthopnea 
 Neck vein distension 
 Rales 
 Cardiomegaly 
 Acute pulmonary edema 
 S3 gallop 
 Increased venous pressure≥16cm 
water 
 Circ.time≥25 sec 
 Hepatojugular reflux 
 Weight loss≥4.5 kg in 5 days in 
response to treatment 
 
MINOR CRITERIA 
 Ankle edema 
 Night cough 
 Dyspnea on exertion 
 Hepatomegaly 
 Pleural effusion 
 Vital capacity decreased 1/3 from 
maximum 
 Tachycardia rate of ≥120 beat/min 
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The current ACC/AHA heart failure guidelines defines the evolution of HF in four stages. Stage 
A heart failure (SAHF) exists in subjects with risk factors for heart failure (HF), in the absence 
of structural heart disease or symptoms 14. These risk factors include obesity, hypertension, 
atherosclerosis, diabetes mellitus (DM), exposure to cardiotoxins and family history of HF, and 
they may be present in up to a third of subjects aged ≥45 years. The natural history of SAHF 
is that patients may progress to functional or structural abnormalities (i.e. reduced ejection 
fraction, left ventricular hypertrophy and chamber enlargement) without symptoms (stage B, 
SBHF), clinical manifestations of HF (stage C) and eventually, refractory or end-stage HF 
(stage D)8 (Table 1.2.)In this system classifies the evolution of HF, rather than the level of 
symptoms captured in the New York Heart Association (NYHA) functional classification 
system. Thus, patients only move forward from prior stages to an advanced stage and do not 
regress. Note that, few certain causes of HF are reversible – including those due to tachycardia-
mediated cardiomyopathy, toxins and mitochondrial abnormalities20. The current ACC/AHA 
HF classification system describes the progression of HF from HF risks through subclinical 
LV dysfunction, to symptomatic clinic HF and end-stage HF. In contrast, the NYHA class 
system is focused on the level of HF symptoms and functional limitations. The identification 
of HF risk should stimulate efforts to identify SBHF, as therapeutic interventions in this setting 
may prevent the development of clinical HF and improve prognosis8.  
Table 1.2 American College of Cardiology/American Heart Association Classification of Heart Failure 
Stage A High risk for HF but without structural heart disease or symptoms 
Stage B Structural abnormalities but without signs of symptoms of HF 
Stage C Structural heart disease with prior or current symptoms of HF 
Stage D Refractory or end-stage HF requiring specialized interventions 
1.1.3 Incidence and Prevalence of Heart Failure in Type 2 Diabetes Mellitus 
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Type 2 diabetes mellitus (T2DM) is the most prevalent form of diabetes; by 2025, it is expected 
to affect 380 million people throughout the world21. Diabetes is a strong and independent risk 
factor for cardiovascular disease (CVD), and the management of cardiovascular health will be 
a cornerstone of managing the T2DM epidemic. Results from a health maintenance 
organization show that about 12% of 10,000 patients with diabetes had HF at baseline, and 3.3% 
of the rest developed heart failure during each year of follow-up 5, 22. The Framingham Heart 
Study reported a 2 to 5 fold increased HF risk in T2DM, and the frequency of HF is even higher 
among elderly subjects 6. Several subsequent studies have confirmed the significant increase 
in incident HF in patients with T2DM compared with non-diabetic patients5, 7, 22-26. Nichols et 
al. published a retrospective study demonstrating that the odds ratio (OR) for incidence of HF 
in patients with T2DM is approximately 2.5 compared with those without diabetes5, 22. A study 
from the Reduction of Atherothrombosis for Continued Health (REACH) registry, an 
international registry of 45,227 individuals and 4-year follow-up published in 2015, reported 
that T2DM was associated with a 33% higher risk of hospitalization for HF (9.4% vs 5.9%; 
adjusted OR 1.33, 95% CI 1.18-1.50) compared with non-diabetic subjects23. 
1.1.4 Prognosis of Heart Failure with Type 2 Diabetes Mellitus 
The presence of T2DM can adversely affect long-term survival as well as risk of hospitalization 
in patients with CHF. The 5-year survival rate of HF is analogous to that of malignancy and 
the morbidity and mortality rates of diabetic heart failure are 4-8 fold higher than in the non-
diabetic population 27.  The mortality ratio is approximately 9-fold higher in elderly patients 7. 
A recently published systematic review including 31 registries and 12 clinical trials with 
381,725 patients with acute and chronic HF over a median follow-up of 2 years showed that 
the presence of diabetes was associated with a greater risk of all causes of death (random-effect 
HR 1.28, 95% CI 1.20-1.50) as well as cardiovascular death (HR 1.34, 95% CI 1.20-1.49)28. 
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However, the trend for in-hospital mortality in HF patients with diabetes reported from a large 
US national inpatient sample survey from 2000 to 2010 has significantly decreased during past 
decade, despite increased diabetes prevalence and comorbid conditions 29. 
In addition, among patients with T2DM, those who develop their first episode of HF have 
markedly worse survival than those who are free of HF. A study of 115,803 elderly US patients  
with diabetes showed that incident significantly increased with age and diabetes-related 
comorbidities, and in patients with diabetes, incident HF was significantly associated with high 
mortality when compared with those who remained HF free over 60-months of follow-up (HR 
10.6, 95% CI 10.4–10.9)7 (Figure 1.2). 
 
Figure 1.2 Five-year Kaplan-Meier survival estimates for 115,803 adults age ≥65 years in fee-for-service 
Medicare with diabetes by incident heart failure status. 
Bertoni AG, et al. Diabetes Care. 2004; 27(3): 699-703 
1.2 Cardiovascular Risks Associated with Type 2 Diabetes Mellitus 
1.2.1 Ischemic Heart Disease in Type 2 Diabetes Mellitus 
Ischemic heart disease (IHD) is recognized as the leading cause of morbidity and mortality in 
T2DM – to the extent that DM contributes to 75% of deaths among all forms of CVD 30. 
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Compared with subjects without diabetes, patients with T2DM have a higher prevalence of 
coronary heart disease (CHD) and are more likely to have myocardial infarction (MI). Stress 
echocardiography is an effective modality for diagnosis and prognostic evaluation of IHD in 
T2DM 31. However, screening for IHD has not proven effective 32 – first, because the observed 
event-rates are less than anticipated in the era of considering DM as an IHD-equivalent 33, 34, 
and second, because of the limited benefits of interventional responses to previously 
unrecognized IHD 35.  
1.2.2 Increased Heart Failure Risk and Mortality in Type 2 Diabetes Mellitus 
The independent association of HF with T2DM is not entirely related to atherosclerosis and 
hypertension. Diabetic cardiomyopathy (DCM), which is manifest by cardiac functional 
abnormalities 36, 37, is defined as diabetes-associated ventricular dysfunction that is not 
attributable to other causes 38. Subclinical left ventricular systolic and/or diastolic dysfunction 
(LVSD/LVDD) may be a precursor of subsequent overt HF in T2DM 39, and the risk of 
progression from asymptomatic LVSD or LVDD to symptomatic HF is increased in DM 40. 
However, ~50% of subjects with LVSD remain unidentified 36.  
Pathophysiologic manifestations of DM include coronary microvascular or macrovascular 
injury, myocardial fibrosis and autonomic dysfunction, and echocardiography permits 
demonstration of the contributions of functional disturbance and left ventricular hypertrophy 
(LVH) 41. Disturbed myocyte contraction and relaxation are related to the underlying metabolic 
disturbances of both pre-diabetes and diabetes - hyperinsulinemia, inflammation and oxidative 
stress. In addition, structural changes arise from changes in extracellular matrix proteins, such 
as excess deposition of collagens, abnormal glycosylation/crosslinking, and alterations in 
diastolic compliance 42. Impaired myocardial relaxation and cardiomyocyte resting tension 
could give rise to increased LV stiffness and diabetic autonomic neuropathy leads to 
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sympathetic imbalance, which in turn drives enhanced fatty acid metabolism and fetal gene 
expression. Activation of the angiotensin-renin system is linked to increased deposition of 
myocardial collagen, advanced glycation and products (AGEs), and cardiac 
remodelling/hypertrophy 36. Diabetic microangiopathy, vascular endothelial dysfunction and 
coronary flow reserve impairment may arise from small vessel disease43.  
1.2.3 Atrial fibrillation in Type 2 Diabetes Mellitus 
Apart from contributing to CHD and HF, DM also favours the occurrence of arrhythmias - 
especially among women, although the underlying mechanism is still unclear. In the 
Framingham Heart Study, DM was associated with an increased risk of new-onset atrial 
fibrillation (AF) among both sexes (odds ratio, OR 1.4 for men and 1.6 for women) at 38 year-
follow-up 44.  Subsequently, a large observational cohort showed that DM was an independent 
determinant of AF prevalence compared with the non-DM population (3.6% vs 2.5%, 
P<0.0001) and also significantly predicted incident AF in women (HR 1.26, 95% CI 1.08-1.46]) 
but not in men (HR 1.09, 95%CI 0.96-1.24) at a mean follow-up of 7.2 years 45. AF and diabetes 
share common antecedents such as obesity, atherosclerosis and hypertension, which can be 
compiled into a clinical risk score 46. The role of DM in embolic risk is reflected in its 
contribution to the CHA2DS2-VASc score 
47.  
1.3 Screening for Diabetic Cardiomyopathy: An Expression of 
Stage B Heart Failure 
In undiagnosed patients with preclinical DCM, treatment is not initiated until the development 
of symptoms (stage C or D HF) 48. At this stage, changes may be irreversible and the ability to 
change the trajectory of the illness may be limited. Consequently, the AHA/ACC heart failure 
guidelines have drawn attention to the earlier stages of HF. DM is a key HF risk factor, meaning 
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that all patients are considered to be in stage A HF. These patients may develop abnormal LV 
structure (LVH) or function, which are features of stage B HF. These patients are at even 
greater risk of transitioning to symptomatic stage C HF – usually HFpEF. 
1.3.1 Role of Diabetes in Pathophysiology of HFpEF 
Pathophysiologic manifestations of DM include coronary microvascular or macrovascular 
injury, myocardial fibrosis and autonomic dysfunction, and echocardiography permits 
demonstration of the contributions of functional disturbance and LVH 41. Disturbed myocyte 
contraction and relaxation are related to the underlying metabolic disturbances of both pre-
diabetes and diabetes - hyperinsulinemia, inflammation and oxidative stress. In addition, 
structural changes arise from changes in extracellular matrix proteins, such as excess deposition 
of collagens, abnormal glycosylation/crosslinking, and alterations in diastolic compliance 42. 
Impaired myocardial relaxation and cardiomyocyte resting tension could give rise to increased 
LV stiffness and diabetic autonomic neuropathy leads to sympathetic imbalance, which in turn 
drives enhanced fatty acid metabolism and foetal gene expression. Activation of the 
angiotensin-renin system is linked to increased deposition of myocardial collagen, advanced 
glycation and products (AGEs), and cardiac remodelling/hypertrophy 36. Diabetic 
microangiopathy, vascular endothelial dysfunction and coronary flow reserve impairment may 
arise from small vessel disease43.  
Advanced echocardiographic techniques including tissue Doppler imaging and deformation 
imaging can not only detect subclinical DCM, but also define the contribution of each aspect 
of pathophysiology. The ratio (E/e′) of pulsed Doppler early diastolic transmitral peak inflow 
velocity (E) to pulsed tissue Doppler mitral early diastolic annular velocity (e′) may be 
clinically valuable to obtain information about LV filling pressure (LVFP) and to unmask the 
pseudonormal Doppler inflow pattern, potentially a turning point in the progression towards 
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advanced heart failure.  The E/e′ ratio can also be assessed following exercise, which offers a 
valuable perspective in patients who are dyspnoeic on exertion. In the absence of epicardial 
coronary artery stenosis, the ultrasound assessment of coronary flow reserve (CFR) may 
identify dysfunction of the coronary microcirculation 49. Deformation imaging allows 
alterations of functional markers (peak strain and strain-rate) to be detected before the 
development of myocardial systolic dysfunction in patients with DM but without overt heart 
disease 50.  
1.3.2 Detection of Diabetic Cardiomyopathy 
Numerous epidemiological and clinical studies have supported the existence of DCM, which 
is defined as left ventricular dysfunction (LVD) and/or left ventricular hypertrophy (LVH) 
independent of hypertension and coronary disease or other potential etiologies, that appears to 
result in cardiovascular complications and congestive HF.51 Echocardiography has been the 
most widely used technique to determine the prevalence of these LV structural or functional 
changes. The structural evidence of preclinical DCM is common in older subjects with diabetes, 
ranging from 36-48% 52, 53. 
1.3.2.1 Left Ventricular Hypertrophy.  
LVH is highly prevalent in asymptomatic DM; Kiencke et al 53 reported that 24% older diabetic 
subjects without evidence of heart disease had LVH while Dawson et al 54 reported 43% in an 
unselected older cohort using the same criteria of LVH. However, as hypertension, 
atherosclerosis, obesity, abnormal lipid profile and LVH frequently coexist, it has been 
controversial as to whether T2DM has an independent association with increased LV mass 
(LVM). Apart from hypertension, the two main risk factors for LVH in diabetes are insulin 
resistance (IR) and visceral adiposity 55. Metformin, as an insulin sensitizer,  is associated with 
an attenuation of LVH in hypertensive diabetes and longer duration of metformin use is 
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associated with greater effect 56. Recently, several studies have shown an association between 
T2DM and LVH and LV remodelling, in the absence of hypertension or atherosclerosis. In the 
multi-ethnic Northern Manhattan Study (NOMAS) cohort study, T2DM increased the risk of 
LVH by about 1.5-fold, independent of various covariates 57. Al-Daydamony et al. reported 
that normotensive patients with the metabolic syndrome had significantly higher LV wall 
thickness, LVM and incident LVH compared with healthy controls 56. However, in the 
Framingham study, DM was associated with increased LV mass only in women, in contrast to 
the Cardiovascular Health Study, where  this association was reported in both sexes 58, 59.   
EKG is a traditional and relatively inexpensive approach in the diagnosis of LVH. In daily 
clinical practice, LVH is usually first noticed on the basis of 12-lead ECG abnormalities. 
However, EKG is considered as an approach with lower sensitivity or specificity to diagnose 
anatomic LVH compared with imaging with either echocardiography or cardiac magnetic 
resonance imaging. Using echocardiography as standard, the sensitivity for different 
electrocardiographic criteria is <30%60, 61.  Because of this problem with low sensitivity, 
particularly in the elderly60, echo was used to determine LVH in our study. 
The prevalence of LVH by echocardiography in subjects with T2DM is highly dependent on 
indexation methodology.  LVM is most widely indexed to either body surface area (BSA), 
height1.7or height2.7. Chowdhury et al have recently proposed that LVH indexed to BSA to the 
power of 115/95shows the best predictive power for both short- and long-term cardiovascular 
events 62. Cardiac magnetic resonance imaging (CMR) is the established non-invasive gold 
standard measurement for LV volume and LVM due to its high accuracy, better spatial 
resolution, less restricted viewing window and reproducibility 63, 64. While 2D 
echocardiography is unlikely to miss substantial LVH, a low concordance was found between 
the diagnosis of LVH by 2D echo and CMRi; the presence of LVH by CMRi was found nearly 
twice as commonly as by echocardiography in the same population 65. 3D echocardiography 
Chapter 1- Introduction 
  12 
 
has closed this gap between echocardiography and CMR, but while it provides the optimal 
echocardiographic means for quantifying LV volume and mass, it still presents challenges.  
1.3.2.2 LV Diastolic Dysfunction.  
Both diabetes and glucose intolerance have a negative influence on LV diastolic filling, and 
abnormal diastolic function often manifests in the presence of normal systolic function. 
Diastolic dysfunction in T2DM has been reported in between 27-75% in different populations 
and with different definitions.53,66, 67LV diastolic dysfunction is significantly associated with 
diabetes duration, glycaemic control, level of serum-free fatty acids and the type of 
hypoglycaemic medication 68. Unfortunately, the diagnosis of diastolic dysfunction may be 
complicated, and recent guidelines have re-emphasized the importance of transmitral flow and 
tissue Doppler measurements69.  Increased left atrial volume is a marker of prolonged elevation 
of filling pressures. 
1.3.2.3 Left Ventricular Strain.  
Not only diastolic, but also systolic function is impaired in T2DM. Despite widespread use, 
LV ejection fraction (EF) may be insensitive to minor changes in LV function. The early 
detection of both systolic and diastolic myocardial dysfunction may be more readily 
accomplished using strain and strain-rate imaging. From the technical standpoint, strain 
measurement is a measure of cardiac tissue deformation, used for quantiﬁcation of regional left 
ventricular (LV) function. During ventricle contraction and relaxation, the myocardium 
shortens, thickens and lengthens. The relative change in length of myocardium during 
contraction and relaxation (expressed as percentage of resting length) defines strain as a 
dimensionless measure (shortening is negative and lengthening is positive). Strain imaging can 
be measured by tissue Doppler imaging (TDI) and speckle-tracking echocardiography (STE) - 
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currently, STE is the most widely used method to measure strain as it is independent of imaging 
angle.  
As the ventricle contracts in systole, there is longitudinal shortening (negative), circumferential 
shortening (negative) and transmural (wall) thickening (positive). Global longitudinal strain 
(GLS) has been well validated against sonomicrometry and MRI70-72, with a normal range 
of >18%73, 74. GLS is a more robust marker than standard parameters such as ejection fraction 
(EF) for several reasons; a) it is automated, b) averaging of individual segments over the entire 
length of the myocardial wall is a means of controlling random noise, c) it is informed by the 
entire myocardium within the region of interest rather than designation of the myocardial 
border75.  However, like any ejection-phase index, GLS is load (especially afterload-) 
dependent, to a similar degree to EF. Nonetheless, GLS is superior to EF because it measures 
longitudinal function, which is an early marker of disease. In contrast, EF is relatively 
insensitive to subclinical abnormalities of LV function and mainly determined by 
circumferential strain76, so GLS is not strongly reflected in EF. This suggests that GLS conveys 
more detailed information about LV systolic function than EF can provide.  
STE is feasible with both 2DE and 3DE, although 2D is the most reproducible approach for 
assessing LV systolic function. The assessment of GLS using 2D is feasible as a routine echo 
assessment in most patients77-79, but it is affected by image quality, BMI, age and atrial 
fibrillation. For 3DSTE, demographic, cardiac factors and technical requirements may all 
influence the values80-82. Currently, the feasibility of 2D STE is higher than it in 3D in daily 
practice as 3D82. The low intra- and inter-observer reproducibility of GLS values has been 
confirmed in many studies74, 83-85. In addition, the variability of GLS measurement among 
different vendors is small, and was superior to conventional echocardiographic measurements 
in many cases86.  
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Previous studies have shown that in asymptomatic T2DM, the reported prevalence of abnormal 
global longitudinal strain (GLS) (≥-18%) ranges from 37-54% (Figure 1.3) 87, 88. Radial and 
circumferential strains have been shown to be sensitive for detection of early LV contractile 
dysfunction in diabetic mice. However, epidemiological studies in patients with uncomplicated 
T2DM have found impairment of LV longitudinal systolic and diastolic function, with 
preserved circumferential and radial function 89, 90. 3D strain offers a means of overcoming 
artefacts due to through-plane motion 91, but this technique has significant challenges for 
measuring strain/strain rate.  
 
(a)
 
(b) 
Figure 1.3. LV longitudinal strain curves in the apical 4-chamber view of asymptomatic individuals with DM and 
normal EF. The normal subject (a) has a normal global strain (GLS) of -22% and the curves are reasonably 
homogeneous. Currently, GLS is more robust than are segmental strains. The patient with subclinical LV systolic 
dysfunction (b) has a reduced GLS (-13%) and heterogeneity of magnitude and timing of segmental strain. 
1.3.2.4 Atrial Size and Function in Diabetes. 
In the absence of atrial fibrillation, left atrial (LA) enlargement (measured as LA volume) is 
recognised as a marker of LV diastolic dysfunction and elevated filling pressures. However, 
the LA does not readily reverse-remodel 92 and functional indices provide incremental 
prognostic value, not only for outcome, but also regarding the risk of atrial fibrillation 93. The 
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conventional indices of LA function are obtained from Doppler imaging of pulmonary venous 
and transmitral flow, and myocardial tissue Doppler 94, 95. Speckle tracking can measure LA 
strain, most simply as the total deformation attributable to LA filling and contraction, by 
triggering the strain curve to the R wave. An alternative is to trigger the strain calculation on 
the P wave, which permits a more direct focus on atrial contraction. Patients with DM develop 
an atriopathy, as evidenced by detection of abnormal LA mechanics in the presence of normal 
LA volume or standard indexes of LA function, independent of other potential clinical and 
echo confounders 95. The effects of DM are incremental to co-existent hypertension 95.  
1.4 Current Evidence and Literature Gaps 
HF is a well-known burden to the health care system and the outcomes of treatment in late 
stage are poor. However, many patients with significant abnormalities of cardiac function are 
apparently asymptomatic. Intervention in these patients may be beneficial. It implies that early 
screening followed by prevention programs will need to be implemented to detect and protect 
these individuals. For the SBHF screening strategy, LVEF is the most commonly used measure 
of systolic function in clinical practice, but it is not a robust index of myocardial or chamber 
contractility because of its variability, load dependence and sensitivity to chamber size. GLS 
is a more robust marker, but before it is designated as the optimal marker, its usefulness in 
clinical decision-making still needs to be tested. For prevention of SBHF, angiotensin 
converting enzyme inhibitor (ACE inhibitor) or angiotensin II receptor blocker (ARB) may be 
prescribed if individuals have diabetes. Once diabetic patients develop Stage B HF, a beta-
blocker (BB) could be added to prevent or delay symptomatic HF. BB and ACEI could reduce 
the risk of incident HF but no evidence is available on the value of a prevention strategy guided 
by GLS. The most effective screening and intervention approach for SBHF among patients 
with T2DM remains unknown. 
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1.5 Hypothesis and Aims of This Thesis 
The overall hypothesis of this thesis is: 
Early detection by strain imaging (GLS) followed by preventive treatment for LV 
dysfunction can prevent the development of HF in elderly asymptomatic patients with 
T2DM. 
Objectives: 
 Prediction on HF in T2DM. What is the effect size of each risk factor for incident HF 
in T2DM? Is it feasible to develop a clinical risk score to predict HF in T2DM? Among 
T2DM, who should undergo screening? 
 Prevalence and functional implications. Is the prevalence of subclinical LV 
dysfunction, exercise capacity, quality of life and clinical outcome different between 
T2DM-SAHF versus other-SAHF? What is the prevalence of stage B HF in patients 
with T2DM in the community? 
 Outcomes. Do asymptomatic diabetic patients with DCM really develop into 
symptomatic HF? If yes, over what period? From a natural history standpoint, how does 
diabetic cardiomyopathy change over time? Is there any predictive factor for evolution 
of diabetic cardiomyopathy? 
 Development of a community screening program. Could a community-based 
screening program combined with cardio-protective therapy improve the prognosis in 
T2DM? 
 Cost-effectiveness. Is the preventive treatment guided by the GLS screening strategy 
for HF in patients T2DM cost-effective? 
1.6 Structure of thesis 
Chapter 1. Introduction 
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Chapter 2. Prediction of heart failure in patients with T2DM 
Chapter 3. Methodology 
Chapter 4. Association of insulin resistance with impaired function capacity in T2DM 
Chapter 5. Subclinical LV Dysfunction, function capacity, quality of life and outcomes in 
                  Stage A Heart Failure 
Chapter 6. Use of Echocardiographic Markers to Predict Heart Failure in T2DM 
Chapter 7. Association of Depression with Heart Failure in T2DM  
Chapter 8. Evolution of Subclinical Left Ventricular Function during a 2-year  
Observation in T2DM 
Chapter 9. Cost-effectiveness implications of a HF screening program 
Chapter 10. Summary and conclusions 
1.6 Concluding remarks 
This chapter provides an overview of the background of T2DM in stage B heart failure. 
Summary of the findings suggests the following; 
1) Stage B heart failure is highly prevalent in patients with T2DM. 
2) The mechanism behind the independent association between incident HF and T2DM is 
through diabetic cardiomyopathy, as defined by subclinical LV systolic dysfunction, diastolic 
dysfunction or LV hypertrophy. 
3) A more aggressive stance towards screening for and better targeting of interventions of 
SBHF in diabetes seems necessary, and GLS is a potential optimal biomarker of SBHF in the 
community.  
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4) Evidence-based studies show an intervention benefit in ischemic Stage B heart failure; 
however, no evidence is available on the basis of a cardio-protective strategy guided by strain 
imaging in asymptomatic patients with T2DM. 
This thesis aims to identify the highest risk diabetic patients for most effective screening and 
follow this with a cardio-protective intervention approach to prevent incident HF.  
1.7 Postscript 
The next chapter is a systematic review and meta-analysis aiming to identify predictors of 
incident HF among clinical, laboratory and echocardiographic parameters in patients with 
T2DM. This study sought to improve the assessment of HF risk in patients with T2DM – a step 
that would be critical for effective HF screening. 
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2.1 Preface 
T2DM is a major predictor of HF, independent of atherosclerosis and hypertension, and HF is 
a leading cause for hospital admissions and death in T2DM. While the outcomes of treatment 
in late stage HF are poor, therapy has been shown to be beneficial in the early stage of 
ischaemic HF with reduced ejection fraction (EF).If (as seems likely) treatment were also 
beneficial in early non-ischaemic HF, the recognition of early stage HF in the community 
would be an important step. Numerous methods including cardiac imaging tests can be used to 
help identify subclinical HF in T2DM. Of these, echocardiography is inexpensive and widely 
available, and recent developments in myocardial strain, 3-dimensional transthoracic 
echocardiography and echo contrast allow detection of subclinical abnormalities of heart. 
However, the best way of identifying the highest risk T2DM patients for screening and therapy 
approach remains undefined.  
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2.2 Abstract 
Background: Heart failure (HF) is a major cause of mortality and disability in type 2 diabetes 
mellitus (T2DM). This study sought to improve the assessment of HF risk in patients with 
T2DM – a step that would be critical for effective HF screening. 
Methods: A systematic literature search was performed on electronic databases including 
MEDLINE and EMBASE, using MeSH terms ‘heart failure’, ‘risk factor’, ‘T2DM’, ‘cardiac 
dysfunction’, ‘stage B heart failure’, ‘incident heart failure’, ‘risk assessment’, ‘risk impact’, 
‘risk score’,  ‘predictor’, ’prediction’ and related free text terms. The search was limited to 
human studies in full-length publications in English language journal from 1946 to 2014. 
Univariable and multivariable relative risk (RR) and hazard ratio (HR) were obtained from 
each study. 
Results: Twenty-one studies (n=1,111,569, including 507,637 subjects with T2DM) were 
included in this analysis with a follow-up ranging from 1 to 12 years. Associations between 
incident HF and risk variables described in >3 studies were reported. This association was 
greatest for insulin use (HR 2.48; 1.24-4.99), HbA1c 7.0-8.0% (2.41; 1.62-3.59), 5 years 
increase in age (1.47; 1.25-1.73), fasting glucose (1.28; 1.10-1.51 per standard deviation) and 
HbA1c (1.18; 1.14-1.23 each 1% increase). After adjustment for confounders, there were 
strong associations with coronary artery disease (1.77; 1.31, 2.39), HbA1c≥10% (1.66; 1.45-
1.89), insulin use (1.43; 1.14-1.79), HbA1c 9.0-10.0% (1.31; 1.14-1.50), fasting glucose (1.27; 
1.10-1.47 per standard deviation) and 5 years increase in age (1.26; 1.13-1.40). 
Conclusion: Among patients with T2DM, five common clinical variables are associated with 
significantly increased risk of incident HF.  
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2.3 Background 
In addition to its association with ischaemic heart disease, diabetes confers a demonstrably 
higher risk of developing cardiomyopathy 48. Subclinical dysfunction may be a precursor to the 
development of subsequent symptomatic heart failure in patients with diabetes mellitus. 
However, at least 50% of those patients with asymptomatic left ventricular (LV) dysfunction 
are still unidentified 48. The underlying metabolic disturbance of both pre-diabetes and diabetes 
leads to hyperinsulinemia, inflammation and oxidative stress. Multiple pathophysiological 
changes at the microscopic level culminate in abnormal cardiac function. Examples include 
impaired myocardial relaxation and cardiomyocyte resting tension giving rise to increased LV 
stiffness and diabetic autonomic neuropathy leading to sympathetic imbalance, which in turn 
drives increased fatty acid metabolism and foetal gene expression. Activation of the renin-
angiotensin system is linked to increased deposition of myocardial collagen, advanced 
glycation and products (AGEs), and cardiac remodelling 48. Diabetic microangiopathy, 
vascular endothelial dysfunction and coronary flow reserve impairment may arise from small 
vessel disease  43.  
Although the epidemiology and mechanisms of the association of diabetes mellitus with heart 
failure are understood, an effective strategy for early diagnosis and effective intervention has 
not yet been demonstrated. Fundamental to this is the fact that not all patients are at equal risk, 
and a screening and intervention approach would be most effective if it involved the highest 
risk patients. The purpose of this study was to better quantify heart failure risk in subjects with 
diabetes mellitus.   
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2.4 Methods 
2.4.1 Search Strategy. 
This approach followed the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guideline 97. A systematic literature search was performed on MEDLINE 
and EMBASE using the medical subject heading (MeSH) terms ‘heart failure’, ‘risk factor’, 
‘type 2 diabetes mellitus’ ‘LV dysfunction’, ‘cardiac dysfunction’, ’stage B heart failure’ 
‘incident heart failure’, ‘risk assessment’, ‘risk impact’, ‘risk score’, ‘predictor’, ‘prediction’ 
and related free text terms. The search was limited to human epidemiological and clinical 
studies in English language (updated on February 2014). The search strategy, study selection, 
and analysis followed the recommendations in the Cochrane Handbook.98  No previous reports 
of this nature have been identified. The review was registered with the Prospective Registration 
Of Systematic Reviews (http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD 
42014008821), as PROSPERO 2014:CRD42014008821.  
2.4.2 Study inclusion. 
Inclusion criteria for the review were: (1) full-length publication of original data in a peer-
reviewed English language journal; (2) human adults >18 years of age with T2DM; (3) reported 
incident HF in subjects with T2DM; (4) analysis of risk factors relating to incident heart failure 
in T2DM, reporting effect sizes as Relative Risk (RR), Odds Ratio (OR) or Hazard Ratio (HR) 
with 95% confidence intervals (CIs). Exclusion criteria were (1) review articles, editorial 
comments, and letters to the editor, practice guidelines, cost-effectiveness study, adjunctive 
therapy study, program evaluation. systematic review, case study and articles without full text; 
(2) studies included T2DM patients had heart failure at baseline or used an inappropriate 
comparison group (the comparison was not between diabetic incident HF group non-HF 
groups),(3) publication in other language. 
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Two independent investigators (YW and TN) assessed the eligibility of the studies. Titles, 
abstracts and keywords, information of identified studies were assessed for the first screening. 
The second screening was based on the full texts review. The information of included studies 
was entered into an inclusion/exclusion form. Full texts were further assessed when the 
collected information of a primary study indicated that it was eligible to be included in this 
review. The references in the identified articles were also reviewed for possible inclusion.  
2.4.3 Data extraction. 
Data were carefully extracted from all eligible studies independently by two reviewers (YW 
and TN). A third reviewer (TM) was included for unresolved discrepancies, all discrepancies 
were reviewed and resolved by consensus. The recorded study characteristics included first 
author’s name, publication information, study design, time frame of study, age, sex distribution, 
follow-up time, number of participants, number of incident HF cases, method of assessment of 
HF, numbers of T2DM subjects with different risk factors of incident HF, and covariates 
included in the adjusted models. Outcome measures (RR, OR, HR) and their associated 95% 
confidence intervals (CIs) were extracted from included studies or calculated from available 
data. Only the largest dataset was included in the analysis when multiple articles represented 
data from the same dataset, except when different variables were reported in each article. 
The outcome was defined as new onset heart failure and the study was excluded if participants 
had a heart failure history. The definition of an incident heart failure event varied somewhat 
from different studies, but in general it was defined as a physician diagnosis of heart failure or 
a hospital discharge diagnosis coded as heart failure (ICD-9, code 428 or 518.4).  
2.4.4 Assessment of Methodological Quality. 
Two investigators (YW and TN) independently assessed the quality of included studies. The 
assessment of methodological quality was based on the Newcastle-Ottawa Quality Assessment 
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Scale (NOS) for cohort studies with slight modifications to accommodate the topic of this 
review (Appendix 2.1).  
2.4.5 Assessment of Heterogeneity. 
Heterogeneity across included studies was tested using the Cochran Q  and I2 tests. A chi-
square >25% and p<0.10 was defined as evidence of significant heterogeneity across studies. 
The I2 test was used to estimate the extent of heterogeneity that is attributable to inter-study 
variation;99, 100 a value >30% represents moderate heterogeneity and a value >50% represents 
substantial heterogeneity. Possible sources of heterogeneity were explored by subsequent 
meta-regression and sensitivity analyses. Meta-regression models were established to screen 
the affected factors resulting in heterogeneity using Comprehensive Meta-analysis software 
(version 2.0, Biostat, Englewood, NJ). For sensitivity analyses, data was extracted from 
relevant articles individually for pooled RRs to test the results of HRs.   
2.4.6 Assessment of Publication Bias. 
Publication bias and ‘small-study effects’ were assessed using funnel plots. Asymmetry 
identified in the funnel plot implied possible publication bias. A modified Egger’s regression 
test was performed to detect such asymmetry, and p<0.10 was used to identify publication bias. 
2.4.7 Data synthesis and analysis. 
The RR, OR or HR for each risk variable was pooled and analysed across studies. The RR (or 
OR) were derived or extracted from each individual study, and HRs with 95% CIs were 
extracted from each available article directly. Calculated effect sizes were then pooled into a 
combined analysis for each RR, OR and HR. Meta-analysis was performed using RevMan 5.2 
(Cochrane Information Management System, Oxford, UK) with random effect-models 
weighted by inverse variance. Two-tailed P values < 0.05 was considered significant.  
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2.5 Results 
2.5.1 Study characteristics.  
We identified 2309 eligible articles for further examination of the title and abstracts by 
electronic and hand search. Of these, 338 duplicated articles were excluded and 1818 articles 
were excluded after title and abstract review. After full text evaluation, 31 articles met the 
inclusion and good quality criteria and were analysed in this meta-analysis (Figure 2.1). These 
articles were published from 2000 to 2013.  
The 21 eligible studies (Table 2.1) included a total of 1,111,569 subjects of which 507,637 had 
T2DM, ranging from 2.2%-100% of total subjects (weighted mean 83%). The reported mean 
age of T2DM participants was 62±5.7 years old and male subjects of T2DM ranged from 39.6% 
to 100% (weighted mean 56.6%). During the mean follow-up period of 4.8 years (range 1-12 
years), the mean cumulative incident HF rate in T2DM participants was 10.7%, an annualised 
rate of 2.2% per year.  
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Figure 2.1 Flow chat of articles selection based on PRISMA guideline 
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Table 2.1 Baseline characteristics of included studies. 
Study 
Publication 
year 
Study Name 
Data 
Collection 
(year) 
Total (n) 
Total T2DM                    
n       % 
Follow-
up 
(years)* 
HF 
develop 
(n)* 
Incident 
Rate (1000 
p-y)* 
Cumulative 
Incidence 
rate (%)* 
Age 
(years)* 
Male(%)* 
Stratton, I. M. et al101 2000 UKPDS 
1977-1997 3642 3642 100% 10.4 NA NA NA 53±8 60 
Adler, A. I. et al102 2000 UKPDS 
Gerstein, H. C.et al103 2001 HOPE study 1994-1999 9043 3498 39% 4.5 156 9.9/1000 4.5 65.4±6.5 62.9 
Iribarren, C. et al104 2001 KPMCP 1995-1997 
48858 46675 
96% 2.2 935 8.7/1000 1.9 58±13 53.1 
Karter, A.J et al105 2005 KPMCP 1999-2002 100% 0.85 320 21.5/1000 1.4 58.9±12.3 52.4 
Nichols, G. A. et al106 2001 KPNW 1997-1999 18747 9591 51% 2.5 650 33.3/10000 7.7 63ᵻ 52.5 
Nichols, G. A. et al107 2004 KPNW 1997-2003 17076 8231 48% 6 1167 30.9/1000 30.9 63.9±11.9 52.2 
Delea, T. E. et al108 2003 U.S.PIOD 1995-2001 33544 33544 100% 3.3 523 4.7/1000 1.6 58.5±12.8 57.1 
Vaur, L.et al109 2003 DIABHYCAR study 1995-1998 4912 4912 100% 4 187 10/1000 3.8 65.2±8 70.1 
Rajagopalan, R. et al110 2004 PMPCD 1998-2002 3336 3336 100% 2 100 15/1000 3 51.2±0.2 50.9 
Maru, S.et al111 2005 U.K. GPRD 1988-1999 25690 25690 100% 2.5 1409 20.8/1000 5.5 61.5ᵻ NA 
Filion,K.B et al112 2011 U.K. GPRD 2000-2006 63462 63462 100% 7 2632 13.7/1000 9.6 72.4±9.1 52.1 
Barzilay, J. et al113 2005 CHS study 1989-2001 829 829 100% 8 203 31.3/1000 24.5 72.8±5.4 46.3 
Banerjee, D. et al114 2013 CHS study 1989-2013 4425 4425 100% 12 1216 21.4/1000 27.5 72.7±5.5 39.6 
Held, C.et al115 2007 ONTARGET/TRANSCEND     2001ᵻ 31546 12714 40% 4.5 668 11.7/1000 5.3 66±7 65 
Erdmann, E.et al116 2007 PROactive study 
2001-2004 5238 5238 100% 2.9 
257 16.9/1000 4.91 
61.8±7.7 66.1 Erdmann, E.et al117 2010 PROactive study 
Pfister, R. et al118 2011 PROactive study 253 16.7/1000 4.84 
Lipscombe, L.L et al119 2007 ODBP 2002-2006 159026 159026 100% 3.8 12491 20.7/1000 7.9 74.7ᵻ NA 
Yang, X. et al120 2008 HKDR 1995-2005 7067 7067 100% 5.5 274 7.17/1000 3.32 57ᵻ 45.4 
McAlister, F. A et al.121 2008 SHD study 1991-1999 5631 5631 100% 4.7 981 41/1000 17.4 65.8±13.3 43 
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Leung, A. A. et al122 2009 SHD study 1991-1999 565037 12272 2.2% 5.2 718 11.7/1000 6 63±13.5 55 
Cheung, N.et al123 2008 ARIC study 1993-2003 1021 1021 100% 8.9 106 11.7/1000 10.1 59.7±5.6 46.2 
Pazin-Filho, A. et al124 2008 ARIC study 1987-2003 1827 1827 100% 9.9 328 18.1/1000 17.9 58.0±5.7 48.4 
From, A. M. et al125 2010 Olmsted County Study 2001-2007 1760 1760 100% 2.9 NA NA NA 60±14 49 
Simone, G.et al126 2010 Strong Heart Study 1989-2001 2740 1206 44% 12 201 13.9/1000 16.7 56.1±7.9 85.2 
Komajda, M. et al127 2010 RECORD clinical trial 2001-2009 4447 4447 100% 5.5 90 2.6/1000 2 58.4±8.3 51.6 
Toprani, A. et al128 2011 VISN 16 1996-2004 3956 3956 100% 5.5 1157 53.2/1000 39 61.5ᵻ 100 
Lind, M.et al129 2012 SNDR 
1998-2009 83021 83021 100% 7.2 10969 18.4/1000 13.2 65.8±11.7 55.3 
Glogner, S. et al130 
2013 
SNDR 
Ebong, I. A. et al131 2013 MESA 2000-2012 5688 616 11% 8.5 48 11/1000 7.8 NA NA 
                          
Sum   Studies 1988-2012 1111569 507637   152.25           
Mean(weighted)       42752.65 19525 83% 4.8     10.7 62 56.6 
SD (Weighted)           30%       9.8 5.7 13.2 
Maximum         159026 100%   12491   39 74.7 100 
Minimum         616 11%   48   1.4 51.2 39.6 
 
*Data all came from T2DM group; 
ᵻ not reported 
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2.5.2 Risk of incident HF for T2DM. 
Fifty-five risk factors were associated with incident HF in T2DM in these 21 studies (Appendix 
2.1). Twenty-five risk variables reported ≥3 times were selected for the meta-analysis 
(Appendix 2.2). Significant risk factors in this meta-analysis for incident HF in T2DM were 
age, hypertension, fasting glucose, HbA1c, atherosclerotic vascular disease (coronary, 
cerebrovascular, peripheral), use of insulin. For risks reported in hazard ratio, the association 
was greatest for insulin use (2.48; 1.24-4.99), followed by HbA1c 7.0-8.0% (2.41; 1.62-3.59), 
5 years increase in age (1.47; 1.25-1.73), fasting glucose (1.28; 1.10-1.51 per standard 
deviation) and HbA1c (1.18; 1.14-1.23 each 1% increase). After adjustment for confounders, 
the association was still strong for coronary artery disease (1.77; 1.31, 2.39), followed by 
HbA1c≥10% (1.66; 1.45-1.89), insulin use (1.43; 1.14-1.79), HbA1c 9.0-10.0% (1.31; 1.14-
1.50), fasting glucose (1.27; 1.10-1.47 per standard deviation), 5 years increase in age (1.26; 
1.13-1.40), male gender (1.15; 1.00-1.32), and HbA1c (1.13; 1.12-1.15 each 1% increase) 
(Table 2.2). Forest plots of individual meta-analysis are listed in Appendix 2.3. 
Adjusted HRs could be analysed from 17 relevant studies and the adjustments for each article 
are listed in Table 2.3. The most frequent adjustment was age (16) followed by gender (15), 
smoking status (12), HbA1c (12), BMI (11), coronary disease history (11), hypertension (10), 
oral hypoglycaemic agents (10), cardio protective medication (11), insulin use (9), diabetes 
duration (8), total cholesterol (7) and peripheral or cerebrovascular disease (7).  
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Table 2.2 Results of meta-analysis - hazard ratio of risk variables of incident HF in T2DM. 
 
 
Risk Variables 
Dichotomous/ 
Continuous 
Unadjusted HR   Fully adjusted HR   
Total (95%CI) I2 P P(I2) Total (95%CI) I2 P P(I2) 
Age 5y increase 1.47[1.25,1.73] 91% P<0.00001 P=0.0007 1.26[1.13,1.40] 100% P<0.0001 P<0.00001 
Gender(male) Y/N       1.15[1.00,1.32] 60% P=0.04 P=0.06 
BMI 1 unit increase         1.04[1.01,1.06] 93% P=0.003 P<0.00001 
Hypertension Y/N         1.06[0.81,1.40] 74% P=0.67 P=0.02 
HbA1c 
1% increase 1.18[1.14,1.23] 0% P<0.00001 P=0.62 1.13[1.12,1.15] 72% P<0.00001 P=0.0004 
6.0-7.0% 1.25[0.47,3.29] 69% P=0.65 P=0.07 1.02[0.73,1.43] 54% P=0.89 P=0.11 
7.0-8.0% 2.41[1.62,3.59] 0% P<0.00001 P=0.51 1.29[0.97,1.70] 75% P=0.08 P=0.003 
8.0-9.0%         1.10[1.02,1.19] 0% P=0.02 P=0.97 
9.0-10.0%         1.31[1.14,1.50] 21% P=0.0001 P=0.28 
≥10%         1.66[1.45,1.89] 18% P<0.00001 P=0.29 
Fasting 
glucose 
1 SD increase 1.28[1.10,1.51] 48% P=0.002 P=0.17 1.27[1.10,1.47] 69% P=0.001 P=0.04 
7.4-8.4mmol/L 1.09[0.40,3.01] 81% P=0.87 P=0.02        
8.5-10.6mmol/L 1.32[0.82,2.12] 19% P=0.26 P=0.27        
10.6-36.5mmol/L 2.01[0.98,4.15] 70% P=0.06 P=0.07        
Insulin use Y/N 2.48[1.24,4.99] 91% P=0.01 P=0.001 1.43[1.14,1.79] 53% P=0.002 P=0.09 
TZDs Y/N         1.42[0.79,2.55] 96% P=0.48 P<0.00001 
Metformin Y/N         0.92[0.69,1.22] 89% P=0.55 P<0.0001 
Sulfonylurea Y/N 1.20[0.98,1.46] 65% P=0.07  1.14[0.85,1.53] 89% P=0.37 P=0.0001 
CAD Y/N         1.77[1.31,2.39] 79% P=0.0002 P=0.002 
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Table 2.3 Confounding factors and statistics methods for adjustments   
*Other diabetes complications refers to renal, ophthalmic, neurological disease. 
Source 
Effect 
size 
      Confounding Factors     
Age 
Gen
der 
BMI 
waist-
to-hip 
ratio 
Hypert
ension 
Smoki
ng 
Status 
HbA1c 
Fasting 
glucose 
Cholester
ol 
Hypogly
caemic 
agents 
Insulin 
use 
Cardio 
protectiv
e meds 
Diabetes 
duration 
BP 
peripheral 
or 
cerebrovasc
ular disease 
coronary 
disease 
history 
Other 
diabetes 
complicat
ions* 
Other 
Stratton, 2000102 HR ☆     ☆ ☆  ☆    ☆ ☆    ☆ 
Iribarren,200110
4 
HR ☆ ☆ ☆  ☆ ☆ ☆   ☆ ☆ ☆      ☆ 
Vaur, 2003109 HR ☆ ☆ ☆   ☆ ☆     ☆  ☆ ☆ ☆  ☆ 
Delea, 2003108 HR ☆ ☆   ☆  ☆   ☆  ☆   ☆ ☆ ☆ ☆ 
Nichols, 2004107 HR ☆ ☆ ☆    ☆    ☆  ☆   ☆ ☆ ☆ 
Barzilay, 
2005113 
HR ☆  ☆ ☆  ☆  ☆  ☆ ☆     ☆  ☆ 
Maru, 2005111 HR ☆ ☆ ☆  ☆ ☆    ☆ ☆  ☆  ☆ ☆  ☆ 
Karter, 2005105 HR ☆ ☆ ☆    ☆  ☆ ☆ ☆ ☆    ☆  ☆ 
Erdmann, 
2007116 
HR ☆ ☆ ☆   ☆ ☆  ☆ ☆ ☆ ☆ ☆  ☆ ☆  ☆ 
Held, 2007115 HR ☆ ☆  ☆ ☆ ☆  ☆    ☆    ☆  ☆ 
Yang, 2008120 HR ☆ ☆ ☆  ☆ ☆ ☆  ☆   ☆ ☆  ☆ ☆ ☆ ☆ 
McAlister, 
2008121 
HR ☆ ☆          ☆      ☆ 
Pazin-Filho, 
2008124 
HR ☆ ☆ ☆ ☆  ☆ ☆  ☆   ☆  ☆    ☆ 
Komajda, 
2010127 
HR ☆ ☆ ☆ ☆ ☆ ☆ ☆  ☆  ☆ ☆ ☆  ☆ ☆  ☆ 
Toprani, 2010128 HR ☆  ☆   ☆ ☆  ☆ ☆ ☆ ☆  ☆ ☆ ☆  ☆ 
From, 2010125 HR ☆ ☆ ☆  ☆           ☆  ☆ 
Lind, 2012129 HR ☆ ☆ ☆  ☆ ☆ ☆   ☆ ☆ ☆ ☆   ☆  ☆ 
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2.5.3 Sensitivity analysis. 
The pooled RRs were used to verify the results of crude and adjusted HRs of risk factors. Data 
was extracted from relevant studies in which comparison in incident HF was made between 
DM and non-DM group, and then pooled into a combined analysis for crude RRs. For pooled 
RR, atherosclerotic vascular disease (coronary, cerebrovascular, peripheral) had a strong 
association with incident HF (RR 1.5-2.5), followed by insulin use (RR 1.95; 95%CI1.52-2.50), 
rosiglitazone (RR 1.82; 95%CI 1.38-2.40), TZDs (RR 1.67; 95%CI1.43-1.96), hypertension 
(RR 1.63; 95%CI1.21-2.20) and male gender (RR 1.16; 95%CI 1.08-1.25) (Table 2.4) 
Table 2.4 Results of meta-analysis – pooled RRs for risk factors of incident HF in T2DM 
Risk Variables 
RR 
Total (95%CI) I2 P P(I2) 
Gender(male) 1.16[1.08,1.25] 48% P<0.00001 P=0.05 
Smoking(Current smoker) 1.00[0.93,1.09] 0% P=0.92 P=0.92 
Hypertension 1.63[1.21,2.20] 90% P=0.001 P<0.00001 
Microalbuminuria and proteinuria 2.15[0.84,5.47] 95% P=0.11 P<0.00001 
Microalbuminuria 1.68[0.44,6.39] 99% P=0.45 P<0.00001 
Insulin use 1.95[1.52,2.50] 89% P<0.00001 P<0.00001 
Metformin 1.18[1.06,1.31] 0% P=0.002 P=0.75 
TZDs(Rosiglitazone & Pioglitazone) 1.67[1.43,1.96]  0% P<0.00001 P=0.84 
    Rosiglitazone 1.82[1.38,2.40] 57% P<0.0001 P=0.13 
    Pioglitazone 1.33[0.76,2.30] 68% P=0.32 P=0.08 
Sulfonylurea 1.02[0.86,1.22] 82% P=0.80 P=0.0231 
Beta-blockers 1.83[1.04,3.24] 92% P=0.04 P<0.00001 
ACEI/ARB 1.55[1.38,1.74] 17% P<0.00001 P=0.30 
Calcium-channel blocker 1.76[1.30,2.40] 78% P=0.0003 P=0.01 
Diuretics 2.41[2.25,2.59] 0% P<0.0001 P=0.92 
Nitrates 2.59[2.39,2.80] 0% P<0.00001 P=0.36 
Ischemic heart disease 2.50[2.28,2.75] 46% P<0.00001 P=0.13 
Peripheral vascular disease 1.91[1.71,2.13] 0% P<0.00001 P=0.74 
Peripheral and cerebrovascular vascular disease  1.82[1.68,1.96] 0% P<0.00001 P=0.78 
Stroke 1.77[1.21,2.60] 51% P=0.003 P=0.13 
2.5.4 Meta-regression. 
The summary of meta-regression analyses across different clinical, laboratory and geographic 
factors is presented in Table 2.5. There were positive associations between BMI (p=0.03) and 
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coronary heart disease history (p=0.01) with log RR of male gender; age (p=0.01), BMI (p=0.01), 
follow-up years (p=0.02), insulin use (p<0.05) and coronary heart disease history (p<0.05) with log RR 
of insulin use. However, there were no significant associations of effect measures of current smoker, 
hypertension and cardiac protective drugs with listed clinical, laboratory and geographic factors. 
 
2.5.5 Publication Bias. 
Publication bias was estimated visually by funnel plots and Begg and Egger test. The funnel 
plot analysis and statistical tests were presented in Appendix 2.4 and showed no indication of 
potential publication bias. 
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Table 2.5 Results of meta-regression of univariate meta-analyses. 
Characteristic Trails 
logit 
coefficient 
P 
value 
  Characteristic Trails 
logit 
coefficient 
P value 
Male Gender     Current smoker    
male  9 <0.002 0.53  male  6 0.002 0.43 
Age  9 0.005 0.23  Age  6 -0.004 0.63 
BMI  6 -0.037 0.03  BMI  5 0.020 0.58 
SBP  7 -0.014 0.12  SBP  5 -0.011 0.23 
DBP  5 -0.001 0.88  DBP  3 0.022 0.15 
Follow-up years 9 0.013 0.08  Follow-up years 6 0.005 0.61 
current smoker 6 0.006 0.57  current smoker 6 0.006 0.57 
diabetes duration 5 0.034 0.11  diabetes duration 4 0.005 0.94 
fasting blood glucose 3 -0.025 0.16  
fasting blood 
glucose 3 -0.025 0.16 
HbA1c  5 0.131 0.43  HbA1c  3 -0.044 0.86 
creatinie  4 -0.035 0.32  creatinine  3 -0.044 0.30 
ACEI use  3 0.002 0.79  ACEI use  3 0.002 0.79 
insulin use 4 -0.006 0.38  hypertension 3 -0.001 0.93 
coronary heart disease 4 0.011 0.01       
hypertension 4 0.007 0.22       
Hypertension         Insulin use         
male  5 0.001 0.72  male  4 0.010 0.32 
Age  5 0.006 0.34  Age  4 0.014 0.01 
BMI  4 -0.005 0.90  BMI  3 -0.047 0.01 
SBP  4 -0.001 0.93  SBP  3 0.024 0.46 
DBP  3 0.002 0.97  DBP  3 -0.006 0.51 
Follow-up years 5 0.018 0.23  Follow-up years 3 0.039 0.02 
current smoker 4 0.001 0.93  insulin use  3 -0.052 <0.05 
HbA1c  4 0.125 0.44  
coronary heart 
disease 3 0.021 <0.05 
creatinie  3 -0.034 0.33       
ACEI use  3 0.002 0.79       
insulin use 3 <-0.001 1.00       
coronary heart disease 3 0.005 0.31       
hypertension 4 0.007 0.22             
Cardiac protective drugs(β-blockers, ACEI, Calcium 
channel blockers, diuretics) 
      
      
male  3 <-0.001 0.97       
Age  3 0.001 0.89       
BMI  3 -0.004 0.91       
Follow-up years 3 <-0.001 1.00       
current smoker 3 -0.001 0.93       
diabetes duration 3 0.009 0.90             
Abbreviations: BMI, body mass index;HbA1c,hemoglobin A1c;MI,myocardial infarction; ESRD, end-
stage renal disease; Hb, blood haemoglobin; SBP, systolic blood pressure; DBP, diastolic blood 
pressure; UAC, urinary albumin concentration; eGFR, estimate glomerular filtration rate. 
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2.6 Discussion 
The results of this study show that five common clinical risk variables (coronary artery disease, 
glycaemic control (HbA1c and fasting glucose), insulin use and increasing age) are associated 
with incident HF in T2DM. These findings supplement the association of older age, 
hypertension, atherosclerotic vascular disease and diabetes with incident HF in the general 
population.  
2.6.1 Preclinical diabetic cardiomyopathy. 
In undiagnosed patients with preclinical diabetic cardiomyopathy, treatment is not initiated 
until the development of symptoms (stage C or D HF).48 At this stage, changes may be 
irreversible and the ability to change the trajectory of the illness may be limited. Asymptomatic 
patients with cardiac structural changes are considered to have stage B HF, and have a greater 
risk of developing HF 15.  
Numerous epidemiological and clinical studies have supported the existence of diabetic 
cardiomyopathy, which is defined as left ventricular (LV) dysfunction and/or left ventricular 
hypertrophy (LVH) independent of hypertension and coronary disease, that appears to result in 
cardiovascular complications and congestive HF.51 Echocardiography has been the most 
widely used technique determine the prevalence of these LV structural or functional changes. 
Diastolic dysfunction in T2DM has been reported in between 27-75% in different populations 
and with different definitions.53,66, 67 LVH is also prevalent in older and/or hypertensive T2DM 
populations; Kiencke et al 53 reported that 24% older diabetic subjects without evidence of 
heart disease had LVH while Dawson et al 54 reported 43% in an unselected older cohort using 
the same criteria of LVH. Thus, structural evidence of preclinical diabetic cardiomyopathy is 
common in older subjects with DM, ranging from 36-48% 52, 53. Although the cost-
effectiveness of screening tests for early HF screening of asymptomatic T2DM patients still 
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needs to be defined, a feasible and practical risk score would help physicians to identify high-
risk individuals for preventive programs. 
2.6.2 Risk factors for HF in T2DM. 
While the association of coronary artery disease and increasing age with incident HF are 
expected from the general population, the importance of glycaemic control (HbA1c and fasting 
glucose) and therapy are specific to DM. Although weight gain and oedema have been 
recognised as complications of TZDs 132, in our meta-analyses, the strong association between 
TZD and incident HF in T2DM disappeared after fully adjusting for confounders. However, 
this literature is inconsistent, with the reported association of rosiglitazone with the increased 
risk of incident HF 133 being preceded by negative retrospective cohort studies 128. 
Unfortunately, the systematic review approach does not lend itself well to distinction of study 
quality and avoidance of undocumented confounders in retrospective studies.  
For HbA1c, our results confirm previous evidence that poor glycemic control is a predictor of 
incident HF in T2DM. The mechanism of this process is likely multifactorial, including both 
1) higher HbA1c as a marker of poor adherence to not only diabetic therapy, but also 
antihypertensive therapy and lipid lowering medication; 2) worse glycaemic control as a true 
risk for incident HF. It is possible that the poor glycaemic control reflects insulin resistance – 
a contributor to both diabetic cardiomyopathy and atherosclerosis. 104 
Coronary artery disease (CAD) is a well-known risk factor of HF in not only diabetes but also 
non-diabetes patients. In this systematic review and meta-analysis, 21 studies were included 
and coronary artery disease was reported as a risk variable ≥3 times, so it was selected into the 
meta-analysis. In the analysis, CAD was also found having strong association with incident HF 
in patients with T2DM even after adjustment for confounders (HR 1.77; 1.31, 2.39). However, 
the downside is that screening for CAD is attended by many false positives134  and it has not 
Chapter 2- Prediction of HF in T2DM 
  38 
 
been shown to be beneficial in any studies to date135. Moreover, even if CAD is identified, 
many large scale clinical trials have failed to show the long-term prognostic benefit from any 
intervention over optimal medical therapy. In BARI-2D, in diabetic patients with stable CAD, 
the 5-year survival rate was not statistically different between prompt revascularization group 
(either CABG or PCI) and optimal medical therapy group136. Similarly, COURAGE (Clinical 
Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) also failed to show 
the benefit of early PCI to optimal medical therapy can reduce the risk of cardiac event and 
death in diabetes137.  
The development of a risk score is an important step in estimating individuals’ risk of incident 
HF in T2DM. Such method would facilitate the identification and classification of 
asymptomatic subjects with sufficient risk to provide detection from screening and other 
targeted public health interventions. The effect sizes of the risk factors in this systematic review 
may help clinicians to make decisions about screening the diabetic population. These results 
are analogous to a previously-described risk score for HF hospitalization in diabetes 120, with 
the benefit of derivation from a larger group. The risk variables in our findings were derived 
from a large number of patients, and could be expected to perform well in general populations.  
2.6.3 Limitations. 
Like all meta-analyses, this work is limited by variations in the original studies, although all 
involved at-risk individuals. Likewise, the constituent observational studies may be limited by 
biases in the recruitment process. The apparent paradoxical effects of cardio-protective 
medication are likely due to association with other cardiovascular diseases which might lead 
to HF, and therefore reflect confounding by indication. 
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2.7 Conclusion 
This systematic review shows that among 507,637 patients with T2DM, five common clinical 
variables are associated with significantly increased risk of incident HF in T2DM. 
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2.8 Postscript 
In this chapter, we have used a systematic review and meta-analysis to identify clinical, 
laboratory and echocardiographic predictors of incident HF in T2DM. The overall results of 
this meta-analysis showed that among patients with T2DM, 5 common clinical variables are 
associated with significantly increased risk of incident HF. The combination of these risks may 
be estimated for HF prediction in T2DM – a step that would be critical for effective HF 
screening. 
As mentioned previously, numerous studies showed that intervention would be of benefit in 
the early stages of ischemic HF, but no evidence is available regarding early stage non-ischemic 
HF. It is also unclear as to whether CAD is a contributor to subclinical LV dysfunction, 
although previous studies in patients with DM have shown few positive stress test results and 
even fewer positive coronary angios. Therefore, we hypothesised that new echocardiographic 
measures – including strain imaging - can permit the recognition of asymptomatic early stage 
HF and permit the initiation of therapy that will reduce the development of HF. 
In the forthcoming chapter, I will introduce the Tasmanian Study of Echocardiographic 
detection of Left ventricular dysfunction (Tas-ELF study), which integrates clinical and 
echocardiographic screening to permit early treatment of subclinical HF in the Tasmanian 
community. The next chapter will describe the study design and methodology that have been 
used in this study. The findings in the remainder of this thesis have been derived from this 
study.  
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2.9 Appendix 
Appendix 2.1 Assessments - Newcastle-Ottawa Quality Assessment Scale. 
Author Study(Trial) 
01_Represen
tativeness of 
the exposed 
cohort 
02_Selection 
of the non 
exposed 
cohort 
03_Ascerta
inment of 
exposure 
04_Outcome 
demonstratio
n at start 
05_Compara
bility 
06_Assessm
ent of 
outcome 
07_Follow-up 
length long 
enough for 
outcome to occur 
08_Follow-up 
adequacy 
Total☆ 
Stratton, I; Adler, A UKPDS ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ 8 
Gerstein, H HOPE study ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ 8 
Iribarren, C; Karter, A KPMCP ☆ ☆ ☆ ☆ ☆ ☆  ☆ 7 
Nichols, G KPNW ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ 8 
Delea, T U.S. PIOD ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ 8 
Vaur, L DIABHYCAR study ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ 8 
Rajagopalan, R PMPCD ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ 8 
Maru, S; Filion,K U.K. GPRD ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ 8 
Barzilay, J; Banerjee, D CHS study ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ 8 
Held, C 
ONTARGET/TRANSCE
ND ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ 8 
Erdmann, E; Pfister, R PROactive study ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ 8 
Lipscombe, L.L et al ODBP ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ 8 
Yang, X. et al HKDR ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ 8 
McAlister, F; Leung, A SHD study ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ 8 
Cheung, N; Pazin-
Filho, A. 
ARIC study ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ 8 
From, A. M. et al Olmsted County Study ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ 8 
Simone, G.et al Strong Heart Study ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ 8 
Komajda, M. et al RECORD clinical trial ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ 8 
Toprani, A. et al VISN 16   ☆ ☆ ☆ ☆ ☆ ☆ 6 
Lind, M; Glogner, S SNDR ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ 8 
Ebong, I. A. et al MESA ☆ ☆ ☆ ☆ ☆ ☆ ☆ ☆ 8 
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01_Selection: No☆ is given to a)men or women only cohort; b) with age selection; c) with diabetes duration selection 
05_Comparability: No☆ is given if not adjusted for confounders or without subgroup analysis         
07_Follow-up length: No☆ is given if <24 months     
08_Follow-up adequacy: No☆ is given if number of lost >20% or without description of those lost 
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Appendix 2.2 Frequency of risk variables reported 
  
Frequency   
n  % 
KPN
W  
PROac
tive  
U.K.
GPR
D  
U.S. 
PIO
D 
VISN 
16  
HK
DR 
DIABH
YCAR  
Olmsted 
County 
study 
RECO
RD  
SHD MESA  
KP
MC
P  
ARI
C  
SND
R 
UKP
DS 
Strong 
Heart 
Study  
ONTARG
ET/TRAN
SCEND 
CHS 
PMPC
D 
ODB
P 
HOPE  
Age 11 53% * * * * * * * * * *   *                   
HbA1c 9 43% * *     * * *         * * * *             
TZDs(Rosigtzone,
Pioglitazone) 
8 38% * *P 
*T,P
,R 
* *       
*R+M/
S 
    *               *   
Hypertension 7 33% *   * *     * * *             *           
BMI 6 29% *   *   *       *         *   *           
Systolic blood 
pressure 
5 24% *       * *     *           *             
Insulin use 5 24% *   *     *           *             *     
Albuminuria 4 19% *           *   *                       * 
History of 
vascular disease 
4 19%   * * * *                                 
History of 
atherosclerotic 
disease 
4 19%     * *    * *                           
Sulfonyurea 3 14% *   *             *                       
Diabetes duration 3 14% * *       *                               
Metformin 3 14% *   *   *                                 
Gender 2 10%                   *   *                   
Smoking 2 10%     *       *                             
Serum creatinine 2 10% * *                                       
TG 2 10%         *           *                     
LDL cholesterol 2 10%   *     *                                 
Antidiabeic oral 
agents 
2 10% *   *                                     
Prior MI 2 10%   * *                                     
Diastolic blood 
pressure 
1 5% *                                         
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Fasting plasma 
glucose 
1 5%                                 * *       
Fating insulin 1 5%                                   *       
HDL-C 1 5%                     *                     
HDL-C or 
TC/HDL-C ratio 
1 5%                     *                     
Non HDL-C 1 5%                     *                     
Beta-blockers 1 5%                   *                       
Diuretic use 1 5%   *                                       
Nitrates use 1 5%                   *                       
Diabetic 
retinopathy 
1 5%                         *                 
ECG signs                                               
    heart rate 1 5%   *                                       
    cQT-interval 1 5%   *                                       
    bundle branch 
blocks 
1 5%   *                                       
Echocardiographi
c signs 
                                              
    E/e' 1 5%               *                           
    Ejection 
Fraction 
1 5%               *                           
    Left ventricular         
mass index 
1 5%               *                           
History of 
ischemic heart 
disease 
1 5% *                                         
Stroke 1 5%       *                                   
Neurological 1 5%       *                                   
Cardiac 
arrhythmias 
1 5%       *                                   
ESRD 1 5% *                                         
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Appendix 2.3 Forest plot 
Age (per 5 years) (Hazard Ratio – Adjusted)  
 
 
Male Gender (Relative Risk –unadjusted) 
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Male Gender (Hazard Ratio – adjusted) 
 
 
BMI (per 1 unit) (Hazard Ratio – adjusted)
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Current Smoker (Relative Risk – unadjusted) 
 
 
Hypertension (Relative Risk– unadjusted) 
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Hypertension (Hazard Ratio – adjusted) 
 
 
 
 
HbA1c (per 1%) (Hazard ratio – unadjusted) 
 
 
 
Chapter 2- Prediction of HF in T2DM 
  49 
 
HbA1c (per 1%) (Hazard ratio – adjusted) 
 
 
HbA1c (6.0-7.0%) (Hazard Ratio – adjusted) 
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HbA1c (7.0-8.0%) (Hazard Ratio – adjusted) 
 
 
HbA1c (8.0-9.0%) (Hazard Ratio – adjusted) 
 
 
HbA1c (9.0-10%) (Hazard Ratio – adjusted) 
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HbA1c (≥10%) (Hazard Ratio – adjusted) 
 
 
 
Insulin use (Relative Risk- unadjusted) 
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Insulin use (Hazard Ratio - adjusted) 
 
 
Metformin (Hazard Ratio - adjusted) 
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TZDs (Hazard Ratio – adjusted)  
 
 
Sulfonylurea (Hazard Ratio – unadjusted) 
 
 
Sulfonylurea (Hazard Ratio – adjusted) 
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β-blocker (Relative Risk – unadjusted) 
 
 
 
ACE-inhibitors (Relative Risk – unadjusted) 
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Calcium-channel blockers (Relative Risk – unadjusted) 
 
 
Diuretics (Relative Risk – unadjusted) 
 
 
 
Coronary heart disease (Hazard Ratio – adjusted) 
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History of peripheral vascular disease (Relative Risk – unadjusted) 
 
 
 
History of vascular disease (Hazard Ratio – adjusted) 
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History of stroke (relative risk – unadjusted) 
 
 
 
Fasting Glucose (1 SD increase) (Hazard Ratio - adjusted) 
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Appendix 2.4 Funnel plot 
1) Funnel plot: age. The size of the data marker represents the weight of each trial. 
 
Egger’s P-value= 0.42 
2) Funnel plot: BMI. The size of the data marker represents the weight of each trial. 
 
Egger’s P-value= 0.40 
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3) Funnel plot: hypertension. The size of the data marker represents the weight of each 
trial. 
 
Egger’s P-value= 0.92 
4) Funnel plot: insulin use. The size of the data marker represents the weight of each 
trial. 
 
Egger’s P-value= 0.29 
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5) Funnel plot: smoking. The size of the data marker represents the weight of each trial. 
 
 
Egger’s P-value= 0.86 
6) Funnel plot: male gender. The size of the data marker represents the weight of each 
trial. 
 
Egger’s P-value= 0.68 
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7) Funnel plot: cardiac protective medication. The size of the data marker represents 
the weight of each trial. 
 
Egger’s P-value= 0.33 
8) Funnel plot: HbA1c. The size of the data marker represents the weight of each trial. 
 
Egger’s P-value= 0.13
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Chapter 3. Methodology 
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3.1 Preface 
The research reported in this thesis is derived from the data collected on participants in the 
Tasmanian Study of Echocardiographic detection of Left ventricular dysfunction (Tas-ELF 
study). This chapter provides the study design, research rationale and the measurements used 
in this study. The specific details of each study are described in following chapters. 
3.2Subjects 
The Tasmanian Study of Echocardiographic detection of Left ventricular dysfunction was a 
prospective, randomized, open, blinded, end-point (PROBE) designed trial. The aim of this 
project was to reduce incident HF in the Tasmanian community, through implementation of a 
screening program for cardiac dysfunction and the use of cardio-protective therapy to limit 
the development of HF. Self-referred patients with at least one of the following risk factors 
for HF and aged≥ 65 years old from a community-based population in Tasmania were enrolled. 
The risk factors are T2DM, overweight, hypertension, family history of HF, cardiotoxin 
exposure and known cardiac disease (but not existing HF). Patients with symptoms of HF or 
existing HF or known ischaemic heart disease (CABG and/or AMI with regional scar) were 
excluded, as were patients with more than moderate valve disease, a history of HF and LV 
ejection fraction (LVEF) <40%, or life expectancy <12 months. In addition, as strain imaging 
was a requirement to assess subclinical cardiac dysfunction, patients with inability to acquire 
adequate echocardiographic images for speckle tracking imaging analysis at baseline were 
excluded. The target number of patients was 800 and the length of this study was 12 months 
for recruitment and 24 months for follow-up.   
An overview of the study flow chart, updated to January 2017 is shown in Figure 3.1. Among 
1,026 potentially eligible community participants volunteering for assessment, 378 were 
excluded due to failure to meet clinical inclusion criteria and 30 participants were excluded 
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after baseline echo screening, leaving 618 participants were included in the baseline analysis. 
After 2-years of follow-up, 4 participants lost contact and 39 participants were alive but unable 
to attend follow-up. Therefore the follow-up study was conducted in 576 remaining 
participants.  
Among 618 patients included at baseline analysis, 310 (50%) had T2DM, 272 (44%) had 
obesity, 488 (79%) had hypertension, 229 (37%) had family history of HF, 74 (12%) had past 
chemotherapy, 52 (8%) had past heart disease. Among 310 patients with T2DM, 153 (49%) 
also had obesity, 236 (76%) had hypertension, 97 (31%) had family history of HF, 30 (24%) 
had past chemotherapy, and 22 (7%) had past heart disease. Among the non-diabetes group, 
hypertension was the most common risk factor, followed by family history of HF. Patients 
with past heart disease and cardiac sequelae of oncology management made up a relatively 
small percentage of the whole population and non-diabetic group.  
The present thesis describes the subgroup of patients with T2DM. In the TasELF study, there 
were 310 T2DM patients were eligible for baseline analysis and 290 for follow-up analysis.  
3.3 Clinical evaluation 
 
3.3.1 Anthropometrics 
Demographic characteristics, disease history, lifestyle factors, family history and medication 
use was collected using a standardized questionnaire. The questionnaire is provided in 
Appendix 11.1. Body weight was measured to nearest 0.1 in kilograms and height was 
measured to nearest 0.01 metres, both with shoes off.  Body mass index (BMI) was calculated 
as weight in kilograms divided by height in metres squared. In addition to standardised weight 
and height measurements, waist circumference (WC) was measured with a tape measure to the 
nearest millimeter at the midpoint between the lower costal margin and the iliac crest by a 
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trained examiner. Supine resting blood pressure (BP) was measured twice and averaged in each 
patient after at least 5 minutes’ rest. 
Figure 3.1 Flow chart of study inclusion. 
 
3.3.2 Questionnaires 
EQ-5D questionnaire. The EuroQol-5 Dimensions (EQ-5D) questionnaire was used to assess 
the current general health status. The first part consists of five dimensions: mobility, self-care, 
usual activities, pain or discomfort and anxiety or depression. There are five levels of each 
dimension: 1) no problems; 2) slight problems; 3) some problems; 4) severe problems; 5) 
extreme problems. The second part EQ-5D visual analog scale (EQ-5D-VAS)  is used as a 
quantitative measure of health status on a 20cm vertical with 0 to 100 points scale representing 
the ‘worst imaginable health state’ and ‘best imaginable health state’ 138. 
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DASI questionnaire. The Duke Activity Status Index Questionnaire (DASI) assessed the 
functional capacity of patients and the scores from DASI are expressed in metabolic 
equivalents (METs) which could be used to get a rough estimate of a patient’s peak oxygen 
uptake. The questionnaire includes 12 items focused on daily activities such as personal care, 
ambulation, household tasks, sexual function and recreation with respective metabolic costs139. 
Each item had two answers - ‘yes’ and ‘no’ and each ‘yes’ corresponded to different values.  
The final value of DASI score (between 0 to 58.2 points)was obtained by adding all performed 
scores together – the highest score represents better functional capacity.  
PHQ-9 questionnaire. The Patient Depression Questionnaire-9 (PHQ-9) was used to score for 
common mental disorders which scores each of the nine Diagnostic and Statistical Manual of 
Mental Disorders (DSM-IV) criteria as "0" (not at all) to "3" (nearly every day) 140, 141. The 
total value of PHQ-9 score ranged from 0 (no depression) to 27(severe depression)138.  
All questionnaires used in the TasELF study are provided in Appendix 11.2. 
3.3.3 Six-minute walk test (6MWT) 
The six-minute walk test (6MWT) was conducted on a hard, flat 25-metre track to test the 
distance an individual is able to walk as far as possible over a total of six minutes. Patients 
were allowed to self-pace as needed as they traversed back and forth along the straight marked 
pathway 142.It was ensured that patients walked the same course on each re-test. At the end of 
the test, the total distance walked was recorded.  
3.3.4 Echocardiographic evaluation 
A comprehensive echocardiogram including standard transthoracic 2D,  Doppler 
echocardiographic studies and speckle tracking echocardiogram (STE) using sensitive systolic 
and diastolic function parameters was performed using the same ultrasound machine (Siemens 
ACUSON SC2000, 4V1c and 4Z1c probes, Siemens Healthcare, Mountain View, CA) in 
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accordance with the American Society of Echocardiography guidelines 143, 144. Images were 
saved in raw data format and analysed offline. LV internal dimensions and wall thickness, 
chamber volumes and valvular morphology were assessed. LV mass index (LVMi) was 
obtained from LV mass measurement using standard criteria and normalised for body surface 
area. LV hypertrophy (LVH) was defined as LVMi>115 g/m2 in men and >95 g/m2 in women. 
LVEF measurement was used the modified Simpson’s biplane method. LV inflow was 
obtained using pulsed wave Doppler in the apical 4-chamber view; peak early (E) and late (A) 
diastolic velocities, deceleration time (DT) and E/A ratio were assessed. Peak early diastolic 
medial and lateral mitral annular velocity (e’) and the ratio of mitral inflow early diastolic 
velocity to average e’ velocity were obtained from pulsed-wave tissue Doppler and assessed at 
septal and lateral mitral annuli and averaged for calculation for E/e’; E/e’>13 was used as an 
indicator of diastolic dysfunction. For deformation analysis, standard grayscale 2-dimensional 
images were acquired in conventional 4-chamber, 2-chamber, 3-chamber, parasternal short-
axis views at the mid, basal, and apical level. Global longitudinal strain (GLS) was calculated 
by average of three apical views using standard software. Although muscle shortening during a 
cardiac cycle is described as a negative number, for computational simplicity (and because there were 
no positive GLS), we express GLS in this thesis without this information in this thesis. Thus, GLS<18% 
was considered consistent with LV dysfunction 73, 74 while<18% was considered as impaired 
GLS. 
3.3.5 Outcomes 
The primary endpoint for the study was new-onset of HF and all-cause mortality. During the 
follow-up period, potential HF symptoms and signs were assessed through regular phone calls, 
followed by symptom surveillance questionnaires and clinical visits. Records of all-cause 
hospitalisation were obtained and collected. Suspicious HF symptoms and signs were reviewed 
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by three independent cardiologists. The diagnosis of HF was established according to 
Framingham heart failure criteria4.  
3.4 Ethical consideration 
All participants provided written, informed consent prior to enrolment in the study, and all 
procedures in the TasELF study were approved by the Tasmanian Human Research Ethics 
Committee. 
3.5 Data analysis 
Descriptive data are presented as mean ± standard deviation (SD) and dichotomous data as 
subject number and percentage. Comparisons between the groups were performed by 
independent samples t test or analysis of variance (ANOVA) as appropriate; the Kruskal-Wallis 
test was used for comparison of non-normally distributed variables. Linear or logistic 
regression was used to assess associations between one or more interested independent 
variables and dependent variables and reported as Relative Risk (RR) or Odds Ratio (OR) and 
95% confidential intervals (CIs). Cox regression analysis was used in order to identify the 
strongest predictors of outcome among clinical, demographic, echocardiographic variables and 
other interested factors and reported as hazards ratio (HR) and 95% CIs. Analyses were 
performed with standard statistical computer software (SPSS 22, IBM, Chicago, IL); p<0.05 
was deemed to be statistically significant. Non-normally distributed variables were normalised 
based on the Box-Cox transformation technique using STATA software (Stata/IC 12.1, 
StataCorp LP, Plano, TX, USA). 
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Chapter 4. Association of Insulin Resistance with Impaired 
Functional Capacity in T2DM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Published in part in10: 
 Wang Y, Yang H, Nolan M, Negishi K, Burgess J, Marwick TH. Association of waist 
circumference with impaired six-minute walk in type 2 diabetes mellitus is independent 
of cardiac function. J Diabetes Complications. 2016.  
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4.1 Preface 
Clinical and observational studies have determined that impaired functional capacity is a 
powerful predictor of cardiac and all-cause of death in patients with T2DM. Exercise 
intolerance assessed by six-minute walk test (6MWT)was commonly observed in patients with 
T2DM in the TasELF study. Diabetic patients often complain of limited exercise capacity with 
fatigue and although these symptoms may be due to other conditions such as coronary artery 
disease or hypertensive heart disease, the presence of diabetes itself is independently associated 
with limited functional capacity145. LV dysfunction is associated with impaired exercise 
capacity and adverse cardiac outcome in T2DM, but the causes of exercise intolerance in 
T2DM are not clearly understood. As insulin resistance (IR), which is linked to waist 
circumference (WC), is a characteristic feature of HF pathophysiology that affects prognosis, 
we hypothesised that insulin resistance might be a contributor to reduced functional capacity. 
We tested the hypothesis that WC is associated with the distance of 6MWT independently and 
incrementally to clinical, biochemical, therapeutic and echo variables in T2DM without overt 
HF. 
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4.2 Abstract 
Subclinical left ventricular dysfunction has been associated with impaired exercise capacityin 
type 2 diabetes mellitus. In this community-based study of 274 asymptomatic T2DM patients 
(71±4 years, 55% men) with preserved ejection fraction, a comprehensive resting 
echocardiogram was performed to gather sensitive systolic and diastolic function parameters 
(including speckle tracking echocardiography), and a standard six-minute walk test was 
performed. Tertiles of increasing waist circumference were associated with worsening walk 
distance. In this community-based study, we found an association of waist circumference with 
impaired exercise capacity, independent of age, gender, diabetes duration, insulin and 
angiotensin blockade, LV mass, systolic and diastolic function. 
Impaired exercise capacity is a powerful and independent predictor of increased risk of cardiac 
events in type 2 diabetes mellitus (T2DM)146. The mechanism of impaired exercise capacity is 
unclear, but appears to be associated with the presence of diabetes145, as well as left ventricular 
(LV) dysfunction147, 148. LV ventricular dysfunction is common in T2DM; most of these 
patients lack symptoms of heart failure, and ejection fraction is preserved, so it is often 
described as “subclinical”. As insulin resistance (IR) is linked to waist circumference (WC)149, 
150 as well as subclinical LV dysfunction, we sought whether the LV dysfunction was 
independently associated with impaired exercise capacity. 
4.3 Patients and methods 
We prospectively recruited 274 asymptomatic T2DM patients (71±4y, 55% men) with 
preserved ejection fraction from a community-based population. These patients were aged ≥65 
years with ejection fraction ≥55% and without moderate or worse valve disease, history of 
heart failure and inability to acquire adequate echocardiographic images (Table 4.1). In 
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addition to standardized weight and height measurements, waist circumference (WC) was 
measured with a tape measure to the nearest millimeter at the midpoint between the lower 
costal margin and the iliac crest by a trained examiner. The age, gender, disease and family 
history of HF and medication use were obtained using a standardized questionnaire. Supine 
resting blood pressure (BP) was measured twice and averaged in each patient after at least 5 
minutes rest. The EuroQol-5 Dimensions [EQ5D] questionnaire was used to assess the current 
general health status. A six-minute walk test (6MWT) was performed in a 25m indoor corridor 
with a hard, flat surface to test the greatest distance an individual was able to walk over a total 
of six minutes 142. A comprehensive resting echocardiogram including speckle tracking 
echocardiography (STE) using sensitive systolic and diastolic function parameters was 
performed using the same ultrasound machine (SC200, Siemens, Mountain View, CA). Global 
longitudinal strain (GLS) was calculated by average of three apical views using standard 
software, and<18% was considered consistent with LV dysfunction151, 152. The study protocol 
was approved by the Tasmanian Human Research Ethics Committee, and all participants 
provided written consent. 
4.4 Results 
The baseline characteristics of the subjects are shown in Table 4.1.The mean 6MW distance 
(6MWD) was 451±106m (ranging from 100~667m) and mean WC was 103.9cm±13.4 (ranging 
from 70~155cm). Tertiles of increasing WC were associated with worsening 6MWD 
(1st:471±97m; 2nd:469±99m; 3rd:408±116m; p<0.001). In a univariable linear regression 
(Table 4.1), demographics, body habitus, diabetes duration, hypertension, insulin use and 
diastolic function parameters were associated with 6MWD. Age, gender, diabetes duration, 
systolic BP, EQ-5D score, insulin use, ARB use, E/e’ ratio, LVMi, GLS and WC were entered 
into multivariable regression models, guided by clinical judgment and absence of colinearity. 
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WC was associated with reduced exercise capacity, independent of age, gender, diabetes 
duration, insulin and ARB use, E/e’ ratio, LVMi1.7 and GLS (model R2=0.37). The association 
of clinical variables (age, sex, diabetes duration, insulin and ARB use) were not improved by 
adding E/e’ (p=0.82), LVMi (p=0.01) or GLS (p=0.83), but significantly increased by adding 
WC (p<0.01) (Table 4.2).  
Table 4.1 Clinical and echocardiography characteristics and their univariable association with 
6MW distance. 
Variables Mean±SD (n=274) R2 β(95%CI) P value 
Age(years) 71±4 0.07 -6.6(-4.5,-3.8) <0.01 
Male Gender (n, %) 150(54.7) 0.04 45.5(20.2,70.8) <0.01 
Body Mass Index(kg/m2) 30.6±6 0.19 -7.9(-9.9,-6.0) <0.01 
Diabetes Duration(years) 11±9 0.05 -2.6(-4.3,-1.0) <0.01 
Waist(cm) 103.9±13.4 0.14 -2.9(-3.9,-2.1) <0.01 
Hip(cm) 107.6±12.5 0.26 -4.3(-5.2,-3.5) <0.01 
Waist-Hip-Ratio 0.97±0.08 0.02 187(25.1,348.3) 0.02 
Resting Heart Rate(n/min) 69±11 0.01 -0.7(-1.8,0.4) 0.19 
Systolic BP(mmHg) 138±15 0.01 -0.7(-1.5,0.2) 0.11 
Diastolic BP(mmHg) 81±10 0.05 2.4(1.1,3.7) <0.01 
Hypertension (n, %) 209(76.3) 0.01 -43.9(93.1,5.2) 0.08 
Past chemotherapy(n, %) 22(8) 0.01 -38.7(-84.9,7.5) 0.10 
Family history of HF(n, %) 85(31) 0.00 2.6(-25.2,30.4) 0.85 
Insulin (n, %) 65(23.7) 0.07 -68.7(-97.8,-39.6) <0.01 
Metformin (n, %) 184(67.2) 0.00 14.7(-12.6,42.0) 0.29 
ACE Inhibitor (n, %) 98(35.8) 0.00 6.4(-20.5,33.2) 0.64 
Beta-Blocker (n, %) 13(4.7) 0.01 42.9(-17.4,103.2) 0.16 
Calcium Antagonists (n, %) 76(27.7) 0.01 -19.5(-48.2,9.1) 0.18 
Angiotensin II Receptor Blocker (ARB) (n, %) 108(39.4) 0.01 -25.8(-51.9,0.4) 0.05 
Diuretic (n, %) 30(10.9) 0.01 -34.0(-75.0,7.0) 0.10 
Lip Lowering medication (n, %) 201(73.4) 0.00 15.1(-13.9,44.1) 0.31 
EQ-5D score 7±2 0.00 -0.6(-6.2,5.1) 0.85 
Echocardiography        
Mitral early-diastolic inflow velocity (E wave) (m/s) 0.66±0.17 0.06 -152.0(-224.3,-79.8) <0.01 
Mitral late-diastolic inflow velocity (A wave) (m/s) 0.84±0.20 0.04 -105.3(-171.9,-38.9) <0.01 
E/A ratio 0.79±0.21 0.01 -45.8(-109.1,17.6) 0.16 
Mitral valve deceleration time (ms) 248.2±52.9 0.01 0.2(-0.1,0.4) 0.41 
Early diastolic mitral annular velocity (e') (m/s) 0.08±0.02 0.00 -158.5(-952.8,635.7) 0.70 
Average E/e’ ratio (E/e’) 9.28±2.74 0.03 -7.1(-11.7,-2.6) <0.01 
LA maximal volume index (ml/m2) 32.0±10.04 0.00 -0.01(-1.4,1.2) 0.85 
LV mass index (g/m2) 92.4±24.4 0.00 -0.1(-0.6,0.4) 0.71 
LV mass index (g/m1.7) 74.7±22.1 0.02 -0.7(-1.3,-0.2) 0.01 
LV ejection fraction (%) 62.9±6.7 0.00 -0.3(-2.2,1.6) 0.75 
GLS (%) -17.6±2.7 0.00 -0.8(-5.7,4.0) 0.74 
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Table 4.2. A summary of regression models (dependent variable: 6MWD) 
*Normalization of left ventricular mass by height1.7 
4.5 Discussion 
In this study of T2DM patients with preserved ejection fraction (arbitrarily designed on the 
basis of EF >55%), T2DM patients had shorter 6MWT than those published in healthy subjects 
(mean distance range 514~588).153 The results also confirm the presence of resting diastolic 
dysfunction in T2DM154, 155. The major finding was that, on average, 6MWT in T2DM was 
reduced by 2.9 meters for every additional cm of WC. The association of WC with exercise 
capacity in T2DM was independent and incremental to diastolic dysfunction and other 
echocardiographic parameters and clinical and other demographic factors (age, sex, BMI, 
diabetes duration and medication use). This study confirms this finding with submaximal 
testing (6MW). The practical measurement of WC provides a simple tool to predict 6MWT 
that could be used to assess physical function, clinical condition and prognosis in 
cardiovascular diseases. 
This study has confirmed the presence of resting diastolic dysfunction in a large proportion of 
apparently healthy individuals with T2DM. While 6MW distances in T2D are below the 25th 
percentile of published controls of similar age,10 WC predicts 6MW, independent of changes 
in cardiac function. Thus, a simple measurement of WC can inform clinical practice, by leading 
to a heightened attention to functional capacity. 
Model Adjusted R2 R2 change P value 
Age + male gender + diabetes duration + SBP + EQ-5D score 0.18   
Age + male gender + diabetes duration + SBP + EQ-5D score 
+ Insulin + ARB 
0.23 0.06 <0.01 
Age + male gender + diabetes duration + SBP + EQ-5D score 
+ Insulin + ARB + E/e’ + LVMi* + GLS 
0.25 0.02 0.20 
Age + male gender + diabetes duration + SBP + EQ-5D score 
+ Insulin + ARB + E/e’ + GLS + LVMi* + WC 
0.37 0.12 <0.01 
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4.7 Conclusion 
WC is an independent and incremental predictor of exercise capacity over clinical and echo 
information in asymptomatic patients with T2DM. 
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4.6 Postscript 
This chapter focused on characterizing the relationship of clinical parameters, including state 
of deformation imaging and exercise function assessed by 6MWT, provided the clinical 
relevant finding that WC(a marker of IR)is a strong predictor of 6MWD. This finding was 
derived from a cross-sectional analysis of baseline data in the TasELF study. Whether baseline 
6MWD and WC could predict the development of HF in the present cohort after 2-year follow-
up was not determined. Accordingly, the next chapter addresses the incidence of HF and all-
cause mortality in this cohort and the predictors of the endpoint. 
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Chapter 5. Subclinical LV Dysfunction, Function Capacity, 
Quality of Life and Outcomes in Stage A Heart Failure 
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 Wang Y, Yang H, Nolan M, Pathan F, Negishi K, Marwick TH. Variations in 
Subclinical LV Dysfunction, Functional Capacity and Clinical Outcomes in Different 
Heart Failure Aetiologies. ESC Heart Failure. 2017 
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5.1 Preface 
The early detection and prevention of symptomatic HF remains a major goal of cardiovascular 
research as the prevalence of HF is still increasing. In recognition of this concept, the American 
Heart Association and American College of Cardiology proposed the concept of HF stages to 
emphasize the progressive pathophysiology of HF – from risk factors to asymptomatic changes 
in cardiac function and structure to symptomatic HF to overt HF, disability and death. 
Longitudinal community studies are necessary to clarify the rate of progression through 
asymptomatic stage A to stage B HF, in order to define strategies for prevention of HF 
progression. Among the stage A HF risk factors listed in ACC/AHA guidelines, diabetes is one 
of the strongest risk factors, independent of hypertension and atherosclerosis. However, in the 
context of limited resources, the relative merit of screening in the context of diabetes and other 
risk factors has not been determined. In the following chapter, we seek to address this by better 
understanding the prevalence of stage B HF, functional capacity, quality of life and clinical 
outcomes among stage A HF of different aetiologies. 
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5.2 Abstract 
Background. Patients with heart failure (HF) risk factors are described as being in stage A of 
this condition (SAHF). Management is directed towards prevention of HF progression, but to 
date, no evidence has been described to align the intensity of this intervention to HF risk. We 
sought to what extent SAHF of type 2 diabetes mellitus (T2DM) and other HF risks showed 
differences in subclinical LV function, exercise capacity and prognosis.  
Methods. We recruited 551 elder asymptomatic SAHF patients (age 71±5 y, 49% men, 290 
T2DM) with at least one risk factor from a community-based population with preserved 
ejection fraction. All underwent a comprehensive echocardiogram including global 
longitudinal strain (GLS) and a six-minute walk test (6MWT) and were followed for 2 years. 
The primary endpoints were new-onset HF and all-cause mortality. 
Results. The T2DM group was associated with reduced 6MW distance (451±111 vs 493±87m, 
p<0.001), worse diastolic function (E/e’ 9.2±2.7 vs 8.7±2.4, p=0.028) and impaired GLS (-
17.7±2.6 vs -19.0±2.6%, p<0.001). Over a median follow-up of 1.6 years, 49 T2DM-SAHF 
and 27 other-SAHF met the primary endpoint. T2DM-SAHF had significantly worse outcome 
than other-SAHF (p=0.021). In Cox models, obesity (HR=2.46; p=0.007), atrial fibrillation 
(AF) (HR=2.39; p=0.028), 6MWD (HR=0.99; p=0.034) and GLS (HR=1.14; p=0.033) were 
independently associated with the primary endpoint in T2DM-SAHF, independent of age and 
glycemic control.  
Conclusions. T2DM-SAHF has worse subclinical LV function, exercise capacity and 
prognosis than other-SAHF. Impaired GLS, AF, exercise capacity and obesity are associated 
with a worse prognosis in T2DM-SAHF but not in other-SAHF.  
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5.3 Background 
The current ACC/AHA heart failure guidelines define Stage A heart failure (SAHF) as existing 
in subjects with risk factors for heart failure (HF), in the absence of structural heart disease or 
symptoms 156.  These risk factors include obesity, hypertension, atherosclerosis, diabetes 
mellitus (DM), exposure to cardiotoxins and family history of HF, and they may be present in 
up to a third of subjects aged ≥45 years. The natural history of SAHF is that patients may 
progress to functional or structural abnormalities without symptoms (stage B, SBHF), clinical 
manifestations of HF (stage C) and eventually, refractory or end-stage HF (stage D) 8, 157. The 
identification of HF risk should stimulate efforts to identify SBHF, as therapeutic interventions 
in this setting may prevent the development of clinical HF and improve prognosis 8, 157. 
However, an effective screening strategy necessitates an understanding of underlying risk158.  
A recent systematic review of the relative risk of a large range of HF risk factors, showed that 
type 2 diabetes mellitus (T2DM) had nearly double the risk of incident HF while the risk with 
hypertension was relatively lower 159. The frequency of HF in patients with DM is even higher 
among elderly subjects 7. The presence of T2DM adversely affects the prognosis of patients 
with HF, with contributions from coronary heart disease (CAD), diabetic cardiomyopathy, and 
hypertension 160, 161. Even in the absence of ischemic heart disease, T2DM is over-represented 
in HF 24. We hypothesized that non-ischemic SAHF due to T2DM would have more subclinical 
left ventricular (LV) dysfunction, and worse functional capacity and clinical outcomes, 
compared with other SAHF. This finding might justify a more aggressive stance towards 
screening for SBHF in T2DM. 
5.4 Methods 
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5.4.1 Patient selection. 
We prospectively recruited 551 asymptomatic patients aged ≥65 years, with preserved ejection 
fraction but at least one stage A risk factor for HF (DM, obesity, hypertension, known cardiac 
disease), from a community-based population in Tasmania. Patients with existing HF or known 
ischemic heart disease were excluded, as were patients with more than moderate valve disease, 
history of heart failure, LV ejection fraction (LVEF) <40%, inability to acquire adequate 
echocardiographic images for speckle tracking imaging analysis at baseline were excluded 
from recruitment. All participants provided written, informed consent, and the study protocol 
was approved by the Tasmanian Human Research Ethics Committee. 
5.4.2 Clinical features. 
T2DM was based on self-report of diagnosis including medication. Obesity was defined as 
body mass index (BMI) ≥30 kg/m2. Demographics, disease and family history and medication 
use were obtained using a standardized questionnaire. BMI was calculated as weight in 
kilograms divided by height in meters squared. In addition to standardized weight and height 
measurements, waist circumference (WC) was measured with a tape measure to the nearest 
millimetre at the midpoint between the lower costal margin and the iliac crest by a trained 
examiner. Supine resting blood pressure (BP) was measured twice and averaged in each patient 
after at least 10 minutes rest in a quiet room. Active hypertension was defined by   averaged 
systolic blood pressure (BP) ≥140 mmHg or a diastolic BP≥90 mmHg 162.International 
Federation of Clinical Chemistry (IFCC) standardized hemoglobin A1c (HbA1c) (cut-off 64 
mmol/mol) level, estimated Glomerular Filtration Rate (eGFR) and creatinine were obtained 
from local pathology records. Missing values for HbA1c, eGFR and creatinine were estimated 
by imputation using linear regression.  
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5.4.3 Six-minute walk test. 
The six-minute walk test (6MWT) was performed by traversing back and forth along a marked 
pathway on a hard, flat surface, to test the distance an individual was able to walk over a total 
of six minutes. Patients were allowed to self-pace, and the test was performed using a 
standardized protocol142. 
5.4.4 Echocardiography. 
A comprehensive echocardiogram including standard transthoracic 2D,  Doppler 
echocardiographic studies and speckle tracking echocardiogram (STE) using sensitive systolic 
and diastolic function parameters was performed using the same ultrasound machine (Siemens 
ACUSON SC2000, 4V1c and 4Z1c probes, Siemens Healthcare, Mountain View, CA) in 
accordance with the American Society of Echocardiography guidelines 143, 144. Images were 
saved in raw data format and analysed offline. LV internal dimensions and wall thickness, 
chamber volumes and valvular morphology were assessed. LV mass index (LVMi) was 
obtained from LV mass measurement using standard criteria and normalized for body size 
(body surface area or height to the power of 1.7). LVEF measurement was used the modified 
Simpson’s biplane method. LV inflow was obtained using pulsed wave Doppler in the apical 
4-chamber view; peak early (E) and late (A) diastolic velocities, deceleration time (DT) and 
E/A ratio were assessed. Peak early diastolic medial and lateral mitral annular velocity (e’) and 
the ratio of mitral inflow early diastolic velocity to average e’ velocity were obtained from 
pulsed tissue Doppler; E/e’>13 was used as an indicator of diastolic dysfunction. For 
deformation analysis, standard grayscale 2-dimensional images were acquired in conventional 
4-chamber, 2-chamber, 3-chamber, parasternal short-axis views at the mid, basal, and apical 
level. Global longitudinal strain (GLS) was calculated by average of three apical views using 
standard software and <18% was considered consistent with LV dysfunction 73, 74.  
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5.4.5 Outcomes. 
Potential HF symptoms were assessed through regular follow-up phone calls, followed by 
symptom surveillance questionnaires and clinical visits. Records of all-cause hospitalization 
were obtained and collected. Suspicious heart failure symptoms and signs were reviewed by 
three independent cardiologists. The diagnosis of heart failure was established according to 
Framingham heart failure criteria4. The primary endpoint for study was new-onset of HF and 
all-cause mortality. 
5.4.6 Statistical Analysis. 
Descriptive data are presented as mean ± standard deviation (SD) and dichotomous data as 
subject number and percentage. Comparisons between the groups were performed by 
independent samples t test; the Kruskal-Wallis test was used for comparison of non-normally 
distributed variables. Univariable Cox regression was used in order to identify the predictors 
with the primary endpoint among clinical, demographic and echocardiographic variables. 
Multivariable Cox proportional hazards model was performed to determine the independent 
predictors and reported as hazard ratio (HR) with 95% confidence interval (95%CI), guided by 
univariable analyses. Analyses were performed with standard statistical computer software 
(SPSS 22, IBM, Chicago, IL); p<0.05 was deemed to be statistically significant.  
5.5 Results 
5.5.1 Patient characteristics. 
All 551 SAHF patients (age 71±5 years, 49% male) were eligible for inclusion in the final 
analysis. T2DM was present in 290 subjects (53%). The clinical and demographic 
characteristics of the SAHF patients according to T2DM status are listed in Table 5.1. T2DM-
SAHF was characterized by more obesity as well as central obesity, higher heart rate, and lower 
diastolic blood pressure. The 6MW distance (6MWD) was significantly lower in T2DM-SAHF 
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patients compared with other-SAHF patients (451±111 vs 493±87m, p<0.001). Among T2DM-
SAHF patients, 24% patients were treated with insulin and 68% with metformin. The mean 
HbA1c level is 53.7±10.3mmol/mol with 13% had impaired HbA1c level (>64mmol/mol); For 
eGFR, 14 % patients had eGFR>90 mL/min/1.73 m2, 71% had eGRF 60~90 mL/min/1.73 m2 
and 15% had eGFR<60 mL/min/1.73 m2; The mean creatinine value was 92±21 umol/L.  
Table 5.1 Demographic and clinical characteristics of the SAHF population according to 
T2DM status. 
 T2DM-SAHF(n=290) Other-SAHF(n=261) P value 
Age (years) 71±4.4 71±5.1 0.877 
Male gender (n, %) 163(56.2) 106(40.6) <0.001 
Weight (kg) 86.2±17.1 79.7±15.4 <0.001 
Height (cm) 168.4±9.9 166.6±9.4 0.027 
BMI ((kg/m2) 30.4±5.9 28.6±4.7 <0.001 
Waist circumference (cm) 103.7±13.3 96.8±13.7 <0.001 
Obesity (n, %) 142(49.0) 108(41.4) 0.074 
Heart rate (n/min) 69±11 66±11 0.001 
Systolic blood pressure (mmHg) 139±15 141±18 0.143 
Diastolic blood pressure (mmHg) 81±10 83±11 0.021 
Hypertension (n, %) 222(76.6) 231(88.5) <0.001 
Active hypertension (n, %) 143(49.3) 132(50.6) 0.767 
Past heart disease (n, %) 20(6.9) 24(9.2) 0.321 
Family history of HF (n, %) 90(31.0) 115(44.1) 0.002 
Past chemotherapy (n, %) 24(8.3) 25(9.6) 0.592 
Atrial fibrillation (n, %) 29(10) 18(6.9) 0.224 
6MWD (m) 451±111 493±87 <0.001 
Biomarker    
HbA1c (mmol/mol) 53.7±10.3     -         - 
Impaired HbA1c (>64mmol/mol) 38(13.1)     -         - 
eGRR     
    >90 mL/min/1.73 m2 41(14.1)     -         - 
    60~90 mL/min/1.73 m2 207(71.4)     -         - 
    <60 mL/min/1.73 m2 42(14.5)     -         - 
Creatinine (µmol/L) 91.8±21.4     -         - 
Medication    
Insulin 69(23.8)     -         - 
Metformin 196(67.6)     -         - 
ACEi /ARB (n, %) 201(69.3) 190(72.8) 0.368 
Beta-blockers (n, %) 16(5.5) 13(5.0) 0.778 
Calcium antagonists (n, %) 68(23.4) 68(26.1) 0.108 
Diuretics (n, %) 33(11.4) 42(16.1) 0.479 
Lipid lowering meds (n, %) 148(51.0) 149(57.1) 0.155 
Abbreviation: ACEI, Angiotensin-Converting-Enzyme Inhibitor; ARB, Angiotensin II Receptor Blocker. 
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5.5.2 Echocardiographic characteristics. 
Table 5.2 shows the echocardiographic characteristics between T2DM-SAHF and the 
remaining SAHF group. Overall, the mean EF was 63±6% (range 40-80%) and only 2% and 
1% had EF within 40~50% in T2DM-SAHF and other-SAHF patients respectively. Average 
GLS was -18.4±2.7% (range -10.4% to 26.0%). T2DM-SAHF had higher E/e’ ratio, higher 
LVMi and worse GLS than the other-SAHF group. The T2DM group was associated with 
worse diastolic function (E/e’ 9.2±2.7 vs 8.7±2.4, p=0.028) as well as impaired GLS (-17.7±2.6 
vs -19.0±2.6%, p<0.001). T2DM-SAHF also had a much higher prevalence abnormal GLS (50% 
vs 28%, p<0.001) and abnormal E/e’ (10% vs 5%, p=0.011).  
Table 5.2 Echocardiographic characteristics of the SAHF population according to T2DM 
status. 
 
T2DM-SAHF 
(n=290) 
Other-SAHF 
(n=261) 
P value 
LV ejection fraction (%) 62.9±6.5 63.9±5.5 0.048 
    40 - 50% 5(1.7) 3(1.1)  
>50% 285(98.3) 258(98.9)  
Mitral early-diastolic inflow velocity 
(E wave) (m/s) 
0.65±0.17 0.63±0.15 0.057 
Mitral late-diastolic inflow velocity 
(A wave) (m/s) 
0.83±0.19 0.78±0.17 0.001 
Early-to-late peak diastolic 
transmitral flow velocity ratio (E/A) 
0.80±0.21 0.82±0.23 0.167 
Early diastolic mitral annular 
velocity (e') (m/s) 
0.08±0.02 0.08±0.02 0.306 
Average E/e’ ratio (E/e’) 9.2±2.7 8.7±2.4 0.028 
E/e’ ratio >13 (n, %) 30(10.3) 12(4.6) 0.011 
Deceleration time(DT) (s) 246.4±52.4 242.8±49.4 0.414 
LV mass index (g/m2) 92.4±23.8 92.7±22.1 0.912 
LVH/LVMi 167(57.6) 179(68.6) 0.009 
GLS (%) -17.7±2.6 -19.0±2.6 <0.001 
GLS<18% (n, %) 146(50.3) 74(28.4) <0.001 
   Abbreviation: LVH, left ventricular hypertrophy 
In order to determine the incremental impact of T2DM on subclinical systolic and diastolic 
function over hypertension, Table 5.3 lists echocardiographic parameter comparisons between 
patients with isolated active hypertension (HT-SAHF) and patients with both active 
hypertension and T2DM (HT+T2DM-SAHF). HT+T2DM-SAHF had worse GLS than HT-
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SAHF group. HT+T2DM -SAHF also had a much higher prevalence of abnormal GLS (52% 
vs 30%, p<0.001).  
Table 5.3 Echocardiographic characteristics of the SAHF population according to T2DM and 
hypertension status. 
*HT-SAHF: Patients had active hypertension without diabetes **Patients had both T2DM and active 
hypertension. 
5.5.3 Follow-up. 
Over a median follow-up period of 1.6±0.6 years (range 0.6-3.2 years), 49 (16.9%) T2DM-
SAHF and 27 (10.3%) other-SAHF met the primary endpoint of new-onset of HF and all-cause 
mortality. On examination of individual components of the primary endpoint, 46 T2DM-SAHF 
and 24 other-SAHF developed HF, and 3 T2DM-SAHF and 3 other-SAHF died. In the entire 
cohort, the annualized event rate of HF and all-cause of mortality was 8.8% - varying from 
11.2% in T2DM-SAHF to 6.4% in other-SAHF. 
Stepwise nested Cox models were constructed to determine the predictors of primary outcome 
in SAHF patients with and without T2DM. Hazard ratios (HRs) of the primary outcome from 
univariable and multivariable analyses are listed in Table 5.4 Significant variables from 
univariable analyses were entered into the final age- and sex-adjusted model. Among T2DM-
 
HT-SAHF* 
(n=132) 
HT+T2DM-SAHF** 
(n=143) 
P value 
LV ejection fraction (%) 63.6±5.6 62.7±6.9 0.247 
Mitral early-diastolic inflow velocity 
(E wave) (m/s) 
0.61±0.15 0.67±0.17 0.008 
Mitral late-diastolic inflow velocity (A 
wave) (m/s) 
0.80±0.16 0.85±0.20 0.016 
Early-to-late peak diastolic transmitral 
flow velocity ratio (E/A) 
0.78±0.19 0.79±0.23 0.513 
Early diastolic mitral annular velocity 
(e') (m/s) 
0.07±0.02 0.08±0.02 0.220 
Average E/e’ ratio (E/e’) 9.0±2.5 9.4±2.8 0.185 
E/e’ ratio >13 (n, %) 8(6.1) 18(12.6) 0.065 
Deceleration time(DT) (s) 247.5±49.7 246.5±52.1 0.882 
LV mass index (g/m2) 93.4±21.5 95.1±25.1 0.547 
LVH/LVMi 41(31.1) 44(30.8) 0.989 
GLS (%) -19.1±2.4 -17.7±2.5 <0.001 
GLS<18% (n, %) 39(29.5) 74(51.7) <0.001 
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SAHF patients, obesity (HR=2.46 [1.28 to 4.70]; p=0.007), AF (HR=2.39 [1.10 to 5.22]; 
p=0.028), 6MWD (HR=0.99 [0.99 to 1.00]; p=0.034) and GLS (HR=1.14 [1.01 to 1.30]; 
p=0.033) were independently associated with the primary endpoint after adjustment for age, 
gender and glycemic control. In the other-SAHF cohort, history of heart disease (HR=2.97 
[1.19 to 7.4]; p=0.019) was predictive after adjustment for age (HR=1.08 [1.01 to 1.15]; 
p=0.022) and gender. 
Kaplan-Meier survival curves were constructed for the primary endpoint, with log-rank testing 
for significance between strata. Among the whole cohort, T2DM-SAHF had significantly 
worse outcome than other-SAHF (χ2=5.36; p=0.021; Figure 5.1). Subclinical LV systolic 
dysfunction (LVSD) (defined as GLS<18%) was predictive of primary outcome (HF and all-
cause of mortality) in T2DM-SAHF in Kaplan-Meier analysis (χ2=6.75; p=0.009; Figure 5.2a).  
However, there was no statistically significant difference in survival when comparing other-
SAHF with or without LVSD (χ2=2.68; p=0.101; Figure 5.2b). There were significantly more 
events in T2DM-SAHF with obesity compared to those without (χ2=11.86; p=0.001; Figure 
5.3a), but there were no differences when other-SAHF were divided by obesity (χ2=0.09; 
p=0.770; Figure 5.3b). In T2DM-SAHF patients, the most serious prognosis pertained  to those 
with impaired GLS or obesity. However, as shown in Figure 5.4, in other-SAHF individuals, 
the most serious prognosis was seen in those with history of heart disease (χ2=12.49; p<0.001).  
5.6 Discussion 
In these data from a prospectively-enrolled cohort, we examined the prevalence of subclinical 
LV dysfunction, impaired exercise capacity and prognosis in a community-based population 
with HF risk factors. The results suggest that SAHF due to T2DM has a worse 
echocardiographic manifestation, functional capacity and clinical outcome than other-SAHF. 
This work builds on previous reports of an association between increasing HF stage and worse 
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functional status and prognosis,163 by adding evidence about clinical features and functional 
capacity within the early asymptomatic phases of HF.  
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Table 5.4 Prognostic value of baseline clinical and echocardiographic characteristics over time. 
 
Unadjusted  Adjusted 
T2DM-SAHF Other-SAHF 
T2DM-SAHF 
(Chi-square=54.7) 
Other-SAHF 
(Chi-square=25.8) 
 
 HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI) 
P 
value 
Age 1.06(0.99,1.12) 0.070 1.10(1.04,1.17) 0.002 1.02(0.96,1.09) 0.455 1.08(1.01,1.15) 0.022 
Male gender 1.58(0.87,2.86) 0.136 1.47(0.69,3.13) 0.319 1.02(0.51,2.04) 0.946 1.51(0.65,3.51) 0.654 
BMI 1.10(1.06,1.14) <0.001 0.98(0.90,1.07) 0.651     
Waist 1.05(1.03,1.08) <0.001 1.01(0.98,1.04) 0.548     
Heart rate 1.00(0.97,1.03) 0.856 0.98(0.95,1.02) 0.412     
Systolic blood pressure 1.00(0.98,1.02) 0.861 1.00(0.98,1.02) 0.776     
Diastolic blood pressure 1.00(0.99,1.03) 0.811 1.01(0.97,1.04) 0.732     
History of heart disease 1.93(0.82,4.56) 0.131 3.95(1.73,9.03) 0.001   2.97(1.19,7.4) 0.019 
Obesity 2.77(1.51,5.10) 0.001 1.12(0.52,2.42) 0.771 2.46(1.28,4.70) 0.007   
Active hypertension 1.05(0.60,1.84) 0.866 0.87(0.41,1.85) 0.712     
Past chemotherapy  1.34(0.53,3.39) 0.537 1.01(0.24,4.28) 0.987     
Family history of HF 0.62(0.32,1.21) 0.164 0.78(0.36,1.70) 0.525     
Atrial fibrillation 3.96(2.06,7.63) <0.001 2.22(0.77,6.44) 0.141 2.39(1.10,5.22) 0.028   
Dyslipidaemia 1.48(0.83,2.65) 0.187 1.14(0.54,2.45) 0.728     
Beta-blocker 2.89(1.23,6.81) 0.015 1.39(0.33,5.87) 0.654     
ACEi/ARB 1.37(0.71,2.63) 0.343 1.00(0.42,2.37) 0.998     
Insulin 1.57(0.86,2.86) 0.140 - -     
Metformin 0.89(0.50,1.59) 0.688 - -     
6MWD 0.996(0.994,0.999) 0.003 0.995(0.990,0.999) 0.010 0.997(0.995,1.000) 0.034 0.99(0.99,1.00) 0.237 
Biomarker         
HbA1c 1.03(1.01,1.05) 0.008 - - 1.01(0.99,1.04) 0.283   
HbA1c>64mmol/mol  2.83(1.52,5.27) 0.001 - -     
eGRR  0.67(0.40,1.12) 0.666 - -     
Creatinine (µmol/L) 1.01(1.01,1.02) 0.065 - -     
Echocardiography         
GLS 1.27(1.15,1.41) <0.001 1.17(1.03,1.32) 0.016 1.14(1.01,1.30) 0.033 1.04(0.90,1.20) 0.586 
GLS<18% 2.13(1.18,3.84) 0.012 1.87(0.87,4.04) 0.109     
E/e’ 1.06(0.96,1.17) 0.251 1.08(0.93,1.25) 0.295     
E/e’ ratio >13 1.35(0.58,3.18) 0.489 0.84(0.11,6.16) 0.860     
LVMi 1.03(1.01,1.04) <0.001 1.02(1.00,1.04) 0.052 1.01(0.99,1.02) 0.087    
LVH/ LVMi 3.52(2.00,6.18) <0.001 1.02(0.45,2.32) 0.969     
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Figure 5.1 Comparison of primary outcomes between patients with T2DM-SAHF and other-
SAHF. SAHF patients with T2DM had significantly worse outcome than those without T2DM.  
 
No. at risk                    
Other-SAHF               261                 251                     242                    234                234  
T2DM-SAHF             290                 267                     250                    244                241 
Figure 5.2 Prognostic implications of T2MD-SAHF and other-SAHF and the role of left 
ventricular systolic dysfunction.  
 
No. at risk in T2DM-SAHF                                   
Without LVSD             144                       136               130                127                127  
With LVSD                  146                       131               120                117                114  
(a) 
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No. at risk in other-SAHF                                      
Without LVSD             187                     183               178                 171               171 
With LVSD                    74                       69                65                   63                 63 
        (b) 
Figure 5.3 Prognostic implications of T2MD-SAHF and other-SAHF and the role of obesity.  
 
No. at risk in T2DM-SAHF                   
Without obesity             148              144                   139               134               133 
With obesity                  142               137                  112               110               108 
           (a) 
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No. at risk in other-SAHF                   
Without obesity             153                 150                140                   137                 137 
With obesity                  108                  106                103                    97                   97 
                                                                                     (b) 
Figure 5.4 Prognostic implications of T2MD-SAHF and other-SAHF and the role of heart 
disease history.  
 
No. at risk in T2DM-SAHF                   
Without HD                   270                   250                  235                230                 227 
With HD                        20                     17                     15                 14 
                                                                                      (a) 
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No. at risk in other-SAHF                   
Without HD                   237                   230                223                  218                  218 
With HD                        24                     22                   20                    16                   16 
                                                                                      (b) 
5.6.1 LV mechanics in Stage A Heart Failure. 
Previous studies have shown that changes of subclinical LV longitudinal systolic and diastolic 
function begin before structural LV changes in asymptomatic patients with HF risk factors 164-
167. However, comparisons of the degree of LV myocardial dysfunction in early diabetic 
cardiomyopathy compared with other-SAHF have not been documented previously. Our 
results show that abnormalities of diastolic function are more common in T2DM than other 
SAHF groups, as are disturbances of LV longitudinal systolic function (GLS:-17.7±2.6% vs -
19.0±2.6%, p<0.001). In the current study, we report that the prevalence of systolic longitudinal 
dysfunction is 50% among community population-based T2DM-SAHF and 28% among other 
SAHF. Alterations of systolic strain may exist despite normal diastolic function 88. Importantly, 
impaired GLS as a marker of stage B HF is associated with an increased risk of further 
transition to symptomatic stage C HF with preserved EF in diabetes 157. However, in real life 
few asymptomatic SAHF patients have done tests of cardiac morphology and functions. It 
Chapter 5 – Subclinical LVD, function capacity, QoL and outcomes in SAHF 
  94 
 
seems like many of them develop into stage C/D directly without receiving a diagnosis of 
SBHF. Indeed, many SBHF ‘hide’ in SAHF and our results highlight the importance of 
identifying potential SBHF using echocardiogram among SAHF cohorts for preventing further 
transition.  
These findings highlight the fact that the severity of the early LV function impairment is not 
necessarily analogous within different aetiologies of SAHF. Despite rigorous adjustment for 
covariables, each unit decrement of GLS in subjects with T2DM showed a 1.14 fold-higher 
risk of HF and mortality, whereas in subjects with other risks, the predictive value of GLS was 
not found. The worse LV function in T2DM-SAHF may be attributable to diabetic 
complications and associated co-morbidities as well as the presence of a distinct diabetic 
cardiomyopathy.158, 164 The pathogenesis of the latter is complex and likely multifactorial, 
involving cardiac autonomic neuropathy, altered myocardial metabolism, small and large 
vessel damage, insulin resistance and myocardial fibrosis 164. Additionally, in our study patients 
with active hypertension showed relatively preserved GLS, but a combined group with active 
hypertension and T2DM had more abnormal GLS (-19.1±2.4% vs -17.7±2.5%, p<0.001; Table 
5.3), as well as a higher prevalence of abnormal GLS than in T2DM without hypertension (52% 
vs 30%). Although hypertension and T2DM are the two leading aetiologies of early HF, 
impaired GLS is more likely due to diabetic cardiomyopathy than hypertensive heart disease 
168.  
5.6.2 Functional capacity in Stage A Heart Failure. 
In this study, functional capacity at submaximal stress was assessed using 6MWT is a simple, 
safe test of functional capacity that is a well-established diagnostic procedure in cardiovascular 
and pulmonary disease, which has prognostic value 169. A systematic review 170 that is 
performed via 8 database to investigate the reliability between 6MWT and other methods to 
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assess functional capacity defined as peak VO2 level in patients with chronic HF showed that 
6MWT has moderate to good ability to predict VO2 level, good reliability and a significant 
ability to predict functional capacity in those patients particularly in patients who do not walk 
more than 490 meters. Compared with healthy controls, patients with T2DM have lower 
6MWD 171. The results of this study show that, compared with other-SAHF, functional capacity 
was more impaired in T2DM-SAHF.  
The determinants of functional capacity are complex and depend on both psychological and 
physical factors. Although it might be considered that the association of T2DM with functional 
capacity could be driven by obesity– and indeed, advanced age and obesity had strong 
associations with functional capacity - our results suggest that the association of T2DM with 
functional capacity was independent of these features. Subclinical cardiac dysfunction, which 
is often present in both T2DM-SAHF and other-SAHF, could influence functional capacity but 
cannot fully explain the difference of exercise capacity between the two SAHF subgroups. 
Previous work has shown that exercise intolerance in T2DM is independent of obesity and even 
presents with good glycemic control and without clinically apparent cardiovascular disease 172. 
The presence of endothelial dysfunction, decreased myocardial perfusion, decreased muscle 
mitochondrial function, abnormal tissue haemoglobin oxygen saturation and insulin resistance 
may be mediators in the relationship between diabetic oxidative dysfunction and defects in 
functional capacity 172. In addition, good evidence was found that in diabetes both components 
of the autonomic nervous system dysfunction - cardiac sympathetic and cardiac 
parasympathetic nervous system dysfunction is involved 173. Vagal tone inhibits and 
subsequent sympathetic activates immediately after onset of exercise, while parasympathetic 
activates followed by sympathetic inhibition when recovery starts. Parasympathetic control 
may be weakened by persistent hyperglycemia that may also enhance sympathetic 
activity174.Heart rate recovery is associated with vagal tone and T2DM is associated with poor 
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heart rate recovery and chronotropic incompetence175. However, this association in diabetes is 
only found when subjects have both poor physique and autonomic dysfunction175. Previous 
research have shown that cardiac autonomic dysfunction is associated with reduced cardiac 
output response to functional capacity in diabetes, which is probably due to hemodynamic 
instability during exercise 176. Left atrial (LA) dysfunction is also common in patients with 
heart failure with preserved EF and asymptomatic T2DM and contributes to exercise 
intolerance, however, data on the specific influence of diabetes contributing to LA dysfunction 
is limited. LA enlargement in diabetes is an independent predictor of LA dysfunction, probably 
due to a combination of diastolic dysfunction and diabetic atrial myopathy 177. 
5.6.3 Prognosis in Stage A Heart Failure. 
Despite current epidemiological evidence of the greater risk of development of HF in patients 
with diabetes, the natural history of asymptomatic subjects at risk of HF remains poorly 
identified 178, 179.  This study extends present knowledge about the prognosis of the entire SAHF 
cohort in 2 years, based on a community (as opposed to a clinic-based) population. In the entire 
SAHF cohort, the annualized event rate of incident HF and all-cause of mortality was 8.8%. 
The rate in T2DM-SAHF (11.2%) was almost twice that of other-SAHF (6.4%).  
T2DM was associated with more serious outcome, irrespective of whether or not other risk 
factors were present. A recent systematic review of 15 observational studies indicated that 
diabetes (HR=2.0) showed the strongest predictive value for incident HF among the non-
ischaemic SAHF risks, followed by hypertension (HR=1.61) and BMI (per 5kg/m2) (HR=1.15) 
159. In patients with T2DM in the present study, the prognosis was associated with obesity, 
exercise capacity and abnormal GLS independent of glycemic control and renal function. 
Among patients with T2DM, poor glycemic control and related hyperglycemia may be 
associated with the process of developing HF, however, the association between intensive 
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glycemic control and the reduction of cardiovascular complications still remains controversial 
180. Although a large cohort study reported an HbA1c≥10%, relative to HbA1c<7% was 
associated with 1.6 fold risk of incident HF in diabetes, several large clinical trials reported no 
significant benefit for primary cardiovascular events with intensive glycemic control 180. The 
interpretation of our finding is poor glycemic control (HbA1c>64mmol/mol) may not be a 
marker of composite endpoint (HF and all-cause of death) in this elderly asymptomatic diabetes 
cohort. We found a negative association between renal function and outcomes in T2DM-SAHF. 
Previous research showed that reduced eGFR is a risk factor of cardiovascular events and death 
in diabetes patients without advanced renal disease, but the risks are small when considering 
other risk factors181. Although in our study the association is negative, it still has important 
implication to require further research with longer follow-up to examine the impact of sub-
clinical renal dysfunction in patients with diabetes. AF is a strong risk factor for HF. In our 
study the presence of AF shows independent association with increased risk of new-onset of 
HF and all-cause of mortality in T2DM-SAHF but not in other-SAHF. The result is not entirely 
consistent with the recent systematic review and meta-analysis that included 15 cohort studies 
and reported AF seems to predict myocardial infarction, HF and all-cause of mortality 182. The 
inconsistent result in other-SHAF cohort may due to the relatively low prevalence of AF (7%) 
and the exclusion of ischemic heart disease at baseline. 
Although the staging system serves as a reminder to clinicians of the importance of early 
detection and prevention of patients at risks of transitioning to higher stages of HF, these results 
highlight the notion that SAHF associated with diabetes is clinically different from other cause 
of SAHF, and perhaps should have different targets for prevention. These findings have 
important implications for awareness and identification of high-risk individuals and optimal 
management to prevent or delay progression to adverse outcome in SAHF.  
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5.6.4 Limitation. 
The population of the present study was selected from the community, based on the presence 
of at least one known non-ischemic HF risk factor and excluding patients with known HF or 
established asymptomatic LV systolic dysfunction. This limits external validity to the primary 
prevention group. In addition, the prevalence of T2DM is relatively high in this SAHF 
population as in order to acquire sample size that adequate to better justify the hypothesis of 
this study, we had pooled a bigger number of diabetic patients into the present study. The high 
proportion of patients with diabetes in the study population means relatively low classification 
rates within other-SAHF risks and smaller pool sizes. Consequently the study lost a lot of 
information about the clinical heterogeneity between each SAHF group that underlines the 
need for identifying high – risk among the SAHF cohort. In other words, if each SAHF risk 
factor were equally represented in the sample, we may be able to explore the differences among 
different risk groups in more detail and obtain more information about the long-term outcomes 
in each group.T1DM were excluded from our study due to the different mechanism of affecting 
the heart from T2DM. We did not record circumferential and radial strain, which would have 
provided additional details about myocardial mechanics, although longitudinal strain is the 
most robust of these myocardial deformation parameters. Additionally, we do not have data on 
biomarkers, which may also be used as a potential predictor of HF and adverse outcome. Their 
absence may have weakened the ability to predict HF. Moreover, different biomarkers may 
play different roles in T2DM-SAHF and other-SAHF, and provide evidence of the differences 
between two SAHF groups and be potential targets of interventions. 
5.7 Conclusion. 
In this community cohort of patients with HF risks, T2DM-SAHF had worse subclinical LV 
function, functional capacity and adverse outcome than other causes of SAHF. Impaired GLS, 
worse exercise capacity, the presence of obesity or AF were independently associated with 
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prognosis in T2MD-SAHF, whereas a history of heart disease was the driver of subsequent HF 
and mortality in other causes of SAHF. The clinical application of this study provides an 
important caveat that not all types of SAHF are the same. Better targeting of interventions at 
the most vulnerable SAHF group – those with T2DM – seems appropriate. 
5.8 Postscript. 
The results of this study combine data on cross-sectional prevalence with longitudinal 
prognostic data to truly capture the burden of preclinical HF and symptomatic HF in elderly 
individuals in the community. The findings justify our hypothesis that among SAHF patients, 
SAHF due to diabetes is associated with worse prognosis and less well-being. These findings 
underscore the potential benefit of targeting prevention efforts at the T2DM-SAHF group. The 
next chapter will explore how this might be accomplished. 
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Chapter 6. Use of Echocardiographic Markers to Predict 
Heart Failure in T2DM 
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6.1 Preface 
The prevention of HF remains a major goal of cardiovascular research, and diabetes is one of 
the strongest risk factors of incident HF, independent of hypertension and atherosclerosis. A 
number of studies have shown that the presence of asymptomatic LV dysfunction is 
independently associated with the risk of developing HF in diabetes. Treatment strategies of 
more intensive targeting of high-risk but asymptomatic individuals may be an effective way to 
prevent symptomatic HF and future cardiac events in diabetes. Asymptomatic diabetic subjects 
with LV dysfunction (classified as stage B HF) – lie between stage A HF (those with diabetes 
as a HF risk factor) and symptomatic stage C and D HF. Previous studies have demonstrated 
that reduced ejection fraction (EF) as a marker of stage B HF successfully predicts new-onset 
of HF in diabetes. However, although strategies for improving survival have now been 
established for HF patients with reduced EF,183 EF is not a sufficient screening tool to detect 
early myocardial changes in diabetes. This is because HF in diabetes is commonly associated 
with preserved EF. In this chapter, different echocardiographic markers including increased 
LV mass index, left atrial enlargement, LV diastolic dysfunction and impaired global 
longitudinal strain (GLS) were evaluated as potential echocardiographic features of stage B HF 
in T2DM. We hypothesized that GLS would be the optimal echocardiographic feature of stage 
B HF in T2DM for community screening. 
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6.2 Abstract 
Background. Stage B heart failure (SBHF), is a precursor to the development of HF, and its 
recognition justifies initiation of cardioprotective therapy. However, original definitions of 
non-valvular, non-ischemic SBHF was based on LV hypertrophy and impaired ejection 
fraction (EF). We sought whether impaired global longitudinal strain (GLS),LV diastolic 
dysfunction (LVDD) or left atrial enlargement (LAE) should be added to SBHF criteria in 
asymptomatic patients with type 2 diabetes mellitus (T2DM). 
Methods. Asymptomatic T2DM ≥65 years old (age 71±4 y, 55% men) with preserved EF and 
no ischemic heart disease underwent a comprehensive echocardiogram, including assessment 
of LVH, LVE, LVDD(abnormal E/e’) and GLS (<16%), and standard clinical evaluation were 
recruited from a community-based population. Over a median follow-up of 1.5 years (range 
0.5-3), 20 patients were lost to follow-up, and 290 individuals were entered into the final 
analyses.  
Results. The prevalence of SBHF was 10% by LVDD, 23% by LVH, 35% by LAE and 23% 
by impaired GLS. Over a median follow-up of 1.5 years, 45 of 290 patients developed new-
onset HF and 4 died, giving an event rate of 112/1000 person-years. In a competing-risks 
regression analysis that controlled for glycaemic control, LVH (HR=2.90; p<0.001) and 
GLS<16% (HR=2.26; p=0.008), but not LVDD and LAE were associated with incident HF 
and had incremental predictive power to clinical variables. 
Conclusion. Subclinical LV systolic dysfunction is prevalent in asymptomatic elderly patients 
with T2DM, and both LVH and impaired GLS are independent and incremental predictors of 
incident HF.  
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6.3 Background 
Type 2 diabetes mellitus (T2DM) is a potent risk factor for the development of non-ischemic 
heart failure (HF) 157, 158. The development of HF may be preceded by stage B HF (SBHF), 
defined on the basis of valvular disease, evidence of previous infarction, LV hypertrophy and 
impaired ejection fraction (EF) 184. The recognition of this entity is important because cardio-
protective medication may prevent or retard the progression of HF. However, epidemiologic 
studies show that 83% of elderly patients with T2DM and newly diagnosed HF have HF with 
preserved EF (HFpEF) 185, so EF-based criteria seem unsuited to this group. Moreover, LVD 
is highly prevalent in T2DM, with up to half of the patients involved 186. 
Myocardial deformation (strain) may now be readily measured using speckle-tracking 
echocardiography 187. Global longitudinal strain (GLS) is the most robust LV strain parameter, 
which is more sensitive and specific than conventional 2D-EF as a measure of systolic function, 
and can be used to identify subclinical systolic LV dysfunction (LVD) in cardiomyopathies 188. 
Previous studies have has demonstrated that early detection of subclinical LVD by strain 
imaging is independently associated with long-term adverse outcome in asymptomatic patients 
with T2DM 189, 190. However, whether the presence of impaired systolic strain in asymptomatic 
patients with T2DM without reduced EF predicts incident HF is uncertain. We sought whether 
impaired global longitudinal strain (GLS),LV diastolic dysfunction (LVDD) or left atrial 
enlargement (LAE) should be added to SBHF criteria in asymptomatic patients with type 2 
diabetes mellitus (T2DM).  
6.4 Methods 
6.4.1 Patient selection. 
Three-hundred and ten asymptomatic T2DM patients aged ≥65 years with preserved LVEF 
were prospectively recruited from a community-based population in Tasmania from 2013 and 
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2015. The recruitment exclusion criteria were existing HF or known ischemic heart disease, 
more than moderate valve disease, history of  HF or LVEF <40%, and inability to acquire 
adequate echocardiographic images for speckle tracking imaging analysis at baseline.  All 
participants provided written, informed consent, and the study protocol was approved by the 
Tasmanian Human Research Ethics Committee. 
6.4.2 Clinical features. 
The diagnosis ofT2DM was based on self-report including diabetes treatment. Socioeconomic 
status, demographics, medical history, family history and use of medication including diabetes 
treatment were obtained from a baseline survey. Body mass index (BMI) was calculated as 
weight in kilograms divided by height in meters squared and obesity was defined as BMI ≥30 
kg/m2. Waist circumference (WC) was measured to the nearest millimeter by a trained 
examiner using a tape measure at the midpoint between the lower costal margin and the iliac 
crest. Supine resting blood pressure (BP) was measured twice and averaged in each patient 
after at least 10 minutes rest in a quiet room. Hypertension was defined by averaged systolic 
blood pressure (SBP) ≥140 mmHg or a diastolic blood pressure (DBP) ≥90 mmHg . 
International Federation of Clinical Chemistry (IFCC) standardized hemoglobin A1c (cut-off 
64 mmol/mol) level were obtained from local pathology records. Missing values for HbA1c 
were estimated by imputation using linear regression. The ARIC (Atherosclerosis Risk In 
Communities) HF risk scores were used to estimate the absolute risk of HF at 3 years. The 
online ARIC Heart Failure Risk Calculator was used and 10 common clinical variables were 
included (age, gender, race, systolic BP, heart rate, BMI, smoking status, previous coronary 
heart disease, current use of blood pressure-lowering medication and diabetes 80.    
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6.4.3 Echocardiography. 
Patients all underwent a comprehensive echocardiogram including standard transthoracic 2D,  
Doppler echocardiographic studies and speckle tracking echocardiogram (STE) in accordance 
with the American Society of Echocardiography (ASE) guidelines (Siemens ACUSON 
SC2000, 4V1c and 4Z1c probes, Siemens Healthcare, Mountain View, CA) 143, 144. LV internal 
dimensions and wall thickness, chamber volumes and valvular morphology were assessed. 
LVEF measurement was used the modified Simpson’s biplane method. LA volumes were 
calculated using the Simpson biplane method and LA enlargement (LAE) defined as LA 
volume index [LAVi, LA volume indexed to body surface area (BSA)] ≥34 mL/m2143. LV mass 
index (LVMi) was obtained from LV mass measurement using standard criteria and normalized 
for body size [BSA or height to the power of 1.7 or 2.7]. LV hypertrophy (LVH) was defined 
as LVMi (normalized for BSA) >115 g/m2 for men  and >95 g/m2 for women. LV inflow was 
obtained using pulsed wave Doppler in the apical 4-chamber view; peak early (E) and late (A) 
diastolic velocities, deceleration time (DT) and E/A ratio were obtained. Peak early diastolic 
medial and lateral mitral annular velocity (e’) and the ratio of mitral inflow early diastolic 
velocity to average e’ velocity were obtained from pulsed tissue Doppler; E/e’>13 was used as 
a cut-off of LV diastolic dysfunction (LVDD) 154. For deformation imaging, standard grayscale 
2-dimensional images were acquired in conventional 4-chamber, 2-chamber, 3-chamber, 
parasternal short-axis views at the mid, basal, and apical level. Global longitudinal strain (GLS) 
was calculated by average of three apical views using standard software 73, 74. Although in 
deformation analysis, shortening is described as a negative number, for computational 
simplicity (and because there were no positive GLS), we express GLS in this paper without 
this information. Our laboratory uses cut-offs of 16% to designate impaired GLS and 18% to 
designate abnormal GLS, and we evaluated both cut-offs.  
Accordingly, SBHF was defined by; 
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1) Diastolic dysfunction (E/e’ >13); 
2) LA enlargement (LAE>34 mL/m2; 
3) LVH (>115 g/m2 for males, >95 g/m2 for females;  
4) Impaired GLS (cut-off 16%). 
6.4.4 Outcomes. 
Regular phone calls and surveys were performed to identify potential HF symptoms during 
follow-up, and symptom surveillance questionnaires and clinical visits were followed. Records 
of all-cause hospitalization were obtained and collected. Suspicious HF symptoms and signs 
were reviewed by three independent cardiologists. Incident  HF diagnosis was validated 
according to Framingham heart failure criteria 4. The primary composite endpoint for study 
was new-onset of HF and all-cause mortality. The primary endpoint was incident HF, and all-
cause mortality was considered as a competing risk. 
6.4.5 Statistical Analysis. 
Continuous variables are presented as mean ± standard deviation (SD) and categorical data as 
frequencies and percentages. Cox regression models were used to model time to composite 
endpoint and reported as hazard ratio (HR) and 95% confidence interval (95%CI) 191. The 
cumulative survival free of HF incidence and death during the follow-up period was estimated 
using the Kaplan–Meier method and survival curves were compared with the log-rank test.  
Univariable Cox regression was used to assess the predictive power of composite endpoint 
among clinical, demographic, biochemical and echocardiographic variables. Significant 
variables and echocardiographic parameters of interest were selected for entry into multivariate 
analyses to determine independent correlates. To account for the competing risk of all-cause 
death during follow-up, competing risk methods were used to generate hazard ratios (HR) and 
95% confidence intervals (CI) for the associations between each echocardiographic parameter 
and incident HF 191. The cumulative incidences (CIF) of HF were calculated and graphically 
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displayed separately for patients with and without impaired GLS. Gray’s K-sample test was to 
compare the cumulative incidence estimates of HF between patients with and without impaired 
GLS 192. All data were analyzed using standard statistical computer software (SPSS 22, IBM, 
Chicago, IL and Stata, V.12.0, Stata Corp, College Station, Texas, USA); p<0.05 was deemed 
to be statistically significant.  
6.5 Results 
6.5.1 Patient characteristics. 
Of 310 eligible asymptomatic T2DM patients ≥65 years old with preserved EF from the 
community and underwent baseline tests, 2 (0.7%) were lost to follow-up and 18 participants 
(5.8%) were alive but unable to attend for clinic review, after a median follow-up time of 1.5 
years (range 0.5-3 years) (Figure 6.1). This group was no different from the remaining 290 
individuals who completed follow-up (Appendix 6.1). The baseline clinical and 
echocardiographic characteristics of 290 individuals with and without events are summarized 
in Table 6.1.  In the remaining 290 T2DM participants (age 71±4 years, 56% male), the mean 
HbA1c level was 53.7±10.3 mmol/mol. HF risk factors were prevalent among these patients – 
77% had hypertension, 49% had obesity, 31% had family history of HF, 8% had exposure to 
chemotherapy and 7% had history of heart disease.  
Figure 6.1. Flow chart of study inclusion. 
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Table 6.1 Baseline clinical and echocardiographic characteristics of 290 elderly asymptomatic 
patients with T2DM.  
◊ Poor HbA1c, ICFFstd-HbA1c>64mmol/mol;∆ LA enlargement was defined as LA volume>34 mL/m2; *LV hypertrophy was defined as 
LVMi>115 g/m2 for males, >95 g/m2 for females. † The presence of at least one the following: LVH, GLS<18%, E/e’>13, LAE  
Demographic and clinical characteristics  
Age (years) 70.9±4.3 
Male gender (n, %) 163(56.2) 
Weight (kg) 85.9±17.0 
Height (cm) 168.0±10.3 
BMI (kg/m2) 30.3±5.9 
Waist circumference (cm) 103.4±13.0 
HbA1c (mmol/mol) 53.7±10.3 
Poor HbA1c (n, %)◊ 38(13.1) 
Obesity (n, %) 142(49.0) 
Heart rate (n/min) 69±11 
Systolic blood pressure (mmHg) 139±14 
Diastolic blood pressure (mmHg) 81±10 
Hypertension (n, %) 222(76.6) 
Family history of HF (n, %) 90(31.0) 
Past chemotherapy (n, %) 24(8.3) 
Past heart disease (n, %) 20(6.9) 
ARIC HF risk score (3 year) (%) 7.5±6.4 
Medication  
Insulin (n, %) 69(23.8) 
Metformin (n, %) 196(67.6) 
ACEi / ARB (n, %) 201(69.3) 
Beta-blockers (n, %) 16(5.5) 
Calcium antagonists (n, %) 68(23.4) 
Diuretics (n, %) 33(11.4) 
Lipid lowering meds (n, %) 148(51.0) 
Echocardiography  
LV ejection fraction (%) 62.9±6.5 
Mitral early-diastolic inflow velocity (E wave) (m/s) 0.65±0.17 
Mitral late-diastolic inflow velocity (A wave) (m/s) 0.83±0.19 
Transmitral diastolic flow velocity ratio (E/A) 0.80±0.21 
Early diastolic mitral annular velocity (e') (m/s) 0.08±0.02 
Average E/e’ ratio (E/e’) 9.2±2.7 
Deceleration time(DT) (s) 246.4±52.4 
LA volume (mL/m2) 32.3±10.1 
LV mass index (g/m2) 92.4±23.8 
LV mass index (g/m1.7) 74.7±21.4 
LV mass index (g/m2.7) 44.4±12.6 
GLS (%) 17.7±2.6 
Echocardiography categorical variables  
E/e’ ratio >13 (n, %) 30(10.3) 
LA enlargement (n, %) ∆ 102(35.2) 
LV hypertrophy (n, %)* 68(23.4) 
GLS<18% (n, %) 146(50.3) 
GLS<16% (n, %) 68(23.4) 
Presence of any SBHF features (n, %) † 169(58.3) 
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6.5.2 Prevalence of Stage B heart failure. 
The prevalence of conventionally-defined SBHF was 23%, based on the presence of LVH. 
Subclinical LV dysfunction was identified in 10% by abnormal E/e’, 35% by LAE, 50% by 
abnormal GLS (cut-off 18%) and 23 by impaired GLS (cut-off 16%) (Figure 6.2). In the entire 
cohort, 97 (33%) had only one echocardiographic abnormality, 48 (17%) had two, 21 (7%) had 
three and 3 (1%) had four and in total 58% had any feature. The distribution of patients with 
multiple features is shown in Figure 6.3.  
Figure 6.2. Prevalence of SBHF features in elderly asymptomatic patients with T2DM (n=290). More 
than half diabetic patients have abnormal strain (GLS<18%), 23% have impaired strain (GLS<16%) 
and LVH (cut-off >115g/m2 for males, >95 g/m2 for females); LAE (cut-off 34 mL/m) was prevalence 
in 35% subjects and abnormal E/e’ (cut-off 13) was prevalence in 10% subjects.  
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Figure 6.3 Distribution of patients with SBHF features (LVH, LAE, abnormal E/e’ and 
impaired GLS) among elderly asymptomatic patients with T2DM (n=169). 
 
(a) 
 
(b) 
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(c) 
6.5.3 Follow-up. 
Over a median follow-up of 1.5 years, 45 patients developed new-onset HF and 4 died, giving 
an event rate of 112/1000 person-years. Patients who had events we more commonly men, and 
showed greater levels of obesity (especially central obesity), worse glycemic control, higher 
LVMi and LA volume and worse GLS. EF and E/e’ ratio showed no difference between the 
two groups (p=0.096). Of the 49 individuals having events, 82% had any of the 
echocardiographic features. The conventional diagnosis of SBHF was made in 47%, on the 
basis of LVH. In contrast, the diagnosis of subclinical dysfunction was 12% by abnormal E/e’, 
61% by LAE, 65% by GLS <18% and 45% by GLS <16%. 
Survival free of the composite endpoint (HF and death) was about 1.5-fold higher in patients 
without any SBHF feature compared with patients with the presence of any SBHF features 
(Figure 6.4a). The proportion of cumulative event-free survival was less with increasing 
numbers of echocardiographic features of SBHF (Figure 6.4b). 
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Figure 6.4. Comparison of primary outcomes between diabetic patients with (a) and without 
SBHF features. (b)There is decreasing survival rate with increasing numbers of SBHF 
echocardiographic features. 
 
0 SBHF feature                  120                      116                         113                     112                       112                     112 
≥1 SBHF feature                168                      151                         137                     132                       129                     129 
(a) 
 
0 SBHF feature                  119                   115                        112                       111                        111                          111 
1 SBHF feature                  96                       92                         87                         87                           85                             85 
2 SBHF features                47                       43                         37                         34                           34                             34 
≥3 SBHF features              23                       18                         13                         11                           11                             11 
(b)  
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6.5.4 Predictors of the HF and death. 
Cox regression analysis was performed to analyze the association between clinical variables 
and echocardiographic parameters of interest and the time to the primary composite endpoint 
(Table 6.2). Multivariable Cox regression models were constructed to determine whether 
impaired GLS and other echocardiographic SBHF features of interest were associated with 
composite endpoint controlled for ARIC risk score and glycemic control. Significant 
univariable parameters of interest (ARIC risk score, HbA1c >64 mmol/mol, E/e’ >13, LAE, 
LVH and GLS<16%) were entered into the model (Table 6.3). LVH, LAE and GLS<16% were 
associated with increased risk of the composite endpoint, independent of ARIC risk score and 
HbA1c, but abnormal E/e’ was not. Multivariable models were also used to assess the measures 
as continuous variables; LA volume (adjusted HR=1.05, p=0.001) and GLS (adjusted HR=1.16, 
p=0.008) were predictors of the primary endpoint, independent of HbA1c (adjusted HR=1.03, 
p=0.039) (Appendix 6.2). 
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Table 6.2 Baseline clinical and echocardiographic characteristics of patients with T2DM who 
met primary composite outcome. 
 
Event 
(n=49) 
No Event 
(n=241) 
HR (95%CI) p-value 
Demographic and clinical characteristics 
Age (years) 71.9±4.7 70.7±4.2 1.06(0.99,1.12) 0.070 
Male gender (n, %) 33(67.3) 130(53.9) 1.58(0.87,2.86) 0.136 
Weight (kg) 95.4±19.7 84.1±15.7 1.04(1.02,1.05) <0.001 
Height (cm) 169.2±10.4 168.3±9.7 1.01(0.98,1.04) 0.673 
BMI (kg/m2) 33.6±7.7 29.7±5.2 1.10(1.06,1.14) <0.001 
Waist circumference (cm) 110.6±13.5 101.9±12.5 1.05(1.03,1.08) <0.001 
HbA1c (mmol/mol) 57.5±11.6 52.9±9.9 1.03(1.01, 1.05) 0.008 
Poor HbA1c (n, %)◊ 14(28.6) 24(10.0) 2.82(1.52,5.24) 0.001 
Obesity (n, %) 34(69.4) 108(44.8) 2.77(1.51,4.09) 0.001 
Heart rate (n/min) 68±12 69±10 0.99(0.97,1.03) 0.856 
Systolic blood pressure (mmHg) 139±15 139±14 1.00(0.98,1.02) 0.860 
Diastolic blood pressure (mmHg) 81±9 81±10 1.00(0.98,1.03) 0.811 
Hypertension (n, %) 39(79.6) 183(75.9) 1.27(0.63,2.54) 0.505 
Family history of HF (n, %) 11(22.4) 79(32.8) 0.62(0.32,1.21) 0.163 
Past chemotherapy (n, %) 5(10.2) 19(7.9) 1.34(0.53,3.39) 0.536 
Past heart disease (n, %) 6(12.2) 14(5.8) 1.94(0.82,4.56) 0.456 
ARIC HF risk score (3 year) (%) 11.1±8.9 6.8±5.4 1.08(1.05,1.11) <0.001 
Medication     
Insulin (n, %) 16(32.7) 53(22.0) 1.57(0.86,2.86) 0.140 
Metformin (n, %) 31(63.3) 165(68.5) 0.89(0.50,1.59) 0.688 
ACEi / ARB (n, %) 37(75.5) 164(68.4) 1.37(0.72,2.63) 0.344 
Beta-blockers (n, %) 6(12.2) 10(4.1) 2.89(1.23,6.81) 0.015 
Calcium antagonists (n, %) 7(14.3) 61(25.3) 0.50(0.22,1.11) 0.089 
Diuretics (n, %) 6(12.2) 27(11.2) 1.08(0.46,2.54) 0.858 
Lipid lowering meds (n, %) 31(63.3) 117(48.5) 1.48(0.83,2.65) 0.186 
Echocardiography     
LV ejection fraction (%) 61.2±7.9 63.2±6.1 0.95(0.91,0.99) 0.026 
Mitral early-diastolic inflow velocity 
(E wave) (m/s) 
0.69±0.21 0.65±0.16 4.35(0.88,21.44) 0.071 
Mitral late-diastolic inflow velocity (A 
wave) (m/s) 
0.87±0.27 0.82±0.18 2.67(0.62,11.55) 0.190 
Transmitral diastolic flow velocity 
ratio (E/A) 
0.79±0.24 0.80±0.20 0.96(0.20,4.59) 0.960 
Early diastolic mitral annular velocity 
(e') (m/s) 
0.08±0.02 0.08±0.01 1.06(0.89,1.27) 0.502 
Average E/e’ ratio (E/e’) 9.6±3.1 9.1±2.6 1.06(0.96,1.17) 0.251 
Deceleration time(DT) (s) 247.5±57.5 246.1±51.4 1.00(0.99,1.01) 0.757 
LA volume (mL/m2) 38.0±11.5 31.1±9.3 1.06(1.03,1.08) <0.001 
LV mass index (g/m2) 104.0±27.1 90.1±22.5 1.02(1.01,1.03) <0.001 
LV mass index (g/m1.7) 87.0±25.2 72.2±19.7 1.03(1.02,1.04) <0.001 
LV mass index (g/m2.7) 51.6±14.9 42.9±11.6 1.05(1.03,1.07) <0.001 
GLS (%) 16.3±2.9 18.0±2.4 1.27(1.15,1.41) <0.001 
Echocardiography categorical variables 
E/e’ ratio >13 (n, %) 6(12.2) 24(10.0) 1.35(0.58,3.18) 0.488 
LV hypertrophy (n, %)* 23(46.9) 45(18.7) 3.52(2.00,6.18) <0.001 
LA enlargement (n, %)∆ 30(61.2) 72(29.9) 3.29(1.85,5.86) <0.001 
GLS<18% (n, %) 32(65.3) 114(47.3) 2.13(1.18,3.84) 0.012 
GLS<16% (n, %) 22(44.9) 46(19.1) 3.24(1.94,5.69) <0.001 
Any presence of SBHF features (n, %)† 40(81.6) 129(53.5) 4.09(1.62,10.33) 0.003 
◊ Poor HbA1c, ICFFstd-HbA1c>64mmol/mol; 
∆ LA enlargement was defined as LA volume>34 mL/m2; 
*LV hypertrophy was defined as LVMi>115 g/m2 for males, >95 g/m2 for females. 
† The presence of at least one the following: LVH, GLS<18%, E/e’>13, LAE 
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Table 6.3 Independent associations of death and HF in elderly asymptomatic patients with T2DM. Cox regression analysis for primary composite 
endpoint. 
Variable 
Unadjusted 
HR (95%CI) 
P value 
E/e’ Adjusted 
HR(95%CI)* 
P value 
LAE Adjusted 
HR(95%CI)* 
P value 
LVH Adjusted 
HR(95%CI)* 
P value 
GLS Adjusted 
HR(95%CI)* 
P value 
All except LAE. Adjusted 
HR(95%CI)* 
P value 
All except E/e’. Adjusted 
HR(95%CI)* * 
P value 
ARIC HF risk 
score(3 year) 
1.08(1.05,1.11) 
<0.001 
1.08(1.04,1.11) 
<0.001 
1.06(1.03,1.10) 
<0.001 
1.06(1.02,1.09) 
0.001 
1.07(1.04,1.11) 
<0.001 
1.06(1.02,1.10) 
0.002 
1.05(1.01,1.09) 
0.007 
Poor HbA1c 
2.83(1.52,5.27) 
0.001 
2.72(1.45,5.07) 
0.002 
2.79(1.50,5.19) 
0.001 
2.34(1.24,4.40) 
0.008 
2.26(1.20,4.26) 
0.011 
1.97(1.01,3.81) 
0.045 
2.11(1.10,4.04) 
0.025 
Abnormal E/e’ 
1.35(0.58,3.18) 
0.488 
1.11(0.47,2.66) 
0.810 
- - - 
0.86(0.34,2.16) 
0.746 
- 
LAE 
3.29(1.85,5.86) 
<0.001 
- 
2.80(1.55,5.05) 
0.001 
- - - 
2.34(1.27,4.32) 
0.007 
LVH 
3.52(2.00,6.18) 
<0.001 
- - 
2.34(1.26,4.35) 
0.007 
- 
2.04(1.08,3.84) 
0.027 
1.62(0.84,3.14) 
0.149 
Impaired GLS 
3.24(1.84,5.69) 
<0.001 
- - - 
2.67(1.51,4.75) 
0.001 
2.46(1.36,4.45) 
0.003 
2.29(1.26,4.15) 
0.007 
 
Abbreviations: HR=hazard ratio; CI=confidence interval;Poor HbA1c, ICFFstd-HbA1c>64mmol/mol; abnormal E/e’, cutoff 13; LAE, left atrial enlargement, cutoff>34 mL/m2; 
LVH, left ventricular hypertrophy, cutoff >115 g/m2 for males, >95 g/m2 for females; GLS, global longitudinal strain, cutoff -16%. 
* In the multivariate cox model, poor HbA1c, abnormal E/e’, LAE, LVH and impaired GLS were entered into the model. 
* * In the multivariate cox model, poor HbA1c, LAE, LVH and impaired GLS were entered into the model. 
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6.5.5 Prediction of HF. 
A competing risk analysis that controlled for HbA1c was performed to assess whether impaired 
GLS and other echocardiographic SBHF features of interest were associated with incident HF 
in elderly asymptomatic patients with T2DM (Figure 6.5). The baseline model, showing a 
significant effect of poor glycemic control (p=0.009) on incident HF, was improved by LVH 
(p=0.042). However, the addition of impaired GLS (p=0.008) had incremental predictive 
power to biochemical and other echocardiographic SBHF features for the prediction of incident 
HF (Figure 6.5). 
Figure 6.5 Prediction of incident HF in elderly asymptomatic patients with T2DM (competing 
risk analysis). LVH and impaired GLS showed incremental value over glycaemic control for 
incident HF. 
 
 Model 1 Model 2 Model 3 
Chi-square 
P for chi-square 
change 
6.81 
24.42 
P<0.001 
30.30 
P<0.001 
 
HR (95% CI) 
P value 
HR (95% CI) 
P value 
HR (95% CI) 
P value 
Poor HbA1c 
2.37(1.24,4.53) 
0.009 
2.04(1.03,4.05) 
0.042 
1.76(0.86,3.61) 
0.121 
LVH  
3.33(1.87,5.93) 
<0.001 
2.90(1.61,5.25) 
<0.001 
LAE  
1.23(0.69,2.19) 
0.483 
1.29(0.69,2.19) 
0.401 
Abnormal E/e’  
1.49(0.67,3.29) 
0.329 
1.31(0.55,3.08) 
0.541 
Impaired GLS  
 
 
2.26(1.24,4.15) 
0.008 
Abbreviations: HR=hazard ratio; CI=confidence interval; Poor HbA1c, ICFFstd-HbA1c>64mmol/mol; LVH, left 
ventricular hypertrophy, cutoff >115 g/m2 for males, >95 g/m2 for females; LAE, left atrial enlargement, 
cutoff>34 mL/m2;abnormal E/e’, cutoff 13; GLS, global longitudinal strain, cutoff -16%. 
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The cumulative incidence of HF with time among elderly asymptomatic T2DM stratified by 
impaired GLS status is shown in Figure 6.6. By the end of the follow-up, considering the 
competing risk, the cumulative incidence (CIF) of HF was 0.17 in patients with GLS<16% and 
was 0.09 in patients with GLS>16%. Gray’s test also showed that the cumulative incidence 
(CIF) of HF was significantly lower in patients with GLS<16% than those patients with 
GLS>16% (p<0.001). 
Figure 6.6 Cumulative incidence estimates of HF in elderly asymptomatic T2DM stratified by 
patients with and without impaired GLS. 
 
 
6.6 Discussion 
In this prospectively enrolled community-based cohort, poor glycemic control, LVH, LAE and 
GLS<16% were independently associated with new-onset HF and death in elderly 
asymptomatic patients with T2DM who had no evidence of overt LVD. Although previous 
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studies have shown LVD to predict mortality, to our knowledge, this is the first study to show 
that echocardiographic parameters as SBHF markers are useful for screening for new-onset HF 
in asymptomatic patients with T2DM that accounts for all-cause of mortality as a competing 
risk. GLS <16% provides incremental prognostic information in patients with T2DM and 
preserved EF. 
6.6.1 SBHF screening in T2DM. 
T2DM is a risk factor of HF, independent of hypertension, coronary artery disease and other 
potential risk factors 4, 7. The recognition of the pre-clinical stages of HF may permit the 
initiation of cardioprotection for these subjects, but the main functional marker for non-
ischemic SBHF is LVEF. Although readily obtainable, this is not the optimal diagnostic 
parameter, as HFpEF is the most common manifestation of HF in T2DM. GLS is an effective 
means of detecting early changes in myocardial function 193, which is associated with adverse 
cardiac events over long-term follow-up 189, 190.  
A recently-reported cluster analysis of echocardiographic variables in T2DM patients 
identified distinct clinical profiles associated with three different phenotypes 194. The 
phenotype most associated with adverse outcome in this study (LVH with reduced GLS) 
corresponds with one of these groups, and differs from the other two – comprising patients 
with relatively mild dysfunction, and a group with diastolic dysfunction and hypertensive heart 
disease. In our experience, the negative prognostic effect of impaired GLS was most evident 
in patients with GLS<16% - the independent effect of which doubled the risk of HF, and 
provided a 2.4-fold increase in risk of the composite endpoint. As these patients had preserved 
EF at baseline, these results support the use of GLS as a criterion for SBHF in community-
based patients with T2DM. 
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6.6.2 Functional and structural changes in T2DM as indicators of HF. 
Patients with T2DM are at a 1.5-fold increment in risk of LV hypertrophy, independent of 
various confounders including obesity, age and gender 195. This finding is independent of 
hypertension and has been associated with insulin resistance 195. These results were confirmed 
in our study, which showed LVH in 68 patients (23%), and after adjustment for glycemic 
control, LVH by LVMi (indexed by BSA) was superior to biochemical variables in predicting 
incident HF. Although electrocardiography (ECG) is widely available and less expensive than 
echocardiography, it is also less sensitive in detecting LVH in T2DM 196, 197.  
Global longitudinal strain derived from speckle tracking measures the extent of tissue 
deformation as a percentage of the baseline at a longitudinal direction, and it could be used to 
identify sub-clinical LVD in cardiomyopathies. Diabetic cardiomyopathy is defined as LVD 
that is independent of coronary artery disease and hypertension 161, 178. Impaired GLS is 
reported to be highly prevalent even in normotensive asymptomatic T2DM 189, 198. This 
longitudinal dysfunction is due to the complex interaction between metabolic, hemodynamic 
and endocrine abnormalities 190. Limited studies have evaluated its predictive value for adverse 
cardiac events in T2DM.  
E/e’ is an important predictor of cardiovascular events in patients with systolic HF or acute 
coronary syndrome 199, 200.  However, the role of LVDD as a manifestation of diabetic heart 
disease is controversial. Ernande et al reported that GLS was the primary disturbance of T2DM, 
and that LVDD was primarily a consequence of hypertension 186, 189, 194. In a study of 247 
T2DM patients (mean age 60 years) with no history of cardiovascular complications, Liu et al 
showed that the presence of either impaired GLS (<17.9%) or high E/e’ (>13.6) had a predictive 
value of cardiovascular events beyond clinical data 190. However, in a prospective study of 406 
middle-aged patients with DM, diastolic dysfunction (E/e’ ratio >15) was a stronger 
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independent predictor of cardiac death than GLS 201. In contrast, our results showed that GLS 
to be stronger predictor of incident HF than E/e’ ratio. These differences in the reported 
literature are likely to reflect the different contribution of comorbid diseases in different 
populations. 
6.6.3 Limitation. 
The population of the present study has been selected from the community, based on the 
presence of at least one known non-ischemic cardiovascular risk factor and excluding patients 
with a known history of HF or established asymptomatic LV systolic dysfunction. Therefore, 
T2DM patients with established asymptomatic LV systolic dysfunction were excluded. 
Another limitation of the study is that we did not record circumferential and radial strain. 
Although these provide additional information regarding myocardial mechanics, longitudinal 
strain is the most robust and reproducible parameter. Additionally, we did not gather data on 
biomarkers – such as natriuretic peptides - which are potential predictors of HF and adverse 
outcome in T2DM. Finally, recruitment was partly through newspaper advertising, which may 
have resulted in population selection bias. 
6.7 Conclusion. 
Asymptomatic LV systolic dysfunction as an expression of SBHF is highly prevalent in elderly 
asymptomatic patients with T2DM. Impaired GLS (<16%) and LVH (by LVM/BSA) were 
independently associated with incident HF over 2-year follow-up. Importantly, impaired GLS 
adds incremental prognostic value to glycemic control and other conventional 
echocardiographic parameters. The detection of early myocardial dysfunction may allow 
identification of asymptomatic patients with T2DM who are at risk of developing symptomatic 
HF.  
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6.8 Postscript 
Our study shows that in asymptomatic elderly community members with diabetes, GLS is a 
powerful predictor of incident HF, independent of other conventional echo parameters in 
patients with preserved EF. It highlights the importance of performing a comprehensive 
echocardiogram including strain images in asymptomatic patients even with preserved EF. The 
use of GLS to identify high-risk patients for incident HF may lead to changes in follow-up and 
treatment strategies. This study provides new information regarding the use of GLS to predict 
incident HF among T2DM patients. However, the recognition of HF and its progression 
requires more than the evaluation of LV dysfunction with clinical and echocardiographic 
parameters. The influence of depression on the progression of HF in T2DM patients will be 
explored in the next chapter. 
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6.9 Appendix 
Appendix 6.1 Comparison of baseline characteristics between patients who completed follow-
up study (n=290) and patients who loss to follow-up study (n=20). 
Poor HbA1c, ICFFstd-HbA1c>64mmol/mol; LVH, left ventricular hypertrophy, cutoff >115 g/m2 for males, >95 
g/m2 for females; LAE, left atrial enlargement, cutoff>34 mL/m2; abnormal E/e’, cutoff 13; GLS, global 
longitudinal strain, cutoff -16%. 
 
Completed 
n=290 
Loss to FU 
n=20 
P value 
Demographic and clinical characteristics 
Age (years) 70.9±4.3 72±5.1 0.275 
Male gender (n, %) 163(56.2) 8(40.0) 0.159 
Weight (kg) 85.9±17.0 85.7±16.7 0.953 
BMI (kg/m2) 30.3±5.9 31.1±5.6 0.586 
Waist circumference (cm) 103.4±13.0 107.3±15.3 0.213 
HbA1c (mmol/mol) 53.7±10.3 53.9±8.7 0.915 
Poor HbA1c (n, %)◊ 38(13.1) 4(20) 0.364 
Obesity (n, %) 142(49.0) 11(55.0) 0.602 
Heart rate (n/min) 69±11 71±13 0.389 
Systolic blood pressure (mmHg) 139±14 141±23 0.717 
Diastolic blood pressure (mmHg) 81±10 80±10 0.652 
Hypertension (n, %) 222(76.6) 14(70.0) 0.507 
Family history of HF (n, %) 90(31.0) 7(35.0) 0.712 
Past chemotherapy (n, %) 24(8.3) 3(15.0) 0.303 
Past heart disease (n, %) 20(6.9) 2(10.0) 0.602 
Aric risk (3 year) (%) 7.5±6.4 8.2±6.7 0.372 
Medication    
Insulin (n, %) 69(23.8) 5(25.0) 0.127 
Metformin (n, %) 196(67.6) 9(45.0) 0.386 
ACEi / ARB (n, %) 201(69.3) 12(60.0) 0.251 
Beta-blockers (n, %) 16(5.5) 0(0) 0.282 
Calcium antagonists (n, %) 66(23.4) 2(10.0) 0.165 
Diuretics (n, %) 33(11.4) 4(20.0) 0.251 
Lipid lowering meds (n, %) 148(51.0) 10(50.0) 0.929 
Echocardiography    
LV ejection fraction (%) 62.9±6.5 63.0±5.1 0.950 
Mitral early-diastolic inflow velocity (E 
wave) (m/s) 
0.65±0.17 0.74±0.26 0.180 
Mitral late-diastolic inflow velocity (A wave) 
(m/s) 
0.83±0.19 0.88±0.25 0.304 
Transmitral diastolic flow velocity ratio 
(E/A) 
0.80±0.21 0.79±0.28 0.939 
Early diastolic mitral annular velocity (e') 
(m/s) 
0.08±0.02 0.08±0.02 0.442 
Average E/e’ ratio (E/e’) 9.2±2.7 9.8±3.1 0.313 
E/e’ ratio >13 (n, %) 30(10.3) 3(15.0) 0.515 
Deceleration time(DT) (s) 246.4±52.4 244.6±50.7 0.886 
LA volume (mL/m2) 32.3±10.1 34.8±12.2 0.379 
LA enlargement (n, %) ∆ 102(35.2) 10(50) 0.187 
LV mass index (g/m2) 92.4±23.8 89.8±19.0 0.635 
LV mass index (g/m1.7) 74.7±21.4 73.3±17.2 0.772 
LV mass index (g/m2.7) 44.4±12.6 44.0±10.7 0.898 
LV hypertrophy (n, %)* 68(23.4) 3(30.0) 0.513 
GLS (%) 17.7±2.6 16.9±2.9 0.160 
GLS<18% (n, %) 146(50.3) 12(60.0) 0.404 
GLS<16% (n, %) 68(23.4) 7(35.0) 0.244 
Presence of any SBHF features (n, %) † 169(58.3) 13(65.0) 0.555 
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Appendix 6.2 Cox regression analysis for primary composite endpoint in elderly asymptomatic 
patients with T2DM.All covariates were entered as continuous variables. 
Variable 
Unadjusted HR (95%CI) 
P value 
Adjusted HR(95%CI)* 
P value 
HbA1c 
1.03(1.01, 1.05) 
0.008 
1.03(1.00,1.06) 
0.039 
E/e’ ratio 
1.06(0.96,1.17) 
0.251 
1.00(0.91,1.10) 
0.960 
LA volume 
1.06(1.03,1.08) 
<0.001 
1.05(1.02,1.07) 
0.001 
LVMi 
1.02(1.01,1.03) 
<0.001 
1.01(0.99,1.02) 
0.165 
GLS 
1.27(1.15,1.41) 
<0.001 
1.16(1.04,1.30) 
0.008 
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Chapter 7. Association of Depression with Heart Failure in 
T2DM 
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7.1 Preface 
The mechanisms of incident HF risk in T2DM are incompletely understood. While diabetic 
cardiomyopathy is an important potential substrate, the development of HF in T2DM is likely 
to be influenced by a number of other processes, including endothelial dysfunction, 
hyperglycemia, insulin resistance, dyslipidemia and inflammation. One potential risk factor 
that influences these processes is depression.  Depression is highly prevalent in both HF and 
T2DM 202. Depression not only triggers endothelial dysfunction through impaired cellular 
adhesion, migration and proliferation, but also promotes dyslipidemia 203. In this study, we 
explored the association of depression and incident HF in elderly T2DM without any baseline 
cardiovascular symptoms. 
7.2 Abstract 
Background. Depression is a prevalent, independent predictor of mortality in patients with 
heart failure (HF).Depression is also common in type 2 diabetes mellitus (T2DM), which is 
itself an important risk factor for HF. However, association of depression with incident HF in 
T2DM is undefined. The aim of the present study was to evaluate the predictive value of 
depression in predicting incident HF in a community-based cohort of asymptomatic patients 
with T2DM. 
Methods. We prospectively recruited 274 asymptomatic T2DM patients ≥65 years (age 71±4 
y, 56% men) with preserved EF and no ischemic heart disease from a community-based 
population. The patient Health Questionnaire 9 (PHQ-9) was used to detect depression, and 
LV dysfunction was sought with a comprehensive echocardiogram, including LV hypertrophy 
(LVH) and subclinical diastolic function (E/e’). Over a median follow-up of 1.5 years (range 
0.5-3), 20 patients were lost to follow-up and 254 individuals were followed for outcomes. 
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Results. At baseline, depression was present in 9.5%, LVH was identified in 26% and reduced 
E/e’ in 11%. Over a median follow-up of 1.5 years, 37 of 245 patients developed new-onset 
HF and 3 died, giving an event rate of 107/1000 person-years. In a competing-risks regression 
analysis, depression (adjusted HR=2.54, 95%CI 1.18-5.46; p=0.017) was associated with 
incident HF and had incremental predictive power to clinical, biochemical and 
echocardiographic variables. 
Conclusion. Depression is prevalent in asymptomatic elderly patients with T2DM, and 
depression independently and incrementally predicts incident HF. 
7.3 Background 
Heart failure (HF) is a common clinical syndrome in which the heart is unable to pump blood 
at an adequate rate or in adequate volume which is associated with high morbidity and mortality, 
which has been recognized as one of the most common and malignant complications of type 2 
diabetes mellitus (T2DM).36 HF has been reported in >22% elderly patients with diabetes, and 
the HF incidence rate was 12.6 per 100 person-years.7 Among elderly patients with DM, the 5-
year mortality rate was approximately 9-fold higher in those who developed HF than in those 
who did not.7 Depressive symptoms are common in the community, but the 19% prevalence of 
depression in patients with T2DM is about double that of those without DM.204Depression is a 
serious mood disorder that negatively affects people’s feeling, thinking and behaviour that 
affects both physical and mental health. In patients with existing HF, comorbid depression and 
diabetes are associated with a higher mortality and rehospitalisation rate.205 The presence of 
depression more than doubled the risk of all-cause of mortality in HF (Hazard Ratio [HR] =2.29; 
95% CI 0.94 - 5.40; p=0.05), and both DM and depression led to a nearly fourfold increment 
in all-cause mortality (HR=3.71; 95% CI 1.49-9.25; p=0.005).205 
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Depression is an independent predictor of HF onset in elderly patients with isolated systolic 
hypertension, which is independent of demographic characteristics, medical history and 
myocardial infarction risks.206 Although prior studies have found the association of depression 
and adverse outcomes with diabetes alone or heart failure alone, the association of depression 
with incident HF in patients with diabetes has not been determined. The extent to which level 
of depression is able to predict incident HF in asymptomatic T2DM is uncertain. The current 
study was undertaken to evaluate the ability to predict incident HF in a community-based 
cohort of asymptomatic patients with T2DM.  
7.4 Methods 
7.4.1 Study population. 
We prospectively recruited 274 asymptomatic T2DM patients aged ≥65 with preserved LVEF 
from a community-based population in Australia. Patients with existing HF or known ischemic 
heart disease (reported with coronary artery disease including CABG and/or myocardial 
infarction with regional scar) were excluded, as were patients with more than moderate valve 
disease, history of HF, LVEF <40%, or inability to acquire adequate echocardiographic images 
for baseline analysis.  
7.4.2 Ethics, consent and permissions. 
All participants provided written, informed consent, and the study protocol was approved by 
the Tasmanian Human Research Ethics Committee. 
7.4.3 Clinical features. 
T2DM was based on self-report of this diagnosis including the use of relevant medication. 
Obesity was defined as body mass index (BMI) ≥30 kg/m2. Demographics, disease and family 
history and medication use were obtained using a standardized questionnaire. BMI was 
calculated as weight in kilograms divided by height in meters squared. In addition to 
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standardized weight and height measurements, waist circumference (WC) at the midpoint 
between the lower costal margin and the iliac crest was measured to the nearest millimeter by 
a trained examiner. After at least 10 minutes rest in a quiet room, supine resting blood pressure 
(BP) was measured twice and averaged in each patient. Active hypertension was defined by a 
mean systolic blood pressure (BP) ≥140 mmHg or a diastolic BP≥90 mmHg.162 International 
Federation of Clinical Chemistry [IFCC] standardized hemoglobin A1c (cutoff 64 mmol/mol), 
fasting glucose, creatinine and estimated glomerular filtration rate (eGFR) were extracted from 
pathology records. To estimate missing values for HbA1c, we carried out imputation using 
linear regression equation. 
7.4.4 Depression assessment. 
All participants completed the Patient Health Questionnaire 9 (PHQ-9) at baseline assessment. 
Each item in the PHQ-9 questionnaire corresponds to one of the nine DSM-IV criteria for 
diagnosis of major depression. Respondents indicated their level of agreement with each of the 
items (0 = not at all, 1 = several days, 2 = more than half of the days, 3 = nearly every day).The 
validated cutoff PHQ-9 score ≥10 was used as diagnosis for the presence of depression,140 and 
further stratified respondents into four categories of depressive symptomatology based on the 
total PHQ-9 score: minimal (0~4), mild (5~9), moderate (10~20), and severe (≥20).  
7.4.5 Echocardiography. 
A comprehensive echocardiogram including standard transthoracic 2D and Doppler 
echocardiography was performed using the same ultrasound machine (Siemens ACUSON 
SC2000, 4V1c and 4Z1c probes, Siemens Healthcare, Mountain View, CA) in accordance with 
the American Society of Echocardiography guidelines.144, 207 Images were saved in raw data 
format and analyzed offline. LV internal dimensions and wall thickness, chamber volumes and 
valvular morphology were assessed. LV mass index (LVMi) was obtained from LV mass 
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measurement using standard criteria and normalized for body size [body surface area or height 
to the power of 1.7]. LV hypertrophy (LVH) was defined as LVMi (normalized for body 
surface area) >115 g/m2 for males and >95 g/m2 for females. LVEF was measured using the 
modified Simpson’s biplane method. LV inflow was obtained using pulsed wave Doppler in 
the apical 4-chamber view; peak early (E) and late (A) diastolic velocities, deceleration time 
and E/A ratio were assessed. Peak early diastolic medial and lateral mitral annular velocity (e’) 
and the ratio of mitral inflow early diastolic velocity to average e’ velocity were obtained from 
pulsed tissue Doppler; E/e’>13 was used as an indicator of diastolic dysfunction.154 
7.4.6 Outcomes. 
Potential HF symptoms were assessed through regular follow-up phone calls, followed by 
symptom surveillance questionnaires, clinical visits and repeated echocardiography. 
Symptoms and signs that were suspicious for HF were reviewed by three independent 
cardiologists, and the diagnosis of HF was established according to Framingham heart failure 
criteria.4 Records of all-cause hospitalization and mortality were obtained from administrative 
data. The primary endpoint was new-onset of HF, and all-cause mortality was considered as a 
competing risk.  
7.4.7 Statistical Analysis. 
Descriptive data are presented as mean±standard deviation (SD) and dichotomous data as 
subject number and percentage. Comparisons between the groups were performed by 
independent samples t-test; the Kruskal-Wallis test was used for comparison of non-normally 
distributed variables. Univariate and multivariate stepwise forward linear regression was 
performed in order to identify the variables with significant association with PHQ-9 score. 
Univariable Cox regression was used to identify the predictors of incident HF among clinical, 
demographic and echocardiographic variables. We fitted a competing-risk model to compute 
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hazard ratio (HR) and 95% confidence interval (95%CI) for the associations between each risk 
factor and incident HF.191 A multivariable model was constructed to determine the independent 
predictors, guided by univariable analyses and the clinical relevance of the variables. 
Competing risk methods were used to account for the competing risk of death when analyzing 
the endpoint of time to HF. The cumulative incidences of HF were calculated and graphically 
displayed separately for patients with and without depression. Gray’s K-sample test was to 
compare the cumulative incidence estimates of HF between patients with/without 
depression,192 which accounts for all-cause of death as a competing risk of HF. All data were 
analyzed using standard statistical computer software (SPSS 22, IBM, Chicago, IL and Stata, 
V.12.0, Stata Corp, College Station, Texas, USA); p<0.05 was deemed to be statistically 
significant.  
7.5 Results 
7.5.1 Patient characteristics. 
Table 7.1 describes the clinical, echocardiographic and biochemical features of 274 
asymptomatic T2DM patients ≥65 years old with preserved EF from the community who were 
prospectively recruited and underwent baseline tests. Table 7.1 also includes the 254 T2DM 
participants who were included in the final analysis (see below). In the total recruited group of 
274 subjects, the prevalence of LV dysfunction was 26% (by LVH) and 11% (by abnormal E/e’ 
cutoff 13). In the 254 subjects included in the final analysis, baseline HbA1c was available in 
196 individuals (age 71±4yrs, 55% men). In this subgroup, the baseline HbA1c was 53.2±11.4 
mmol/mol. After imputation of missing values, the baseline HbA1c was 53.5±10.1 mmol/mol 
(Table 7.1). 
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7.5.2 Depression. 
Based on PHQ-9 score, 37 (14%) patients had minimal-to-mild depressive symptoms (PHQ-9 
score 5 to 9), and 25 (9%) patients were identified as having moderate-to-severe depressive 
symptoms (PHQ-9 score 10 to 20), and 2 (0.7%) patients were identified as having severe 
depressive symptoms (PHQ-9 score ≥20), and were diagnosed as having depression using the 
cutoff of PHQ-9 score ≥10. Table 7.2 shows the features associated with depression; these 
patients had higher BMI and more central obesity, more insulin use and higher HbA1c level. 
However, there was no difference in age, gender, blood pressure, heart rate and other risk 
factors of HF and echocardiographic parameters among patients with and without depression. 
The significant determinant of PHQ-9 score detected by linear regression was BMI. 
7.5.3 Follow-up. 
After a median follow-up time of 1.5 years (range 0.5-3 years), 2 of 274 T2DM participants 
(0.7%) were lost to follow-up and 18 of 274 participants (6.6%) were alive but unable to attend 
for clinic review (Figure 7.1). This group was no different from the remaining 254 individuals 
who completed follow-up (Appendix 7.1). The primary composite endpoint was reached by 
40 patients; 37 patients developed new-onset HF and 3 died, giving an event rate of 107/1000 
person-years.  
Cox regression analysis was performed to analyze the association between clinical and 
biochemical variables and echocardiographic parameters of interest and the time to the primary 
composite endpoint (Table 7.3).Patients with events were characterized by obesity, worse 
glycemic control, baseline LVEF, LV mass (but not diastolic function parameters), beta 
blockade and depression. For PHQ-9 scores, it was significantly associated with events either 
as continuous covariate or binomial covariate. When categorized PHQ-9 score into three levels 
(0~4, 5~9 and ≥10), PHQ-9≥10 was independently associated with events. The cumulative 
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survival of the included 254 elderly asymptomatic T2DM stratified by the severity of 
depression was listed in Appendix 7.3. A multivariable Cox regression model (informed by 
significant univariable clinical associations and echocardiographic parameters of interest) was 
constructed to determine the independent predictors of the composite endpoint (Table 7.4). 
Obesity, LVH and depression were associated with increased risks of the composite endpoint. 
7.5.4 Prediction of HF in T2DM. 
A competing risk analysis that controlled for age, obesity and poor glycemic control was 
performed to assess whether depression and other echocardiographic parameters of interest 
were associated with incident HF in elderly asymptomatic patients with T2DM (Figure 7.2). 
The baseline clinical model, showing an independent effect of obesity (p<0.001), and poor 
glycemic control (p=0.02) on incident events, was improved by addition of echocardiographic 
features (LVH, p=0.001). However, the addition of depression (p=0.017) had incremental 
predictive power to clinical, biochemical and echocardiographic variables for the prediction of 
incident HF (Figure 7.2).  
The cumulative incidence of HF with time among elderly asymptomatic T2DM stratified by 
depression status is shown in Figure 7.3. By the end of the follow-up, considering the 
competing risk, the cumulative incidence of HF was 0.36 in patients with depression and was 
0.15 in patients without depression. Gray’s test also showed that the cumulative incidence of 
HF was significantly lower in patients with depression than those patients without depression 
(P<0.001). 
Chapter 8 –Evolution of subclinical LV dysfunction in T2DM 
  133 
 
Table 7.1. Baseline characteristics (demographic, clinical, echocardiographic, physiologic) of 
274 elderly asymptomatic patients with T2DM.  
Demographic and clinical 
characteristics 
Age (years) 71±4.4 
Male gender (n, %) 150(54.7) 
Weight (kg) 85.8±17.2 
Height (cm) 168.4±10.0 
BMI (kg/m2) 30.3±5.9 
Waist circumference (cm) 103.2±13.3 
Obesity (n, %) 135(49.3) 
Heart rate (n/min) 69±11 
Systolic blood pressure (mmHg) 139±15 
Diastolic blood pressure (mmHg) 81±10 
Hypertension (n, %) 204(74.4) 
Family history of HF (n, %) 80(29.2) 
Past chemotherapy (n, %) 25(9.1) 
Past heart disease (n, %) 16(5.8) 
Medication Insulin (n, %) 65(23.7) 
Metformin (n, %) 184(67.2) 
ACEi / ARB (n, %) 183(66.8) 
Beta-blockers (n, %) 15(5.5) 
Calcium antagonists (n, %) 64(23.4) 
Diuretics (n, %) 31(11.3) 
Lipid lowering meds (n, %) 133(48.5) 
Questionnaire PHQ-9 score 3.2±4.3 
PHQ-9 score≥10 (yes/no) 26(9.5) 
Echocardiography LV ejection fraction (%) 63.1±6.4 
Mitral early-diastolic inflow velocity (E wave) (m/s) 0.65±0.17 
Mitral late-diastolic inflow velocity (A wave) (m/s) 0.83±0.19 
Transmitral diastolic flow velocity ratio (E/A) 0.79±0.22 
Early diastolic mitral annular velocity (e') (m/s) 0.08±0.02 
Average E/e’ ratio (E/e’) 9.2±2.8 
E/e’ ratio >13 (n, %) 29(10.6) 
Deceleration time(DT) (s) 246.8±52.4 
LV mass index (g/m2) 85.7±19.0 
LV mass index (g/m1.7) 74.4±20.8 
LV hypertrophy (n, %)* 36(13.2) 
Biochemical 
characteristics 
HbA1c (mmol/mol) (n=274) 53.5±10.1 
Fasting glucose ( µmol/L) (n=109) 8.3±3.5 
Creatinine (µmol/L) (n=186) 81.3±24.0 
eGFR (mL/min/1.73m2) (n=187)  
≥90 37(19.8) 
60 to 89 115(61.5) 
45 to 59 25(13.4) 
30 to 44 9(4.8) 
15 to 29 1(0.5) 
*LV hypertrophy was defined as LVMi>115 g/m2 for males, >95 g/m2 for female. 
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Table 7.2Baseline demographic, clinical and echocardiographic variable comparisons among 
T2DM patients categorized by the presence of depression (n=254). 
*LV hypertrophy was defined as LVMi>115 g/m2 for males, >95 g/m2 for females. 
 
Depression 
(n=25) 
No depression 
(n=229) 
p 
Demographic and clinical characteristics    
Age (years) 70.6±3.8 70.9±4.4 0.418 
Male gender (n, %) 11(44.0) 131(57.2) 0.208 
Weight (kg) 92.6±22.8 85.1±16.5 0.122 
BMI (kg/m2) 34.1±7.8 29.8±5.6 0.012 
Waist circumference (cm) 109.0±14.2 102.4±13.1 0.032 
Obesity (n, %) 18(72.0) 106(46.3) 0.015 
Heart rate (n/min) 70±11 68±11 0.280 
Systolic blood pressure (mmHg) 138±17 139±14 0.936 
Diastolic blood pressure (mmHg) 80±12 81±9 0.748 
Hypertension (n, %) 19(76.0) 171(74.7) 0.985 
Family history of HF (n, %) 10(40.0) 63(27.5) 0.191 
Past chemotherapy (n, %) 4(16.0) 18(7.9) 0.170 
Past heart disease (n, %) 3(12.0) 11(4.8) 0.135 
HbA1c (mmol/mol) 57.6±10.6 53.0±10.0 0.049 
HbA1c >64 mmol/mol (n, %) 8(32) 24(10.5) 0.002 
Medication    
Insulin (n, %) 11(44.0) 49(21.4) 0.012 
Metformin (n, %) 18(72.0) 157(68.6) 0.725 
ACEi / ARB (n, %) 19(76.0) 152(66.4) 0.331 
Beta-blockers (n, %) 1(4.0) 14(6.1) 0.571 
Calcium antagonists (n, %) 7(28.0) 54(23.6) 0.524 
Diuretics (n, %) 4(16.0) 23(10.0) 0.360 
Lipid lowering meds (n, %) 14(56.0) 109(47.5) 0.426 
Echocardiography    
LV ejection fraction (%) 61.5±8.7 63.2±6.2 0.222 
Mitral early-diastolic inflow velocity (E wave) (m/s) 0.62±0.18 0.65±0.16 0.530 
Mitral late-diastolic inflow velocity (A wave) (m/s) 0.81±0.16 0.83±0.19 0.525 
Transmitral diastolic flow velocity ratio (E/A) 0.79±0.21 0.77±0.25 0.693 
Early diastolic mitral annular velocity (e') (m/s) 0.07±0.01 0.08±0.02 0.852 
Average E/e’ ratio (E/e’) 8.6±1.9 9.2±2.8 0.336 
E/e’ ratio >13 (n, %) 1(4.0) 25(10.9) 0.280 
Deceleration time(DT) (s) 231.6±50.4 248.6±52.9 0.129 
LV mass index (g/m2) 87.3±16.1 85.4±19.6 0.602 
LV mass index (g/m1.7) 82.3±27.0 73.6±20.2 0.130 
LV hypertrophy (n, %)* 2(8.0) 33(14.4) 0.998 
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Table 7.3 Baseline clinical and echocardiographic characteristics of patients with T2DM who 
met primary composite outcome (n=254). 
 
Event 
(n=40) 
No Event 
(n=214) 
p 
Demographic and clinical characteristics    
Age (years) 72.1±5.1 70.6±4.2 0.054 
Male gender (n, %) 28(70.0) 114(53.3) 0.085 
Weight (kg) 96.5±20.4 83.8±16.0 <0.001 
Height (cm) 169.4±10.5 168.4±9.8 0.561 
BMI (kg/m2) 33.8±7.6 29.6±5.3 <0.001 
Waist circumference (cm) 111.2±14.4 101.5±12.5 <0.001 
Obesity (n, %) 30(75.0) 94(43.9) 0.002 
Heart rate (n/min) 68±13 69±10 0.618 
Systolic blood pressure (mmHg) 137±13 139±14 0.303 
Diastolic blood pressure (mmHg) 81±9 81±10 0.772 
Hypertension (n, %) 30(75.0) 160(74.8) 0.582 
Family history of HF (n, %) 9(22.5) 64(29.9) 0.155 
Past chemotherapy (n, %) 5(12.5) 17(7.9) 0.592 
Past heart disease (n, %) 3(7.5) 11(5.1) 0.106 
HbA1c (mmol/mol) 57.6±11.2 52.7±9.8 0.005 
HbA1c >64 mmol/mol (n, %) 12(30.0) 20(9.3) <0.001 
Medication    
Insulin (n, %) 14(35.0) 46(21.5) 0.155 
Metformin (n, %) 24(60.0) 151(70.6) 0.432 
ACEi / ARB (n, %) 28(70.0) 143(66.8) 0.303 
Beta-blockers (n, %) 6(15.0) 9(4.2) 0.024 
Calcium antagonists (n, %) 6(15.0) 55(25.7) 0.097 
Diuretics (n, %) 4(10.0) 23(10.7) 0.834 
Lipid lowering meds (n, %) 23(57.5) 100(46.7) 0.061 
Questionnaire    
PHQ-9 score 4.8±0.8 3.6±0.3 0.086 
PHQ-9 score≥10 (yes/no) 7(17.5) 18(8.4) 0.077 
Echocardiography    
LV ejection fraction (%) 61.2±7.9 63.2±6.1 0.096 
Mitral early-diastolic inflow velocity (E wave) (m/s) 0.67±0.20 0.64±0.16 0.347 
Mitral late-diastolic inflow velocity (A wave) (m/s) 0.85±0.23 0.83±0.18 0.483 
Transmitral diastolic flow velocity ratio (E/A) 0.79±0.24 0.80±0.20 0.705 
Early diastolic mitral annular velocity (e') (cm/s) 7.59±1.75 7.52±1.50 0.798 
Average E/e’ ratio (E/e’) 9.4±3.1 9.1±2.6 0.511 
E/e’ ratio >13 (n, %) 4(10.0) 22(10.3) 0.632 
Deceleration time(DT) (s) 243.3±57.8 247.7±52.0 0.662 
LV mass index (g/m2) 96.3±21.0 83.6±18.3 0.001 
LV mass index (g/m1.7) 88.0±26.5 72.0±18.9 <0.001 
LV hypertrophy (n, %)* 14(35.0) 21(9.8) <0.001 
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Table7.4 Cox regression analysis for primary composite endpoint in 254 elderly asymptomatic patients with T2DM. 
Variable 
No. of 
patients 
No. of 
HF 
No. of 
Death 
Unadjusted HR (95%CI) 
p value 
LVH-adjusted  
HR (95% CI)† 
p value 
E/e’-adjusted 
HR (95%CI)†† 
p value 
Adjusted HR 
(95% CI)††† 
p value 
Age 254 37 3 
1.06(0.99,1.13) 
0.064 
- - 1.06(0.99,1.14) 
0.055 
Male gender 142 25 3 
1.81(0.92,3.56) 
0.086 
- - 1.36(0.61,2.92) 
0.466 
Obesity 124 29 1 
3.61(1.76,7.39) 
<0.001 
2.87(1.38,5.98) 
0.005 
3.27(1.58,5.75) 
0.001 
2.97(1.44,6.30) 
0.004 
HbA1c 32 10 2 
3.27(1.66,6.43) 
0.001 
2.04(0.99,4.22) 
0.054 
2.47(1.22,5.00) 
0.012 
2.01(0.93,4.10) 
0.077 
LVH 35 13 1 
3.92(2.04,7.52) 
<0.001 
3.24(1.65,6.38) 
0.001 
- 2.67(1.25,,5.99) 
0.011 
E/e’ 26 4 0 
1.04(0.37,2.94) 
0.934 
- 1.11(0.39,3.18) 
0.845 
0.82(0.26,2.52) 
0.724 
Depression 25 7 0 
3.21(1.41,7.30) 
0.005 
2.80(1.16,6.76) 
0.022 
2.39(1.01,5.67) 
0.048 
3.14(1.27,7.74) 
0.013 
Abbreviations: HR=hazard ratio; CI=confidence interval;  
Obesity, BMI≥30kg/m2; Poor HbA1c, ICFFstd-HbA1c>64mmol/mol; LVH, left ventricular hypertrophy, cutoff >115 g/m2 for males, >95 g/m2 for females; E/e’ ratio, cutoff >13; 
Depression, the score of PHQ-9 questionnaire ≥10. 
†
In the multivariate cox model, obesity, poor HbA1c, LVH and depression were entered into the model. 
††
In the multivariate cox model, obesity, poor HbA1c, E/e’ and depression were entered into the model. 
††
In the multivariate cox model, age, male gender, obesity, poor HbA1c, LVH, E/e’ and depression were entered into the model. 
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Figure 7.1. Flow chart of study inclusion (n=254). 
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Figure 7.2 Prediction of incident HF in elderly asymptomatic patients with T2DM (competing 
risk analysis). LVH and depression showed incremental value over clinical parameters for 
incident HF. 
 
 Model 1 Model 2 Model 3 
Chi-square 
P for chi-square 
change 
25.63 
40.92 
P<0.001 
51.44 
P<0.001 
 
HR (95% CI) 
P value 
HR (95% CI) 
P value 
HR (95% CI) 
P value 
Age 
1.05(0.98,1.12) 
0.131 
1.02(0.99,1.11) 
0.124 
1.07(1.01,1.14) 
0.034 
Male gender 
1.54(0.78,3.06) 
0.212 
1.10(0.52,2.32) 
0.798 
1.14(0.53,2.44) 
0.738 
Obesity 
4.49(2.12,9.52) 
<0.001 
3.85(1.83,8.12) 
<0.001 
3.55(1.64,7.66) 
0.001 
Poor HbA1c 
2.06(1.11,3.83) 
0.022 
2.41(1.27,4.58) 
0.007 
2.29(1.18,4.45) 
0.014 
LVH  
3.51(1.67,7.37) 
0.001 
3.48(1.60,7.58) 
0.002 
Abnormal E/e’  
0.90(0.31,2.63) 
0.850 
0.99(0.32,3.02) 
0.980 
Depression   
2.54(1.18,5.46) 
0.017 
Abbreviations: HR=hazard ratio; CI=confidence interval;  
Obesity, BMI≥30kg/m2; Poor HbA1c, ICFFstd-HbA1c>64mmol/mol; LVH, left ventricular hypertrophy, 
cutoff >115 g/m2 for males, >95 g/m2 for females; Abnormal E/e’ ratio, cutoff >13; Depression, the score of 
PHQ-9 questionnaire ≥10. 
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Figure 7.3 Cumulative incidence estimates of HF in elderly asymptomatic T2DM stratified by 
patients with and without depression 
 
 
7.6 Discussion 
The results of this study show that depression (defined as PHQ-9 score ≥10) was significantly 
associated with increased risk of incident HF during follow-up of asymptomatic elderly 
patients with T2DM and preserved EF. This association was independent of clinical factors 
(including age, gender and BMI) and echocardiographic features such as LV hypertrophy and 
diastolic function. The presence of depression increased the likelihood of incident HF by 2.5-
fold, and increased the composite endpoint 3.1-fold, compared with those without depression. 
Although depression has been linked with adverse outcomes in HF patients, to our knowledge, 
this is the first study to show an independent association between depression and incident HF 
in DM.  
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7.6.1 Depression and HF. 
Depression is a common co-morbidity of HF, with variable reports of its prevalence. A meta-
analysis of 25 studies showed depression to be present in 11% HF in NYHA (New York Heart 
Association) functional class I, 20% with class II, and approximately 40% of class III and IV 
HF.  Depression is more widely diagnosed when this diagnosis is made by questionnaire (34%), 
and less with clinical interview (19%).208 From 2008, American Heart Association 
recommended (AHA) recommended Patient Health Questionnaire (PHQ-9) for depression 
screening in cardiovascular patients. Given that there is always a tradeoff between sensitivity 
and specificity for questionnaire testing, PHQ-9 has a high specificity but a low sensitivity209. 
That means this screening method may can not capture all patients with the diagnosis of 
depression, however, it can identify highest risk patients for adverse cardiovascular events. 
Depression is an independent predictor of adverse clinical outcomes in HF, and increases the 
risk of mortality by 40-50%.210In elderly patients with newly diagnosed HF, the presence of 
depression increased 1.2-fold risk of hospital admission and was suggested to routinely 
assessed at the time of HF diagnosis.211Even mild depression (defined as PHQ-9 score >5)has 
been associated with mortality and re-hospitalization in HF.212 Depression is associated with a 
2.4-fold increment of mortality, independent of age, gender, etiology, NYHA class, EF and LV 
systolic dysfunction.213 
Few previous studies have sought whether psychosocial factors could independently predict 
incident HF. 206, 214, 215 Abramson et al206 first found that depression, as defined by Center for 
Epidemiological Studies Depression Scale (CES-D) ≥16, was independently associated with a 
substantial increase in the risk of HF among elderly patients with isolated systolic hypertension. 
Williams et al215 found an independent association between depression (CES-D ≥20, and 
incident HF among elderly women but not elderly men. The results from prospective cohort 
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studies are contradictory – the Nord-Trøndelag Health (HUNT) Study demonstrated the 
prospective association of self-reported depression at baseline with future HF in a dose-
response manner, independent of a large number of baseline cardiovascular risk factors, acute 
myocardial infarction (AMI) and several chronic disorders.214 However, the Multi-Ethnic 
Study of Atherosclerosis (MESA) found no significant association between depression (CES-
D scale ≥16), and subsequent HF in an older population. However, in participants reporting 
fair/poor health status at baseline, this association was significant.216 It is certainly plausible 
that sympathetic over activity might be associated with both HF mortality and HF incidence, 
but this remains unproven. 
7.6.2 Depression and diabetes. 
About 20-30% of elderly patients with diabetes suffer from clinical depression, and around 10% 
of them have major depression.217 Even though the relationship between depression and 
diabetes is incompletely understood, it is clear that depression has an adverse impact on the 
course of diabetes, and diabetes complications may result in both the risk of depression and 
worsening the course of depression. Their association is primarily driven by somatic-affective 
symptoms of depression.202 Additionally, the duration of depression lasts longer (usually ≥2 
years) in most diabetic patients and the relapse rate is relatively high.218 A previous study with 
10-year follow-up also showed that all-cause of mortality increased with the severity of 
depression in diabetic subjects.219 
7.6.3 HF in diabetes. 
The underlying mechanisms between diabetes and the development of HF are multiple, but 
there is a growing recognition of a primary myocardial disease process - “diabetic 
cardiomyopathy” - that may lead to LV dysfunction, and subsequently HF. Hyperinsulinemia, 
inflammation and oxidative stress result in increased fatty acid metabolism and fetal gene 
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expression.178 The resulting pathophysiological changes include impaired myocardial 
relaxation and cardiomyocyte resting tension, activation of the renin-angiotensin system 
(leading to vasoconstriction, salt and water retention, and fibrosis) and diabetic autonomic 
neuropathy. These changes lead to impaired diastolic and systolic function.168Furthermore, 
overweight has been proved to have a greater effect on LV structure in diabetes than in non-
diabetes.220 In our study, obesity has emerged as an important predictor of incident HF, further 
suggesting overweight/obesity are independently associated with LV dysfunction and 
increased risk of incident HF in diabetes. Moreover, NT pro Brain natriuretic peptide (NT-pro 
BNP), an objective measure of cardiac function, was higher but inadequately increased in 
overweight diabetic patients compared with normal weight diabetic patients, regardless of the 
presence/absence of cardiovascular disease, underlying the natriuretic handicap in diabetes.221 
Several shared pathophysiological mechanisms may link T2DM, depressive symptoms and 
incident HF. Pro-inflammatory cytokines and platelet activation, rhythm disturbances, neuro 
hormonal activation, endothelial dysfunction and hypercoagulability are present in patients 
with depression.222 These pathophysiological changes adversely influence the cardiovascular 
system and have been postulated to play an important role in the development and progression 
of HF.222 Endothelial dysfunction plays an important role in cardiovascular homeostasis by 
producing various vascular regulators that mediate fibrinolysis, hypercoagulability, platelet 
activation and vascular tone, disturbances of which constitute the step linking diabetes to 
cardiovascular events.203 Hyperglycemia and insulin resistance are associated with endothelial 
dysfunction223 and cardiac damage.203 Impaired nitric oxide production and oxidative stress 
may also lead to endothelial dysfunction, impaired vasodilation and large vessel impairment.203 
Hyperglycemia and hyperinsulinemia have also been significant contributors to cardiovascular 
complications through their role in stimulating coagulation and impairing fibrinolysis.224 Pro-
inflammatory cytokines are common in diabetes and significantly increase the risk of 
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progression of cardiovascular complications at all stages.225 Additionally, patients with 
depression are more likely to take up risky lifestyles and behaviors and more likely to show 
non-adherence to medical regimens and behavior recommendations that affects the prognosis 
of HF.226 Depression may be also involved with the lower social support that is implicated in 
the development of HF. 
7.6.4 Limitation. 
In the present study, the population were selected from the community with preserved EF, so 
diabetes patients with established asymptomatic LV systolic dysfunction were excluded. We 
used self-reported measures of symptoms of depression rather than diagnostic interviews. 
However, the use of the PHQ-9 survey for screening depression has been validated and has 
been recommended by the American Heart Association for the diagnosis of depression in 
coronary heart disease. 227In addition, the blood examination in the cohort such as BNP or NT-
pro BNP were not part of this study. Lastly, despite the longitudinal study design and high-risk 
nature of this population, the number of events was relatively small.  
7.7 Conclusion 
In this community cohort of asymptomatic patients with T2DM, depression was prevalent, and 
significantly associated with incident HF over 2-years of observation. This association is not 
explained by baseline demographic characteristics, glycemic control and LV dysfunction 
[including LV hypotrophy and subclinical diastolic dysfunction (evidenced by E/e’)]. The 
mechanism of this association requires further investigation, and although it remains unclear 
as to whether a depression intervention in T2DM may prevent HF, depressed patients may 
warrant closer monitoring for the development of HF. 
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7.8 Postscript 
This chapter showed how clinical outcomes were worse in T2DM patients with depression 
compared with those without during a 2-year observation. With adjustment for demographic, 
clinical, biochemical and echo parameters, the risk for incident HF was greater in those with 
depression. While our results also highlight the high prevalence of depression in elderly 
asymptomatic T2DM patients, further management or intervention for depression should be 
based on further research in other populations and age groups to determine if the effect of 
depression is similar to that observed in this study. 
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7.9 Appendix 
Appendix 7.1 Comparison of baseline characteristics between patients who completed follow-
up study (n=254) and patients who loss to follow-up study (n=20). 
*LV hypertrophy was defined as LVMi>115 g/m2 for males, >95 g/m2 for females. 
 
Completed 
n=254 
Loss to FU 
n=20 
P value 
Demographic and clinical characteristics 
Age (years) 70.9±4.3 72±5.1 0.341 
Male gender (n, %) 142(55.9) 8(40.0) 0.389 
Weight (kg) 85.8±17.3 85.7±16.7 0.820 
BMI (kg/m2) 30.2±5.9 31.1±5.6 0.536 
Waist circumference (cm) 103.1±13.3 107.3±15.3 0.255 
Obesity (n, %) 124(48.8) 11(55.0) 0.811 
Heart rate (n/min) 69±11 71±13 0.445 
Systolic blood pressure (mmHg) 139±14 141±23 0.550 
Diastolic blood pressure (mmHg) 81±10 80±10 0.613 
Hypertension (n, %) 190(74.8) 14(70.0) 0.195 
Family history of HF (n, %) 73(28.7) 7(35.0) 0.518 
Past chemotherapy (n, %) 22(8.7) 3(15.0) 0.403 
Past heart disease (n, %) 14(5.5) 2(10.0) 0.103 
HbA1c (mmol/mol)  53.4±10.2 54.2±9.5 0.733 
HbA1c >64 mmol/mol  (n, %)  32(12.6) 4(20) 0.245 
Medication    
Insulin (n, %) 60(23.6) 5(25.0) 0.037 
Metformin (n, %) 175(68.9) 9(45.0) 0.244 
ACEi / ARB (n, %) 171(67.3) 12(60.0) 0.630 
Beta-blockers (n, %) 15(5.9) 0(0) <0.001 
Calcium antagonists (n, %) 62(24.3) 2(10.0) 0.093 
Diuretics (n, %) 27(10.6) 4(20.0) 0.445 
Lipid lowering meds (n, %) 123(48.4) 10(50.0) 0.560 
Questionnaire    
PHQ-9 score 3.2±4.3 2.8±5.1 0.787 
PHQ-9 score≥10 (yes/no) 25(9.8) 1(5.0) 0.009 
Echocardiography    
LVEF (%) 63.1±6.5 63.0±5.1 0.965 
E wave (m/s) 0.65±0.16 0.74±0.26 0.024 
A wave (m/s) 0.83±0.19 0.88±0.25 0.421 
E/A ratio 0.79±0.21 0.79±0.28 0.974 
e' (m/s) 0.08±0.02 0.08±0.02 0.512 
E/e’ ratio 9.2±2.7 9.8±3.1 0.347 
E/e’ ratio >13 (n, %) 26(10.2) 3(15.0) 0.086 
DT (s) 247.0±52.8 244.6±50.7 0.844 
LV mass index (g/m2) 85.6±19.3 86.9±15.4 0.735 
LV mass index (g/m1.7) 74.5±21.1 73.3±17.2 0.775 
LV hypertrophy (n, %)* 35(13.8) 1(5.9) 0.354 
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Appendix 7.2 Univariable Cox regression analysis for primary composite endpoint in elderly 
asymptomatic patients with T2DM. 
*LV hypertrophy was defined as LVMi>115 g/m2 for males, >95 g/m2 for females. 
 
 
 
 
 HR (95% CI) P value 
Demographic and clinical characteristics   
Age  1.06(0.99,1.32) 0.064 
Male gender (yes/no) 1.81(0.92,3.56) 0.086 
Weight  1.04(1.02,1.05) <0.001 
BMI  1.10(1.06,1.15) <0.001 
Waist circumference  1.05(1.03,1.08) <0.001 
Obesity (yes/no) 3.61(1.76,7.39) <0.001 
Heart rate  0.99(0.97,1.03) 0.727 
Systolic blood pressure 0.99(0.97,1.01) 0.314 
Diastolic blood pressure  0.90(0.99,1.03) 0.895 
Hypertension (yes/no) 1.07(0.52,2.19) 0.854 
Family history of HF (yes/no) 0.70(0.33,1.47) 0.349 
Past chemotherapy (yes/no) 1.54(0.60,3.93) 0.536 
Past heart disease (yes/no) 1.46(0.45,4.74) 0.529 
HbA1c (mmol/mol)  1.03(1.01,1.06) 0.009 
HbA1c >64 mmol/mol  (n, %) 3.27(1.66,6.43) 0.001 
Medication   
Insulin (yes/no) 1.77(0.92,3.39) 0.086 
Metformin (yes/no) 0.72(0.38,1.36) 0.310 
ACEi / ARB (yes/no) 1.12(0.57,2.20) 0.749 
Beta-blockers (yes/no) 3.25(1.36,7.77) 0.008 
Calcium antagonists (yes/no)  0.50(0.21,1.18) 0.114 
Diuretics (yes/no) 0.91(0.33,2.65) 0.909 
Lipid lowering med (yes/no) 1.32(0.71,2.48) 0.382 
Questionnaire   
PHQ-9 score 1.08(1.01,1.16) 0.021 
PHQ-9 score≥10 (yes/no) 3.21(1.41,7.30) 0.005 
Echocardiography   
LV ejection fraction  0.95(0.90,0.99) 0.018 
Mitral early-diastolic inflow velocity (E wave) 3.46(0.54,22.39) 0.192 
Mitral late-diastolic inflow velocity (A wave)  1.81(0.32,10.31) 0.503 
Transmitral diastolic flow velocity ratio (E/A) 0.92(0.16,5.31) 0.929 
Early diastolic mitral annular velocity (e')  1.05(0.86,1.28) 0.644 
Average E/e’ ratio (E/e’) 1.05(0.94,1.17) 0.437 
E/e’ ratio >13 (yes/no) 1.04(0.37,2.94) 0.934 
Deceleration time(DT) 0.99(0.99,1.00) 0.363 
LV mass index (g/m2) 1.03(1.02,1.04) <0.001 
LV mass index (g/m1.7) 1.03(1.02,1.04) <0.001 
LV hypertrophy (yes/no)* 3.92(2.04,7.52) <0.001 
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Appendix 7.3 Cumulative survival of 254 elderly asymptomatic T2DM stratified by severity 
of depression. 
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Chapter 8. Evolution of Subclinical Left Ventricular 
Systolic Function during a 2-year Observation in T2DM 
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8.1 Preface 
As discussed in previous chapters, GLS is potentially a useful marker of patients at risk for the 
development of incident HF in diabetes. The role of GLS rather than ejection fraction in this 
setting is consistent with the predominance of HF with preserved EF in patients with diabetes 
– but little is known about the natural history of GLS over time. Whether the initiation of 
medical therapy in response to abnormal GLS can result in better outcome still needs to be 
tested. To address these gaps in knowledge, we investigated the longitudinal changes of GLS 
as well as other echo parameters in asymptomatic patients with preserved EF in the community. 
In addition, we sought to determine the predictors of deterioration of subtle myocardial 
dysfunction.                                           
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8.2 Abstract 
Background. Left ventricular (LV) systolic function is an important predictor of incident heart 
failure (HF) in the community, including in patients with preserved ejection fraction. However, 
little is known about the natural history of subclinical LV function, measured by global 
longitudinal strain (GLS).  
Methods. 246 asymptomatic elderly patients with T2DM (age 71±4yrs, 57.3% men) were 
recruited from a community-based population with preserved EF. All underwent a 
comprehensive clinical evaluation and echocardiography including GLS. All were followed 
for the development of HF symptoms over 2 years. 
Results. Patients with T2DM and normal LVEF [mean age 71±4 years, 141 (57%) male] were 
evaluated. After 2-years follow-up, LVEF remained preserved and LVMi remained unchanged. 
In contrast, a significant worsening of GLS (17.8±2.6% to 17.3±2.9%, p=0.01) and increased 
of LAV index (24.3±5.2 to 29.6±7.9 g/m2, p<0.001). Diastolic function as assessed by E/e’ 
ratio showed a mild decline during follow-up (9.1±2.6 to 9.7±2.9, p<0.001). During 2-year 
follow-up, 17% patients experienced worsening subclinical LV function and 8% experienced 
worsening diastolic function. 
Conclusions. During a 2-year observation, elderly asymptomatic patients with T2DM and 
preserved EF showed mild deterioration of subclinical LV function by GLS and diastolic 
function by E/e’, which warrant prospective  evaluation. 
 
 
8.3 Background 
Diabetes mellitus (DM) can increase the risk of heart failure (HF) in the absence of coronary 
artery disease and hypertension, and some investigators have invoked the presence of a 
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“diabetic cardiomyopathy (DMC)”. Previous studies have demonstrated that in patients with 
diabetes, subclinical left ventricular systolic dysfunction (LVSD) is frequent despite normal 
left ventricular ejection fraction (LVEF) and normal diastolic function. This subclinical LVSD 
may be the earliest marker of preclinical DMC 88.  
LV global longitudinal strain (GLS) assessed by two-dimensional speckle tracking 
echocardiography (STE) has been proposed as an optimal marker of LVSD despite a normal 
LVEF. In the community, the prevalence of abnormal GLS but normal LVEF has as four times 
the prevalence of abnormal LVEF 228.  Echocardiographic changes consistent with LVSD, LV 
diastolic dysfunction (LVDD) and LV hypertrophy (LVH) in diabetic population have been 
described extensively and particularly when hypertension and obesity coexist 88, 194, 229. 
Recently, the presence of impaired systolic strain in addition to demographic data and HbA1c 
level has been shown to help risk stratification for future cardiovascular events in patients with 
diabetes 190. However, limited data are available on the time-course and determinants of 
impaired systolic strain in individuals with diabetes, and worsening of LV dysfunction may 
contribute significantly to an increasing risk of HF. In order to identify the predictors of 
deterioration of systolic strain over time, the present study aimed to analyze GLS on repeated 
echocardiograms over 2 years in patients with type 2 diabetes mellitus (T2DM) with preserved 
EF and without overt HF in the community. 
8.4 Methods 
8.4.1 Study population. 
A total of 274 consecutive patients with T2DM self-referred between 2013 and 2015 were 
prospectively recruited from the Tasmanian community. The inclusion criteria were: age ≥ 65 
years, no symptoms or history of heart failure and LVEF ≥ 40%. Exclusion criteria were: more 
than moderate valve disease, known coronary artery disease (CAD) including ischemia or 
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infarction, coronary artery bypass graft and coronary stenting, atrial fibrillation (AF) and 
inability to acquire adequate echocardiographic images for speckle tracking imaging analysis 
at baseline and follow-up. All participants provided written, informed consent, and the study 
protocol was approved by the Tasmanian Human Research Ethics Committee. After 2 years 
follow-up, 246 patients were included in the final analysis. There were 28 patients missing to 
attend for the follow-up echocardiogram due to 1) died, lost contact or moved to other States; 
2) were alive but could not attend the clinic due to various reasons including time, traffic and 
temporary emergency. 
8.4.2 Clinical data. 
The diagnosis ofT2DM was based on self-report and diabetes treatment. Data on demographics, 
family history, medical history and use of medication were collected from an interviewer-
administered questionnaire. Body mass index (BMI) was calculated as weight in kilograms 
divided by height in meters squared and obesity was defined as BMI ≥30 kg/m2. Waist 
circumference (WC) was measured to the nearest millimeter by a trained examiner using a tape 
measure at the midpoint between the lower costal margin and the iliac crest. Supine resting 
blood pressure (BP) was measured twice and averaged in each patient after at least 10 minutes’ 
rest in a quiet room. Hypertension was defined by average systolic blood pressure (SBP) ≥140 
mmHg or a diastolic blood pressure (DBP) ≥90 mmHg. International Federation of Clinical 
Chemistry (IFCC) standardized haemoglobin A1c (cut-off 64 mmol/mol) levels were obtained 
from local pathology records. Missing values for HbA1c were estimated by imputation using 
linear regression. 
8.4.3 Echocardiography. 
All patients were examined at baseline and after 2 years by a comprehensive echocardiogram 
including standard resting transthoracic 2D, Doppler echocardiographic studies and speckle 
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tracking echocardiography (STE). Calculations of morphometric parameters were done in 
accordance with the recommendations of American Society of Echocardiography (ASE) 
(Siemens ACUSON SC2000, 4V1c and 4Z1c probes, Siemens Healthcare, Mountain View, 
CA)207. LV internal dimensions and wall thickness, chamber volumes and valvular morphology 
were assessed. The biplane Simpson’s method was used for calculation of LVEF. LA volumes 
were calculated using the Simpson biplane method and LA enlargement (LAE) was defined as 
LA volume index [LAVi, LA volume indexed to body surface area (BSA)] ≥34 mL/m2 (10). 
LV mass index (LVMi) was obtained from LV mass measurement using standard criteria and 
normalized for body size [BSA and height to the power of 1.7 or 2.7]. LV hypertrophy (LVH) 
was defined as LVMi (normalized for BSA) >115 g/m2 for men and >95 g/m2 for women.  
LV inflow was obtained using pulsed wave Doppler in the apical 4-chamber view; peak early 
(E) and late (A) diastolic velocities, deceleration time (DT) and E/A ratio were obtained. Peak 
early diastolic medial and lateral mitral annular velocity (e’) and the ratio of mitral inflow early 
diastolic velocity to average e’ velocity were obtained from pulsed tissue Doppler; E/e’>13 
was used as a cut-off of LVdiastolic dysfunction (LVDD). For deformation analysis, standard 
grayscale 2-dimensional images were acquired in conventional 4-chamber, 2-chamber, 3-
chamber, parasternal short-axis views at the mid, basal, and apical level. Global longitudinal 
strain (GLS) was calculated by the average from three apical views using standard software.73 
Although shortening is described as a negative number, for computational simplicity (and 
because there were no positive GLS), we express GLS in this paper without this information. 
Our laboratory uses cutoffs of 16% to designate impaired GLS and 18% to designate normal 
GLS, and we evaluated both cutoffs. Significant deterioration of strain was defined as strain 
reduced by >20% of absolute value from baseline to follow-up assessment. 
8.4.4 Outcomes. 
The primary endpoint was deterioration of strain (as a continuous variable). 
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8.4.5 Statistical analysis. 
All collected data were tabulated and analyzed using standard statistical computer software for 
windows (SPSS 22, IBM, Chicago, IL and Stata, V.12.0, Stata Corp, College Station, Texas, 
USA). Continuous variables are summarized as mean ± standard deviation (SD) and categorical 
data as frequencies and percentages. Paired Student’s t-test and non-parametric tests were 
performed as appropriate, to assess changes between baseline and 2-year follow-up; p<0.05 
was deemed to be statistically significant. Linear regression analyses were performed to 
identify factors associated with LV function evolution. Cox regression analyses were 
performed to identify predictors associated with composite endpoint during follow-up.  
8.5 Results 
8.5.1 Characteristics of Participants. 
A total of 246 T2DM patients with preserved EF [mean age 71±4 years, 141 (57%) male gender] 
attended the follow-up study with echocardiographic data including GLS measurement. Table 
8.1 lists the baseline clinical, demographic and biochemical characteristics of the 246 T2DM 
patients. Mean haemoglobin A1c was 53.7±9.4 mmol/mol and 32(13%) had poor control 
(defined by haemoglobin A1c level cut-off 64 mmol/mol). In addition, 78(32%) patients had 
hypertension, 56(23%) patients had insulin injection and 163(66%) patients were taking 
metformin.  
Echocardiographic parameters are summarized in Table 8.2. Systolic function based on the 
measurement of LV ejection fraction remained preserved from baseline to follow-up study. 
Likewise, mean E/e’ ratio, LVMi and LA volume (24.3±5.2 vs 29.6±7.9 mL/m2, p<0.001) were 
within the normal range. In contrast, the mean GLS decreased from 17.8±2.6% at baseline to 
17.3±2.9% at follow-up (p=0.01). 
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Table 8.1   Characteristics of study population at baseline (n=246). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Family history of HF was deﬁned as a history of HF in ﬁrst degree family member; 
◊Poor HbA1c, ICFFstd-HbA1c>64mmol/mol. 
 
Overall 
(n=246) 
Demographic and clinical characteristics 
Age (years) 70.7±4.2 
Male gender (n, %) 141(57.3) 
Weight (kg) 86.6±17.5 
Height (cm) 168.6±9.8 
BMI (kg/m2) 30.5±6.0 
Waist circumference (cm) 103.7±13.3 
Obesity (n, %) 124(50.4) 
Heart rate (n/min) 68±11 
Systolic blood pressure (mmHg) 139±15 
Diastolic blood pressure (mmHg) 81±10 
Hypertension (n, %) 189(76.8) 
Family history of HF (n, %) 78(31.7) 
Past chemotherapy (n, %) 20(8.1) 
Past heart disease (n, %) 18(7.3) 
Biomarkers  
HbA1c (mmol/mol) 53.7±9.4 
Poor HbA1c (n, %)◊ 32(13.0) 
Medication  
Insulin (n, %) 56(22.8) 
Metformin (n, %) 163(66.3) 
ACEi / ARB (n, %) 173(70.3) 
Beta-blockers (n, %) 16(6.5) 
Calcium antagonists (n, %) 54(22.0) 
Diuretics (n, %) 32(13.0) 
Lipid lowering meds (n, %) 124(50.4) 
Antiplatelet meds (n, %) 85(34.6) 
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Table 8.2 Evolution of echocardiographic parameters over time: between baseline and 
follow-up. (n=246). 
 Baseline 2-year follow-up p 
LV ejection fraction (%) 62.7±6.5 59.1±6.5 <0.001 
Mitral early-diastolic inflow velocity (E wave) 
(m/s) 
0.65±0.17 0.66±0.18 0.198 
Mitral late-diastolic inflow velocity (A wave) (m/s) 0.83±0.20 0.81±0.19 0.701 
Transmitral diastolic flow velocity ratio (E/A) 0.79±0.20 0.83±0.32 0.786 
Early diastolic mitral annular velocity (e') (cm/s) 7.55±1.58 7.26±1.66 <0.001 
Average E/e’ ratio (E/e’) 9.1±2.6 9.7±2.9 <0.001 
Deceleration time(DT) (s) 248.7±53.2 232.3±59.8 <0.001 
LV mass index (LVMi)(g/m2) 85.8±19.3 87.2±24.0 0.255 
LA volume index(mL/m2) 24.3±5.2 29.6±7.9 <0.001 
GLS (%) 17.8±2.6 17.3±2.9 0.010 
Echocardiography categorical variables    
LA enlargement (n, %) 89(36.2) 114(46.3) 0.004 
LV hypertrophy (n, %) 33(13.4) 39(15.9) 0.405 
E/e’ ratio >13 (n, %) 23(9.3) 34(13.8) 0.028 
GLS<18% (n, %) 121(49.2) 103(41.9) 0.170 
GLS<16% (n, %) 56(22.8) 55(22.4) <0.001 
 
8.5.2 Change in function 
Over a median follow-up of 1.5 years (range 0.6~2.6), conventional echocardiography 
demonstrated no worsening in LV systolic function (Table 8.2). LVEF (62.7±6.5 vs 59.1±6.5, 
p<0.001) remained preserved and LVMi (85.8±19.3to 87.2±24.0 g/m2, p=0.255) remained 
unchanged.  LAV index was significantly increased from baseline assessment to follow-up 
(24.3±5.2to 29.6±7.9 g/m2, p<0.001).  For LV diastolic function, E/e’ ratio was significantly 
increased during 2-year time (9.1±2.6 to 9.7±2.9, p<0.001) but still within normal range, 
indicating a mild decline in subclinical diastolic function. Despite subclinical LV systolic 
function as assessed by GLS at baseline (17.8±2.6%), there was a significant decline to 
17.3±2.9% at follow-up (p=0.010). According to the value of GLS at baseline and follow-up, 
patients were divided into four groups: 78 (32%) patients were persistently normal, 27 (11%) 
patients became normal, 44 (18%) patients became abnormal and 97 (39%) patients were 
persistently abnormal (Figure 8.2).  Among other echocardiographic parameters, e’ and DT 
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were significantly worse compared with baseline examination (Table 8.2). Figure 8.1 shows 
the histograms of changes over time in absolute number of GLS, E/e’ ratio and LAV index and 
their percentage. The changes of these parameters followed a unimodal distribution with a 
predominance of deterioration (negative change) in GLS and worsening (increase) in E/e’ and 
LAV index. The mean within-subjects percentage change of GLS was -1.61±15.8%, compared 
with change in EF of -4.8±14%, change in LAV index of 21.2±46.3% and change in E/e’ ratio 
of 9.4±26.6% (Figure 8.3).  
Figure 8.1 The histograms of change in (a) absolute GLS; (b) E/e’ ratio; (c) LAV index in 246 
T2DM patients. The curves represent the fitted normal density plots.  
 
                                          (a) 
 
                                            (b) 
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                                              (c) 
 
Figure 8.2 Within-individual change in systolic and diastolic function from baseline to 2-year 
follow-up. The number of patients (right) are presented for the four groups of changes, from 
baseline to 2 years. (a)The absolute value of GLS in asymptomatic T2DM with preserved EF 
grouped according to changes of GLS over time. (b) Progression of E/e’ in asymptomatic 
T2DM with preserved EF grouped according to changes of E/e’ over time. 
 
(a) 
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(b) 
Figure 8.3 Mean within-subjects changes (%) in EF, GLS, E/e’ ratio and LVA index during 
2-year observation. 
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8.5.3 Factors predictive of worsening systolic and diastolic function. 
In multivariate linear regression models (Table 8.3), baseline GLS (β -0.44 [-0.68 to -0.21]; 
p<0.001) was independently associated with worsening of GLS after adjustment for age, 
gender, obesity, follow-up duration, changes of heart rate and systolic BP. Age (β 0.10, [0.01 
to 0.19]; p=0.027), gender (β -0.82, [-1.61 to -0.02]; p=0.04) and baseline E/e’ (β -0.33, [-0.51 
to -0.16]; p<0.001) were independent predictors of change in E/e’. For changes of LVA index, 
gender (β -2.87, [-5.66 to -0.07]; p=0.04), baseline E/e’ ratio (β 0.92, [0.36 to 1.47]; p=0.001), 
LVMi (β 0.09, [0.03 to 0.16]; p=0.0070, LAV index (β -0.67, [-0.80 to -0.54]; p<0.001) and 
impaired GLS (cutoff 16%) (β 6.40, [3.03 to 9.77; p<0.001) were significant and independent 
predictors.  
Table 8.3. Multivariate correlation of evolution of different subclinical LV function parameters 
(ΔGLS, ΔE/e’ and ΔLVA index) in patients with T2DM. 
 
ΔGLS 
β(95%CI) 
P value 
ΔE/e’ 
β(95%CI) 
P value 
ΔLVA index 
β(95%CI) 
P value 
Chi-square 0.132 0.160 0.544 
Age  
0.037(-0.078,0.940) 
0.528 
0.102(0.012,0.192) 
0.027 
-0.149(-0.439,0.141) 
0.312 
Male gender  
0.555(-0.525,1.636) 
0.311 
-0.817(-1.611,-0.024) 
0.044 
-2.868(-5.664,-0.073) 
0.044 
Obesity  
-0.346(-1.402,0.709) 
0.517 
0.185(-0.616,0.100) 
0.648 
0.573(-1.981,3.128) 
0.657 
Follow-up duration 
-0.086(-0.212,0.039) 
0.175 
0.001(-0.098,0.100) 
0.982 
- 
ΔHeart rate 
-0.002(-0.049,0.044) 
0.931 
-0.014(-0.049,0.021) 
0.436 
- 
Δ Systolic BP 
0.005(-0.017,0.028) 
0.644 
-0.010(-0.028,0.007) 
0.229 
- 
Past heart disease  - 
- 5.970(-0.202,12.142) 
0.058 
Poor HbA1c◊ - 
0.470(-0.887,1.827) 
0.494 
- 
E/e’ ratio - 
-0.334(-0.509,-0.159) 
<0.001 
0.917(0.363,1.471) 
0.001 
LVMi - 
- 0.094(0.026,0.162) 
0.007 
LAVi - 
- -0.673(-0.802,-0.543) 
<0.001 
GLS 
-0.444(-0.682,-0.205) 
<0.001 
- - 
GLS<16%  - 
- 6.402(3.032,9.772) 
<0.001 
Abbreviations: CI=confidence interval; ◊Poor HbA1c, ICFFstd-HbA1c>64mmol/mol. 
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8.6 Discussion 
In addition to cross-sectional estimates of the prevalence of subclinical LV dysfunction in 246 
elderly asymptomatic T2DM with preserved EF. in the community, this study shows a 
longitudinal change in left ventricular systolic (GLS), and diastolic function measurements (E/e’ 
and LVA). Each marker showed a meaningful change - for GLS, 11% patients improved, 18% 
became abnormal and 71% patients were unchanged, while for E/e’, 8% patients experienced 
worsening, 3% improved and 89% were unchanged.  
8.6.1 Assessment of subclinical LVD. 
GLS has shown to be a better parameter than the conventional systolic marker LVEF for 
prognostic stratification in patients with HF and T2DM 189, 230.  It is well supported by previous 
research of the role of GLS in detecting LV function in patients with preserved EF and 
deterioration of GLS despite no change of EF73. Isolated diastolic dysfunction is commonly 
seen in patients with DM, however preclinical LV dysfunction defined by strain imaging may 
precede diastolic dysfunction. Holland et al189 have highlighted the high prevalence of LV 
systolic dysfunction in elderly asymptomatic diabetes subjects with a normal EF and the role 
of abnormal GLS in predicting longitudinal adverse outcomes over a 10-year course.  
8.6.2 Changes in GLS. 
Previous work has demonstrated that GLS was more impaired in diabetic patients, 6-months 
after ST-segment elevation myocardial infarction, compared with nondiabetic patients (-
15.8±0.3% vs -17.3±0.2%, p<0.001), despite having similar EF at baseline and follow-up.231 
However, the natural history of GLS in asymptomatic diabetic individuals with preserved EF 
had not been systematically evaluated. Roos et al232, showed progression of multidirectional 
LV strain in 112 asymptomatic patients with type 2 diabetes mellitus during a 2-year 
observation, and mild progression of subclinical LV dysfunction assessed by 2D speckle 
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tracking imaging was observed in patients with stable clinical status. The difference is that we 
followed for change in strain and other echo parameters for LV and LA function and structure 
in a community-based population with aged ≥65years regardless of the clinical status of the 
patients at follow-up. In our study, elderly asymptomatic patients with DM demonstrated 
subclinical LV systolic dysfunction, and nearly 20% developed abnormal GLS over 2-year 
follow-up. Baseline GLS was associated with this process, independent of clinical and other 
echocardiographic characteristics. These results highlight this as being in a high-risk patient 
group that warrants consideration of further therapeutic strategies to prevent HF progression 
and to improve prognosis. Additionally, this reflects a contribution to this increased risk from 
diabetic cardiomyopathy (DCM), independent of coronary artery disease and hypertension. 
8.6.3 Changes in diastolic function. 
In our study, as expected, advancing age and male gender were independently associated with 
the deterioration of diastolic function. However, blood pressure as well as changes of blood 
pressure were not determinants of diastolic function changes in our study, which has been 
indicated in both diabetes and non-diabetes cohort in previous research 88, 233, 234. Bergerot et 
al.235 also reported a negative association between blood pressure and diastolic function in 
diabetes, similar to the results of our study. This may be due to the relatively well-controlled 
blood pressure at baseline in his and our study. Our results serve as a reference for the natural 
history of the diastolic function assessed by E/e’ ratio in elderly asymptomatic patients with 
T2DM, which emphasizes the need of a prospective population-based study for a more accurate 
range and trend of diastolic function changes in this population group for better understanding 
the mechanism and progression of diabetic cardiomyopathy. 
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8.6.4 Changes in left atrial volume 
LA enlargement (LAE) and dysfunction is of particular importance in patients with diabetes 
and LV dysfunction as evaluation of patients with diabetes using LA function may reflect 
underlying diastolic dysfunction and estimating atrial contractile function that contribute to 
cardiac workload236. Previous research has demonstrated that T2DM patients were found to 
have increased LA volume and impaired atrial compliance and contractility237. In addition, 
LAE in diabetes was independent of hypertension and diastolic function236. In our study, it is 
likely that impaired global strain and diastolic dysfunction both contributed to the increased 
LA volume. It suggested that subclinical systolic dysfunction in T2DM may independently 
influence the LA structure with the additive impact of LV diastolic dysfunction. 
8.6.3 Limitation. 
First, T1DM were excluded from our study as the mechanism affecting the heart may be 
different from that in T2DM. Second, circumferential and radial strain were not recorded, 
which would have provided additional details about myocardial mechanics, although 
longitudinal strain is the most robust of these myocardial deformation parameters. Additionally, 
for biomarkers, in the present study only HbA1c was collected. Other biomarkers were lacking 
which may potentially be related to the changes of LV function in T2DM. Furthermore, LV 
mass did not significantly increase and it may due to the short duration of follow-up. Lastly, as 
the present cohort was more than 95% white, inferences to other ethnic or racial populations is 
not valid. 
8.7 Conclusion 
During a 2-year observation, elderly asymptomatic patients with T2DM and preserved EF 
showed mild deterioration of subclinical LV function by GLS and diastolic function. The 
implications of these findings for screening and repeat testing warrant further evaluation.
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8.8 Postscript 
Among 246 community-based T2DM patients followed longitudinally, we found that changes 
in subclinical LV function by GLS and diastolic function over time was only mild, and 
subclinical systolic dysfunction in T2DM may independently influence the LA structure with 
the additive impact of LV diastolic dysfunction. These findings for screening and repeat testing 
warrant further evaluation. The clinical implications of these findings are two-fold. First, in 
evaluating the evolution of subtle cardiac dysfunction, a contribution to the increased risk from 
diabetic cardiomyopathy DCM should be paid more attention to. Second, more studies are 
required in this area to the need of more accurate range and trend of subclinical LV function 
changes in this population group for better understanding the mechanism and progression of 
diabetic cardiomyopathy. 
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8.9 Appendix 
Appendix 8.1. Univariate correlation of evolution of different subclinical LV function 
parameters (ΔGLS, ΔE/e’ and ΔLVA index) in patients with T2DM. 
 
ΔGLS 
β(95%CI) 
P value 
ΔE/e’ 
β(95%CI) 
P value 
ΔLVA index 
β(95%CI) 
P value 
Demographic and clinical characteristics   
Age  
0.016(-0.066,0.098) 
0.702 
0.059(-0.007,0.125) 
0.079 
0.002(-0.306,0.310) 
0.991 
Male gender  
-0.203(-0.901,0.494) 
0.566 
-0.262(-0.824,0.300) 
0.359 
0.430(-2.187,3.047) 
0.747 
Weight  
-0.013(-0.033,0.007) 
0.191 
0.000(-0.016,0.016) 
0.988 
0.059(-0.015,0.133) 
0.118 
Height  
-0.005(-0.040,0.030) 
0.766 
-0.009(-0.037,0.020) 
0.547 
-0.032(-0.163,0.100) 
0.634 
BMI  
-0.035(-0.093,0.022) 
0.225 
0.014(-0.032,0.060) 
0.544 
0.195(-0.019,0.409) 
0.073 
ΔBMI 
0.035(-0.022,0.093) 
0.228 
-0.014(-0.061,0.032) 
0.547 
-0.194(-0.406,0.018) 
0.073 
Waist 
circumference  
-0.016(-0.043,0.010) 
0.215 
-0.003(-0.024,0.018) 
0.780 
0.091(-0.005,0.187) 
0.062 
Obesity  
-0.338(-1.027,0.352) 
0.336 
0.083(-0.474,0.640) 
0.769 
3.494(0.942,6.046) 
0.007 
Heart rate 
0.005(-0.027,0.038) 
0.748 
0.002(-0.024,0.029) 
0.858 
0.002(-0.120,0.124) 
0.972 
ΔHeart rate 
0.020(-0.026,0.065) 
0.389 
-0.011（-0.046,0.024） 
0.540 
-0.074(-0.227,0.079) 
0.338 
Systolic blood 
pressure 
0.007(-0.016,0.030) 
0.525 
0.012(-0.007,0.030) 
0.204 
0.005(-0.081,0.092) 
0.904 
Δ Systolic blood 
pressure 
0.011(-0.007,0.028) 
0.232 
-0.014(-0.028,0.000) 
0.053 
0.051(-0.014,0.117) 
0.125 
Diastolic blood 
pressure  
-0.012(-0.047,0.024) 
0.526 
-0.002(-0.031,0.027) 
0.877 
0.030(-0.104,0.164) 
0.660 
Δ Diastolic blood 
pressure 
0.020(-0.009,0.050) 
0.169 
-0.014(-0.037,0.010) 
0.257 
0.008(-0.102,0.118) 
0.884 
Hypertension  
-0.135(-0.953,0.683) 
0.745 
-0.303(-0.961,0.356) 
0.367 
1.077(-1.989,4.142) 
0.490 
Family history of 
HF  
-0.563(-1.302,0.176) 
0.135 
-0.689(-1.281,-0.097) 
0.023 
-0.346(-3.128,2.436) 
0.807 
Past chemotherapy 
-0.570(-1.831,0.692) 
0.375 
-0.119(-1.138,0.900) 
0.818 
2.516(-2.211,7.243) 
0.296 
Past heart disease  
-0.263(-1.589,1.063) 
0.969 
0.403(-0.665,1.471) 
0.459 
6.982(2.088,11.876) 
0.005 
Biomarkers    
HbA1c  
-0.016(-0.053,0.020) 
0.382 
0.016(-0.013,0.046) 
0.277 
0.087(-0.049,0.223) 
0.207 
Poor HbA1c  
-0.618(-1.642,0.405) 
0.235 
1.005(0.187,1.823) 
0.016 
1.082(-2.765,4.928) 
0.580 
Chapter 8 –Evolution of subclinical LV dysfunction in T2DM 
  166 
 
Medication    
Insulin 
-0.188(-1.017,0.641) 
0.656 
0.359(-0.308,1.025) 
0.290 
0.795(-2.266,3.857) 
0.609 
Metformin 
-0.089(-0.832,0.654) 
0.813 
-0.524(-1.119,0.071) 
0.084 
0.746(-1.997,3.489) 
0.593 
ACEi 
-0.196(-0.915,0.523) 
0.592 
-0.0244(0.0824,0.335) 
0.407 
1.661(-0.990,4.312) 
0.218 
ARB 
0.278(-0.444,1.000) 
0.448 
0.163(-0.419,0.745) 
0.582 
-0.015(-2.686,2.656) 
0.991 
Beta-blockers  
0.759(-0.0789,2.308) 
0.335 
-0.694(-1.942,0.553) 
0.274 
2.237(-3.488,7.962) 
0.442 
Calcium antagonists  
0.018(-0.744,0.779) 
0.964 
0.142(-0.472,0.755) 
0.650 
0.798(-2.014,3.609) 
0.577 
Diuretics  
0.691(-0.399,1.781) 
0.213 
-0.384(-1.264,0.496) 
0.391 
-2.313(-6.341,1.716) 
0.259 
Lipid lowering 
meds  
-0.098(-0.903,0.707) 
0.811 
-0.576（-1.220,0.069） 
0.080 
1.461(-1.508,4.430) 
0.333 
Baseline Echocardiography 
LV ejection fraction  
0.034(-0.019,0.087) 
0.203 
-0.040（-0.082,0.003） 
0.066 
-0.149(-0.050,0.347) 
0.141 
ΔLV ejection 
fraction 
-0.068(-0.108,-0.028) 
0.001 
0.007(-0.026,0.040) 
0.667 
0.006(-0.147,0.158) 
0.940 
E/A 
0.155(-1.634,1.943) 
0.865 
-2.529(-3.935,-1.123) 
<0.001 
-2.258(-11.717,1.201) 
0.110 
E/e’ 
0.071(-0.060,0.203) 
0.286 
-0.253(-0.354，-0.152) 
<0.001 
0.527(0.037,1.017) 
0.035 
LVMi 
0.009(-0.006,0.023) 
0.244 
0.002(-0.010,0.014) 
0.759 
0.057(0.002,0.112) 
0.042 
ΔLVMi 
0.005(-0.012,0.023) 
0.536 
0.014(0.000,0.027) 
0.055 
0.145(0.083,0.208) 
<0.001 
LAVi 
-0.005(-0.039,0.029) 
0.780 
0.006-0.022,0.034） 
0.664 
-0.273(-0.397,-0.149) 
<0.001 
GLS 
-0.451(-0.573,-0.329) 
<0.001 
0.048(-0.060,0.1570 
0.380 
0.429(-0.072,0.9310 
0.093 
LA enlargement  
0.048(-0.673,0.769) 
0.896 
0.211(-0.369,0.791) 
0.474 
-5.694(-8.300,-3.088) 
<0.001 
LV hypertrophy  
0.599(-0.213,1.411) 
0.148 
0.005(-0.652,0.661) 
0.989 
2.641(-0.399,5.682) 
0.088 
E/e’ ratio >13  
0.031(-1.155,1.217) 
0.959 
-1.420(-2.359,-0.480) 
0.003 
4.501(0.090,8.913) 
0.046 
GLS<18%  
-1.627(-2.286,-0.967) 
<0.001 
-0.011(-0.568,0.546) 
0.970 
2.207(-0.368,4.4782) 
0.093 
GLS<16%  
-1.843(-2.633,-1.053) 
<0.001 
0.167(-0.496,0.831) 
0.620 
3.219(0.158,6.280) 
0.039 
 
Chapter 9- Cost-effectiveness of screening for LV dysfunction 
  167 
 
Chapter 9. Cost-effectiveness Implications of a HF 
Screening Program in Diabetes
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9.1 Preface 
The cost of HF as well as diabetes are a huge burden to the health care system. The incidence 
of HF appears to be stable, but will likely increase as the population ages and the proportion 
with T2DM increases. Early diagnosis and intervention may have a role in the avoidance of an 
epidemic of diabetic HF. Nonetheless, the establishment of a screening process is dependent 
on a number of steps. Evidence of an effective prevention strategy in non-ischemic HF is 
limited. Such a prevention strategy for early HF might be based on beta blockers and/or ACE 
inhibitors, The recent TOPCAT study demonstrated that the mineralocorticoid antagonist 
spironolactone, could reduce HF mortality in subgroups of patients with preserved EF 238. The 
assumption that early recognition of LV dysfunction could improve outcome is based on 
defining the efficacy of such a treatment strategy. However, the process of screening by 
echocardiogram) and/or treatment of LV dysfunction involves additional costs. These costs 
may be partially or fully offset by reductions in longer-term complications and mortality and 
their associated costs. 
According, we developed a Markov model to assess the cost-effectiveness among three 
strategies from a healthcare payer perspective. These three strategies are 1) usual care, 2) 
primary prevention and 3) screening of LVD and GLS guided prevention.   
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9.2 Abstract 
Background. The derivation of global longitudinal strain (GLS) from 2D echocardiography 
can identify asymptomatic left ventricular dysfunction (LVD), a precursor of heart failure (HF) 
in type 2 diabetes mellitus (T2DM). Screening and early intervention for LVD might reduce 
the frequency of HF. We assessed the cost-effectiveness of GLS screening and early 
intervention for LVD, primary prevention with aldosterone antagonist (AA) for 
cardioprotection, and usual care in T2DM.   
Methods. A Markov model, based on a US healthcare payer perspective, an annual cycle and 
ten-year horizon was developed to compare the costs and quality-adjusted life years (QALYs) 
in T2DM >65 years of 1) usual care, 2) primary prevention and 3) screening of LVD and GLS 
guided prevention.  Transition probabilities, costs and utilities were based on an observational 
study of 290 subjects and the literature. QALYs, costs and incremental costs/QALY gained 
were calculated. Univariable and probabilistic sensitivity analyses assessed robustness of 
results and accounted for uncertainty. 
Results. Usual care was dominated by all other strategies.  GLS-guided prevention resulted in 
higher QALYs than primary prevention (6.43 vs 6.26) and lower costs ($55,588 vs 58,598), 
with acceptable incremental cost-effectiveness in 81.5% of simulations. The projected 10-year 
survival was 82% with normal GLS, 70% for treated abnormal GLS and primary prevention, 
67% for untreated abnormal GLS and 67% for usual care. HF and mortality incidence, and the 
relative risk of incident HF and death in diabetes taking AA had the greatest impacts on results.   
Conclusion. GLS-based guidance of HF prevention in elderly asymptomatic T2DM patients 
appears to be cost-saving. 
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9.3 Background 
Type 2 diabetes mellitus (T2DM) is a well-recognized independent risk factor for incident heart 
failure (HF), with an incidence rate 2-5 times greater than in the general population 5.  HF 
remains a leading cause of hospitalization among people >65 years of age and imposes an 
immense economic burden, estimated to be $108 billion annually 239, 240. The incidence of HF 
appears to be stable 241, but will likely increase as the population ages and the proportion with 
T2DM increases.  
Myocardial fibrosis is thought to be a contributor to LV dysfunction in T2DM, and studies of 
mineralocorticoid antagonists in patients with asymptomatic diastolic dysfunction or HF 
patients with preserved ejection fraction (HFpEF) have shown significant improvement in 
diastolic function and markers of cardiac fibrosis 242. In a recent trial of patients with 
symptomatic HFpEF, aldosterone blockade led to better functional capacity 243 – a result 
concordant with most (American rather than European) patients recruited to the Treatment of 
Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial (TOPCAT), in 
whom spironolactone preserved myocardial function and reduced HF admissions 238, 244. The 
recognition of early LV dysfunction may limit treatment to those who would benefit the most, 
thereby minimizing the number of patients at risk of side-effects from spironolactone 88, 245. 
Reduced LV global longitudinal strain (GLS) to ≥-18% – which may be detected despite 
normal diastolic function 88, 240 - has been identified in 32-37% of asymptomatic patients with 
T2DM and preserved ejection fraction, and is a powerful independent predictor of adverse 
cardiac events 88, 240, 245. A recent cost-effectiveness study showed screening for unrecognized 
clinical HF in elderly community-dwelling T2DM patients by checking the electronic record 
is cost-effective, at a willingness-to-pay threshold of €20,000/QLAYs 246. However, 
recognition of HF in the preclinical phase (LVD) may be more effective in preventing the 
progression of the condition. Although strain imaging has now provided a robust means of 
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detecting LVD, screening for and/or treatment initiation of LVD may involve additional costs. 
It has not been shown whether these may be partially or fully offset by reductions in longer-
term complications and mortality and their associated costs. Accordingly, we sought to assess 
the cost-effectiveness of two potential strategies versus usual care to address LVD in elderly 
subjects (>65 years) with T2DM, from a healthcare payer perspective. 
9.4 Methods 
9.4.1 Model development. 
We developed a Markov model to evaluate the outcomes and costs associated with three 
strategies for the early detection and prevention in asymptomatic elderly people with T2DM 
(Figure 9.1). 1) Usual care – no cardioprotection, 2) Primary prevention - taking 
spironolactone without GLS measurement, 3) GLS guided therapy – selective use of 
spironolactone based on GLS.  
Figure 9.1 Markov process for comparing primary prevention, GLS-guided prevention and 
usual care. 
 
Chapter 9- Cost-effectiveness of screening for LV dysfunction 
  172 
 
The time horizon of the model was ten years, with a cycle length of one year. Outcomes and 
costs of 10,000 patients were generated using a Markov model with Monte Carlo simulation 
developed with standard software (TreeAge Pro 2017, TreeAge, and Williamstown, MA). The 
reference case involved men and women of initial age 65 years. Half-cycle correction was used 
as recommended by current modelling guidelines 247. The model estimated 10-year costs and 
quality-adjusted life years (QALY). Discounting at 3% annually was performed for both costs 
and QALYs 248. Costs were reported in 2015 US dollars.  
9.4.2Health states, transitions and assumptions. 
A simplified presentation of the model is depicted in Figure 9.1. In the usual care arm, patients 
could remain asymptomatic or progress to cardiac events (i.e. cerebrovascular disease and HF) 
or death. As a consequence of receiving spironolactone, the primary prevention cohort could 
develop an adverse drug reaction (e.g. allergy, side-effect and intolerance) and then discontinue 
medication and jump to the usual care state, or remain adherent to spironolactone (then remain 
asymptomatic or progress to cardiac events or death). The GLS-guided prevention cohort 
started with echocardiographic screening, and based on normal or abnormal GLS diagnosis, 
patients would be prescribed spironolactone or not. Asymptomatic patients with abnormal GLS 
who were unable to tolerate taking medication for prevention, also jumped to the usual care 
state. 
Transition probabilities data were weighted based on evidence from the literature and our 
experience in a prospective study of 290 asymptomatic T2DM patients, with definition of the 
following health states and transitions (Table 9.1): 
1) Subclinical LV dysfunction. The reported prevalence of abnormal GLS (≥-18%) in 
asymptomatic subjects with T2DM ranges from 32-54% with a weighted average of 39% 88, 
189, 245. The relative risks (RR) of all-cause mortality and hospitalization in elderly subjects with 
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T2DM for abnormal and normal GLS are 1.24 (95%CI 0.90-1.70) and 0.81 (95%CI 0.56, 1.17), 
respectively 189. Based on our experience, the RR of incident HF in elderly subjects with T2DM 
for abnormal and normal GLS are 1.29 (95%CI 0.85-1.96) and 0.71 (95%CI 0.42-1.21), 
respectively 249. These RRs were used to estimate the annual incidence rate of HF in abnormal 
and normal GLS subjects with T2DM. Spironolactone significantly reduced the mortality and 
incident heart failure rate in symptomatic patients (RR 0.83, 95%CI 0.69, 0.99) 238. This RR 
was used to estimate the annual incident rate of cardiac events in T2DM patients taking 
spironolactone. As this effect size is extrapolated from symptomatic patients, it was thoroughly 
tested in sensitivity analysis. The adherence rate of taking cardio-protective medication after 
abnormal GLS diagnosis was assumed to be 26.5%, based on our experience 250. 
Discontinuation rates for spironolactone were taken from the TOPCAT cohort and were 24.7% 
in the first year and varied annually from 7.1-10.5% (average 7.5%) 238. Sensitivity analyses 
were conducted using a range from minimum to maximum (0~90%) proportions of these and 
other rates.  
2) Heart Failure (HF).The incidence rate of HF in asymptomatic T2DM is 0.7-3%, reaching 
13% in sicker patients of more advanced age 7, 22, 251, 252. We used a weighted average incidence 
rate of 1.4% per year, and the highest reported rate in the sensitivity analysis. The estimated 
annual HF event rates in T2DM with and without subclinical dysfunction were 1.8% and 1.0% 
respectively 249. Based on the effect size of spironolactone, the estimated HF incident rate 
reduced to 1.2% per year for all asymptomatic T2DM patients and 1.5% for abnormal GLS 
T2DM patients. For a scenario analysis of T2DM with comorbidities, we anticipated a HF 
incidence of 10.3% based on our experience 249, providing an incident HF rate of 13.3% in 
those with impaired GLS and 7.4% with preserved GLS. 
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3) Mortality. The reported all-cause mortality for T2DM in the base case varied from 1.7% to 
3.7% between studies; the weighted average was 3.3% per year 7, 251-253. Diabetes patients with 
screening-detected HF had a higher annual mortality rate than those without (3.1% vs 1.5%) 
254. Spironolactone was expected to reduce the risk of mortality in T2DM to 2.8% per year for 
treated elderly asymptomatic T2DM 238. The mortality rates for T2DM patients with abnormal 
and normal GLS were estimated at 4.1% and 2.7% respectively 189. The estimated mortality 
rate for abnormal GLS diabetes patients with cardio-protection was 3.4% 189, 238.  
Table 9.1 Transition probabilities and mortality rates 
Parameters Mortality refs HF refs HF - Death refs 
Distribution Beta  Beta    
Usual care 0.033 7, 251-253 0.014 7, 22, 251, 252 0.176 7, 89 
Primary 
prevention group 
(+spironolactone) 
0.028 7, 238, 251-253 0.012 
7, 22, 238, 251, 
252 
0.138 7, 89, 255 
Echo group 
(Abnormal GLS + 
spironolactone) 
0.034 7, 189, 238, 251-253 0.015 
7, 22, 238, 251, 
252, 256 
  
Echo group 
(Abnormal GLS - 
spironolactone) 
0.041 7, 189, 251-253 0.018 
7, 22, 251, 252, 
256 
  
Echo group 
(Normal GLS) 
0.027 7, 189, 251-253 0.010 
7, 22, 251, 252, 
256 
  
 
9.4.4 Utilities. 
Utility parameters are summarized in Table 9.2, and were obtained from literature by searching 
the words “utility’” and “quality of life” in conjunction with the relevant health states. Utility 
weights were multiplied by the duration in each health state to calculate quality adjusted life 
years (QALYs). The utility weight for elderly T2DM was obtained from the Translating 
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Research into Action for Diabetes (TRIAD) study 257. Elderly HF patients’ utility varied 
according to functional class and hospitalization 258, 259.  
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Table 9.2 Utility values and costs for each health state. 
 Utility Cost ($/yr; ±SD) 
Echocardiography  $466±320260 
Cardio-protective medication  $105±53261 
T2DM 0.80±0.17257 $4,500±353262 
HF 0.51±0.19258, 259 $14,400±3,327263, 264 
Annual follow-up costs $5,800±3,054 
Death 0 $14,740±410265 
 
9.4.5 Cost information. 
The cost analysis was taken from the perspective of the healthcare provider and consequently 
used the amount reimbursed to the provider as the cost of care. The costs incorporated direct 
costs related to ultrasound screening, diagnosis and each health state. Costs were converted to 
2015 US dollars using the healthcare inflation index. A willingness to pay threshold of 
$50,000/QALY gained was applied 266. The annual costs of medications and echocardiography 
costs were obtained from published sources 260, 261. The health care costs of the last year of life 
of elderly people differed according to hospitalization, long-term care and age 265. The first 
year and annual follow-up costs of HF and annual costs of T2DM all have been stated in 
literature (Table 9.2). 
9.4.6 Sensitivity analysis. 
One-way sensitivity analyses were conducted to identify the critical sources of variation in the 
input data - such as cardiac event rate and mortality in the primary prevention group, and the 
balance of heart failure risk in each group. A threshold analysis was conducted on the variables 
with the greatest influence to determine the point when additional cost per QALY exceeded 
$50,000 for the dominant strategy. Second order Monte Carlo simulations were performed as 
probabilistic sensitivity analyses on a hypothetical 10,000 patient cohort.  Beta distributions 
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were assigned to utilities and probability weights, gamma distributions were assigned to costs 
and triangular distributions were assigned to RRs. Each input factor was varied by its standard 
error derived from the associated literature. Means and 95% credible intervals (95% confidence 
intervals) were computed for each of the posterior distributions. Cost-effectiveness 
acceptability curves (CEACs) were generated from the probabilistic sensitivity analysis and 
quantified and graphically represented uncertainty 247. We estimated the probabilities that 
interventions would be considered “good value for money” as the willingness to pay threshold 
was incrementally increased from zero to $100,000/QALY gained 266.  
9.4.7 Scenario analysis. 
A scenario analysis was conducted based on our study reporting relatively high annual rates of 
HF and death in diabetes with impaired GLS, which would give the high mortality and HF 
incidence in cardioprotective medication management of the asymptomatic diabetes patients. 
9.5 Results 
9.5.1 Health outcomes and costs of primary prevention, GLS-guided prevention and usual 
care. 
The costs and QALYs from 10,000 simulations are listed in Table 9.3. The outcomes of both 
GLS-guided prevention and primary prevention were superior to usual care. QALYs post GLS-
guided prevention were slightly greater than those obtained from primary prevention (6.43 vs 
6.26) and the costs were lower for GLS-guided prevention than primary prevention ($55,588 
vs $58,598). GLS-guided prevention was cost-saving compared with primary prevention.  
The survival curves from 10,000 simulations showed that normal GLS group had the highest 
survival rate (82%), followed by the treated abnormal GLS group, primary prevention group 
and then usual care group. The treated abnormal GLS group suggested an early survival 
advantage with eventual equalization with the primary prevention group (70%). The highest 
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mortality rate was in the untreated abnormal GLS group (67%) and usual care group (67%) 
(Figure 9.2).  
Figure 9.2 Comparison of survival with GLS-guided prevention, primary prevention and usual 
care. 
 
Figure 9.3 Tornado diagram (willingness to pay [WTP] =$50,000) identifying the main 
sources of variance in the input parameters that determine net health benefit in the model. The 
variables that have the greatest impact on the balance among the three strategies are the annual 
event rate of HF and death and the relative risk of incident HF and mortality with 
spironolactone in asymptomatic elderly T2DM patients. 
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Table 9.3 Costs (USA$), effectiveness (QALYs), and incremental cost-effectiveness ratio ($/QALYs) of usual care, primary prevention and GLS-
guided prevention in elderly asymptomatic T2DM.  
 Costs and QALYs for 
each strategy 
Incremental analysis    
Base case QALYs Cost ($) Incremental 
QALYs 
Incremental 
Cost($) 
ICER compared to 
next best option 
Implication 
Usual care  6.12 60,109 -- -- -- -- 
Primary prevention 6.26 58,598 0.14 -1,511 Dominant to usual 
care 
Primary prevention is a better option 
than usual care 
GLS-guided 
prevention  
6.43 55,588 0.17 -3,010 Dominant to 
primary prevention 
GLS-guided prevention is a better 
option than primary prevention 
Scenario analysis       
Usual care 5.20 82,313 -- -- -- -- 
Primary prevention 5.48 78,333 0.28 -3,980 Dominant to usual 
care 
Primary prevention is a better option 
than usual care 
GLS-guided 
prevention 
5.73 73,513 0.25 -4,820 Dominant to 
primary prevention 
GLS-guided prevention is a better 
option than primary prevention 
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9.5.2 Sensitivity analyses. 
The effect of variation of parameter values was explored in sensitivity analyses. Threshold 
analyses were used to investigate the limits of transition probabilities, mortalities, costs and 
utilities which could have an impact on the outcome of the model. The main impacts on 
outcomes are illustrated in a “tornado diagram” (Figure 9.3), which identified that the 
parameters with the greatest impact were: the annual incidence of HF and death in 
asymptomatic T2DM as well as the RR for cardiac events with spironolactone. Each factor was 
analyzed across a clinically plausible range as shown in the one-way sensitivity analyses in 
Figure 9.4. GLS-guided therapy had a superior net monetary benefit from lower HF incident 
rate to higher rate (0.3%~12.6%) in asymptomatic T2DM (Figure 9.4a). GLS-guided therapy 
had a superior net monetary benefit when the RR for incident HF and death in diabetes taking 
spironolactone exceeded 0.60 (Figure 9.4b) and the annual mortality rate exceeded 2.6% 
(Figure 9.4c). 
9.5.3 Monte Carlo Simulation. 
A probabilistic sensitivity analysis (second order Monte Carlo simulation) with 10,000 random 
samples simultaneously drawn from all distributions was used to assess uncertainty due to the 
distributions of transition probabilities, utilities and costs (Figure 9.5). The cost-effective 
points for GLS-guided prevention lying to the right of WTP line comprise 81.5% of patients, 
including 81% of simulations where this strategy was dominant (better outcomes and less cost) 
and 0.5% with incremental cost-effectiveness relative to primary prevention. The points lying 
to the left of WTP line included 0.1% where GLS-guided prevention had better outcome but at 
excessive cost and 12.6% where primary prevention was a better choice. The left quadrant 
includes 5.8% of subjects where GLS-guided prevention was dominated by primary prevention. 
A cost-effectiveness acceptability curve (Figure 9.6) illustrates the results of costs and QALYs 
from 10,000 samples. In the base case, at a WTP threshold of $50,000/QALY, 82% of GLS-
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guided simulations were considered cost-effective, versus only 18% for primary prevention 
and 0% for usual care. When the willingness to pay was $100,000, the results were the same 
as at the WTP of $50,000. For a WTP in the range of $50,000/QALY to $100,000/QALY, 
GLS-guided prevention had a higher rate of simulations considered cost-effective compared 
with the other two strategies.  
9.5.4 Scenario analyses. 
The costs and QALYs from 10,000 simulations for the scenario analyses are listed in Table 
9.3. Because of the high incidence rate of HF, GLS-guided prevention was still cost-saving 
compared with primary prevention. In this circumstance, usual care was dominated by the other 
two strategies. At a WTP threshold of $50,000, 77% percentage simulations were considered 
cost-effective with primary prevention and this increased modestly to 78% at a WTP threshold 
of $100,000.  
Figure 9.4 One-way sensitivity analyses to assess the impact of variations in (a) annual HF 
incidence rate in elderly asymptomatic T2DM, (b) RR for incident HF and mortality with 
spironolactone, and (c) annual mortality in elderly asymptomatic T2DM on net monetary 
benefits of three strategies, given willingness-to-pay (WTP) of $50,000. 
(a)  
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(b)  
(c)  
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Figure 9.5 Scatter plot of cost-effectiveness in the Monte Carlo simulation of 10,000 elderly 
asymptomatic patients undertaking GLS-guided prevention and primary prevention. In this 
figure, the cost-effective points for “GLS-guided prevention” lying to the right of WTP line 
comprise 81% of patients where this strategy was dominant (better outcomes and less cost) and 
0.5% of patients where this strategy is incrementally cost-effective relative to primary 
prevention.  
 
Figure 9.6 Cost-effectiveness acceptability curves. 
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9.6 Discussion 
In this decision analysis exploring alternative strategies for HF prevention in asymptomatic 
T2DM, the model accounted for adverse cardiac events: heart failure, changes in length and 
quality of life and 10-year total costs. The two most important findings of this decision analysis 
relate to the difference between quality of life results and costs. Despite similar survival of 
three strategies (except the normal GLS sub-group), differences in QALYs and costs were 
observed between each protective strategy, but both protective strategies dominated usual care. 
The analysis demonstrated that more selective treatment - based on the identification of 
preclinical LVD using GLS (QALYs 6.43, Cost $55,588) - was cost-saving compared with 
primary prevention (QALYs 6.26, Cost $58,598). This suggests that treating diabetes with 
reduced GLS or preserved EF can improve survival and is cost-effective.  
9.6.1 Scenario Analysis 
In the scenario analysis, relatively high annual rates of HF and death in diabetes with impaired 
GLS from our study (Tas-ELF study) were applied. The result is consistent with the result in 
base case model as GLS-guided therapy is always dominant and cost-saving. As GLS is of 
higher prognostic value, the model outcome is more favorable to GLS-guided therapy when 
event rates are higher – as in T2DM patients with abnormal GLS. 
9.6.2 Model Assumptions 
In our model, assumptions including transition probabilities, utilities, and costs were subject to 
sensitivity analysis with a broad range to determine the impact of the assumptions. Use of a 
sensitivity analysis provides the opportunity of reassessment using different assumptions. The 
main impacts on the outcomes are the efficacy of the cardio-protective medication, annual 
incidence of HF and death in asymptomatic patients with T2DM. When spironolactone is used 
as the cardio-protective medication, GLS-guided therapy dominates the other strategies. 
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However, when annual mortality rate decreases to below 2.6%, both primary prevention and 
usual care derive superior net monetary benefit to GLS-guided therapy. In other words, in a 
low death rate population, either primary prevention or usual care are a better option than GLS-
guided prevention.   
9.6.3 Age and T2DM as contributors to subclinical LV dysfunction. 
The sustained growth of HF burden has been driven by increased survival following acute 
events, combined with population aging 267. The prevalence of HF increases with advancing 
age, accounting for 2-3% in the general population, and ≥10% among people ≥75 years of age 
268. The prognosis of HF in elderly people is worse than in younger patients, reflecting the 
impact of age-related structural and functional abnormalities as well as co-existing co-
morbidities and worse health status 269. However HFpEF in elderly patients may be 
underdiagnosed, because the initial symptoms of HF (e.g. exercise intolerance, decreased 
functional capacity) are often attributed to aging.  Hence, the recognition of preclinical HF 
using sensitive diagnostic methods such echocardiography may be of value in trying to delay 
or prevent HF 267. GLS is superior to LVEF as a predictor of prognosis 270.  
The detection of preclinical DCM may be important for preventing progression to HFpEF 245. 
Although subclinical dysfunction has been recorded by both systolic (e.g. GLS) or diastolic 
markers (e.g. tissue Doppler imaging), in the presence of preserved EF 189, 270, recent reports 
have proposed that abnormal GLS is a more specific marker of DCM 88. While GLS is not 
specific for pathology, being abnormal in myocardial fibrosis 271 and myocardial dysfunction 
189 from other causes, it may be sufficiently sensitive to follow therapeutic interventions.  
The appropriate preventive therapy in patients with subclinical LVD is undefined. Angiotensin 
converting enzyme inhibitors are widely used for renal protection in T2DM, but their 
cardioprotective effects do not seem to have reduced the problem of HF in this group. 
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Mineralocorticoid receptor antagonists are beneficial in treating diabetic nephropathy 
independent of their effect on blood pressure 272. The recent post hoc analysis from TOPCAT 
showed that despite failing to achieve a reduction in the primary composite outcome in the 
overall study, spironolactone was associated with 26% cardiovascular mortality reduction and 
25% total HF hospitalized events in Western communities 238. Perhaps more importantly, 
mineralocorticoid antagonists improve LV function and hemodynamics in LV dysfunction and 
HFpEF 242.  
9.6.4 Limitations. 
Whenever possible, we chose transition probabilities from our own experience, but the utilities 
and costs in this model are drawn from various independent sources, which may cause 
inconsistencies. Transition probabilities were estimated using relative risk. Inevitably, although 
these values were considered to be the most realistic estimates, they are not firm values, hence 
the need for sensitivity analysis and distribution sampling. Although some parameters were 
based on assumptions, the most influential parameters (HF and mortality in various health 
states) were derived from published data and our own observations. It should be noted that the 
results of sensitivity analyses showed that variations of these transition probabilities had 
limited impact on outcomes. 
9.7 Conclusion 
Based on this Markov model, screening for asymptomatic LV dysfunction (evidenced by 
abnormal longitudinal myocardial deformation) in elderly patients with T2DM appears cost-
saving. These results could be used to inform clinical trials aimed at the early detection and 
treatment of LV dysfunction, with the intent of preventing the development of HF in T2DM.  
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Chapter 10. Summary and Conclusions 
The aim of this thesis was to determine the role of strain imaging (GLS) in early detection of 
LV dysfunction for HF prevention in elderly asymptomatic patients with T2DM. From this 
thesis, I am able to make a number of conclusions: 
1. Prediction on HF in T2DM. 
 Five common clinical variables (coronary artery disease, impaired HbA1c, 
insulin use, increased fasting glucose and advanced age) are identified which 
are significantly associated with increased risk of incident HF in patients with 
T2DM.  Diabetic patients with these risk factors are at high risk for development 
of HF and should undergo screening. 
2. Prevalence and functional implications.  
 Simple measurement of waist circumference which is linked to insulin 
resistance is a predictor of function capacity in elderly asymptomatic T2DM, 
independently and incrementally to clinical, biochemical, therapeutic and echo 
variables. 
 SBHF defined as subclinical LV dysfunction detected by GLS is highly 
prevalent in elderly asymptomatic patients with T2DM in the community. GLS 
is associated with incident HF in elderly asymptomatic T2DM- importantly, this 
is independent and incremental to clinical and echo parameters and glycemic 
control. 
 Compared with SAHF due to other causes, SAHF due to T2DM have more 
impaired LV function (both systolic and diastolic), less well-being and worse 
functional capacity. Not all types of SAHF are the same. 
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3. Outcomes.  
 The incidence rate of new-onset of HF in elderly asymptomatic T2DM was high 
in TasELF study cohort ~ 15.5% per year (112/1000 person-years). T2DM-
SAHF showed a worse prognosis compared with other-SAHF. T2DM with 
impaired GLS and exercise capacity, AF and obesity is associated with a worse 
outcome.  
 In T2DM-SAHF, depression is prevalent and independently and incrementally 
predicts incident HF. 
4. Development of a community screening program. 
 There is a mild deterioration of subclinical LV function by GLS and diastolic 
function in elderly asymptomatic patients with T2DM and preserved EF.  
 GLS is a feasible and reliable marker in the community and provides 
incremental predictive value of incident HF in elderly asymptomatic T2DM. 
5. Cost-effectiveness of screening LV dysfunction. 
 The preventive treatment guided by screening for asymptomatic LV 
dysfunction (evidenced by abnormal GLS) for HF in elderly patients T2DM is 
cost-saving. This result could be used to inform clinical trials aimed at the early 
detection and treatment of LVD, with the intent of preventing the development 
of HF in T2DM. 
As the growing needs of early diagnosis of incident HF for early intervention in diabetes, we 
have found that GLS with its strong predictive value of incident HF is potentially a useful 
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marker for early screening strategy, while current literature do not offer strong evidence of its 
usefulness in clinical decision-making. In addition, I have done a systematic review and meta-
analysis study to identify the highest risk T2DM patients for most effective screening and 
intervention approach. Furthermore, I have built up a decision tree cost effectiveness model to 
determine the cost-effectiveness of screening LV dysfunction program in T2DM in the 
community and the results showed that the preventive treatment guided by GLS for HF 
prevention in elderly patients T2DM is cost-saving.  
In conclusion, early detection by strain imaging followed by preventive treatment for LV 
dysfunction can prevent the development of HF in elderly asymptomatic patients with T2DM. 
The measurement of GLS should be integrated into the early diagnosis of LVD and following 
decision-making in elderly T2DM.  
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Appendix 11.1HF screening survey in Tas-ELF study. 
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Appendix 11.2 Questionnaires used in TasELF study.
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Appendix 11.3 Information sheet of Tas-ELF study. 
 
PARTICIPANT INFORMATION SHEET  
CLINICAL TRIAL 
 
TAsmanian Study of Echocardiographic detection of Left ventricular 
dysfunction (TAS-ELF) 
 
Invitation 
You are invited to participate in a research study to identify whether an additional 
investigation designed to identify the early stages of heart muscle damage can avoid heart 
failure or its consequences in people at risk of heart failure. 
 
The study is being conducted by Prof Tom Marwick, Dr Kaz Negishi, Leah Wright and Hilda 
Yang of Menzies Research Institute Tasmania, Hobart. It will be performed at Menzies 
Research Institute and regional locations, based around the Menzies Biobus. Eight hundred 
subjects will be involved. 
 
Before you decide whether or not you wish to participate in this study, it is important for you 
to understand why the research is being done and what it will involve. Please take the time 
to read the following information carefully and discuss it with others if you wish. 
 
1. ‘What is the purpose of this study?’ 
Heart failure is a common and serious problem in our community. Early stages of heart 
failure can develop in apparently well people who have risk factors for heart failure.  If this 
process is left unchecked, it can sometimes progress to heart failure. Some new cardiac 
imaging methods have allowed the early detection of cardiac problems before the patient 
develops heart failure. We are trying to establish whether this information could guide 
treatment to protect patients from developing heart failure. Sensitive measures of the heart 
and an exercise test will be taken in order to measure cardiac status. 
 
2. ‘Why have I been invited to participate in this study?’ 
You are eligible to participate in this study because you have risk factors that make you 
more likely than other people to develop heart failure. 
 
3. ‘What if I don’t want to take part in this study, or if I want to withdraw later?’ 
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Participation in this study is voluntary. It is completely up to you whether or not you 
participate. If you decide not to participate, it will not affect the treatment you receive now or 
in the future. Whatever your decision, it will not affect your relationship with the GP or other 
clinicians caring for you. 
 
New information about the treatment being studied may become available during the course 
of the study. You will be kept informed of any significant new findings that may affect your 
willingness to continue in the study. If you wish to withdraw from the study once it has 
started, you can do so at any time without having to give a reason. 
 
4. ‘What does this study involve?’ 
If you agree to participate in this study, you will be asked to sign the Participant Consent 
Form. 
 
This study is a randomised trial (see definition below) that will be conducted over at least two 
years. Cardiac measurements will be performed using a painless ultrasound test of the heart. 
You will be randomised to have either have a standard measurement (ejection fraction, EF) 
or a new measurement (global longitudinal strain, GLS) from these ultrasound pictures. The 
aim is to identify whether the information provided by the new test leads to better heart 
outcomes because your physician is more likely to start you on medications to protect the 
heart. 
We will follow the response of your heart at the beginning and end of these treatment 
periods by taking ultrasound pictures, an exercise test and blood samples.  You will need to 
attend the clinic on each of these occasions, as well as during regular follow-up. 
 
Definition 
‘Randomised trial’:  
Sometimes doctors don’t know the best way of treating patients with a particular condition so 
comparisons need to be made between different treatments. To do this, study participants 
are put into groups and given different investigations or treatments, and the results are 
compared to see whether one approach is better. To ensure the groups are similar to start 
with, a computer allocates each study participant into a group randomly, like the flip of a 
coin. Neither the doctor nor the study participant can decide which investigation the 
participant receives.  
 
If you agree to participate in this trial, you will then be asked to undergo the following 
procedures: 
 A screening questionnaire to confirm eligibility, relevant medical history and quality 
of life. 
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 Ultrasound pictures of your heart , obtained by pressing an ultrasound probe against 
the skin. This machine transmits sound waves and collects the reflected waves to 
make a picture of the reflecting structures. 
 We will measure the distance you are able to walk in 6 minutes. 
 We will take up to 30 mls (about 2½ table spoons) of blood to test for biochemical 
markers. 
 
In addition, the researchers would like to have access to your medical record to obtain 
information relevant to the study. 
 
At the end of the follow-up period, you will then be asked to undergo: 
 A repeat questionnaire regarding symptom status and quality of life. 
 We will measure the distance you are able to walk in 6 minutes. 
 
We wish to stay in touch with you (by phone or email) for at least 2 years, and have 
permission to contact you again in the future. 
 
5. ‘How is this study being paid for?’ 
The study is independently supported by the investigators. The Tasmanian Community Fund 
has partially funded the ultrasound equipment for this study, and the study is also supported 
by and equipment company (Siemens), who are supporting the application of new software 
and providing training. None of the investigators have any duality or conflict of interest. No 
money is paid directly to individual researchers. 
 
6. ‘Are there risks to me in taking part in this study?’ 
The treatments used to protect the heart will be at the discretion of your doctor, informed by 
the results from the investigator. The types of medications used to respond to an abnormal 
test are the same, whichever test is used. The classes of drugs we expect to use have been 
used extensively and are generally safe and well tolerated. Side-effects occur rarely but 
include low blood pressure (dizziness), gastrointestinal disturbances and skin reactions. If 
you have a significant symptoms that you think may be due to the agent, please call us and 
we will discuss stopping the drug. 
 
It is important that women participating in this study are not pregnant and do not become 
pregnant during the study as the medication we might use may damage an unborn baby. If 
you are a woman of childbearing age and there is any possibility that you are pregnant, the 
researchers will need to perform a urine pregnancy test before you start in the study.  If 
necessary, you should use reliable contraception (such as oral or implanted contraception, 
an IUD or have had a tubal ligation if you are female). If at any time you think you may be 
pregnant, it is important to let the researchers know immediately. 
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All medical procedures involve some risk of injury. In addition, there may be risks associated 
with this study that are presently unknown or unforeseeable. In spite of all reasonable 
precautions, you might develop medical complications from participating in this study. In 
addition to the risks related to the medication, the other known risks of this study are 
possibly: 
 Discomfort associated with having blood samples taken. 
 Discomfort associated with the ultrasound test – which involved pressure against the 
chest wall. 
 Inconvenience associated with visits for the study, or follow-up phone calls. 
There may also be risks associated with this trial that are presently unknown or 
unforeseeable. 
 
7. ‘What happens if I suffer injury or complications as a result of the study?’ 
It is extremely unlikely that you will suffer any injuries or complications as a result of this 
study. However, if this occurs, you should contact the study doctor as soon as possible, who 
will assist you in arranging appropriate medical treatment.   
 
You may have a right to take legal action to obtain compensation for any injuries or 
complications resulting from the study. Compensation may be available if your injury or 
complication is sufficiently serious and is caused by unsafe drugs or equipment, or by the 
negligence of one of the parties involved in the study (for example, the researcher, the 
hospital, or the treating doctor). If you receive compensation that includes an amount for 
medical expenses, you will be required to pay for your medical treatment from those 
compensation monies. You do not give up any legal rights to compensation by participating 
in this study. 
 
If you are not eligible for compensation for your injury or complication under the law, but are 
eligible for Medicare, then you can receive any medical treatment required for your injury or 
complication free of charge as a public patient in any Australian public hospital. 
 
8. ‘Will I benefit from the study?’ 
This study aims to further medical knowledge and may improve treatment of patients at risk 
of heart failure, however it may not directly benefit you. 
 
9. ‘Will taking part in this study cost me anything, and will I be paid? 
Participation in this study will not cost you anything. However, you may be reimbursed for 
parking/travel expenses. 
 
10.‘What will happen to my blood and ultrasound images after the study?’ 
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The images will be stored on a secure computer and blood samples you provide during the 
study will be stored in a freezer and tested for biochemical markers. The samples will be 
destroyed 7 years after completion of the study. They will not be used for other research 
projects, except with your written consent or, under some circumstances, with the approval 
of a Human Research Ethics Committee at that time. 
 
11. ‘How will my confidentiality be protected?’ 
Of the people treating you, only the investigators and nursing staff involved in the study will 
know whether or not you are participating in this study. Any identifiable information that is 
collected about you in connection with this study will remain confidential and will be 
disclosed only with your permission, or except as required by law. Only the researchers 
named above will have access to your details and results that will be held securely at 
Menzies Research Institute Tasmania. 
 
12. ‘What happens with the results?’ 
If you give us your permission by signing the consent document, we plan to publish the 
results in peer-reviewed journals and present the findings at scientific conferences. In any 
publication, information will be provided in such a way that you cannot be identified. Results 
of the study will be provided to you, if you wish. 
 
13. ‘What happens to my treatment when the study is finished?’ 
You may be able to continue with treatments following completion of this study if your doctor 
considers them to be of benefit to you. This decision will be made in consultation between 
you and your treating doctor about the most appropriate treatment for you at that time. 
 
14. ‘What should I do if I want to discuss this study further before I decide?’ 
When you have read this information, the researcher will discuss it with you and any queries 
you may have. If you would like to know more at any stage, please do not hesitate to contact 
Prof Tom Marwick on 03 6226 7703. 
 
15. ‘Who should I contact if I have concerns about the conduct of this study?’ 
This study has been approved by the Tasmanian Health and Medical Human Research 
Ethics Committee.  If you have concerns or complaints about the conduct of this study 
should contact the Executive Officer of the HREC (Tasmania) Network on (03) 6226 7479 or 
email human.ethics@utas.edu.au.  The Executive Officer is the person nominated to receive 
complaints from research participants. You will need to quote [HREC project number 
H0012445]. 
 
Thank you for taking the time to consider this study. 
This information sheet is for you to keep. 
Appendix 
  233 
 
Appendix 11.4 Participant Consent Form 
 
 
 
PARTICIPANT CONSENT FORM 
Project Title: Tasmanian Study of Echocardiographic detection of Left ventricular 
dysfunction (TAS-ELF) 
 
 
I have read and I understand the Participant Information Sheet version 1 dated 01/06/2013. 
I freely agree to participate in this project according to the conditions in the Participant 
Information.  
I will be given a copy of the Participant Information Sheet and Consent Form to keep  
The researcher has agreed not to reveal my identity and personal details if information about 
this project is published or presented in any public form.   
I am aware or I have been informed of the risk associated with the study. 
 
Participant’s Name (printed) …………………………………………………… 
Signature        Date 
 
Name of Witness to Participant’s Signature (printed) ………………………… 
Signature        Date 
 
Researcher’s Name (printed) …………………………………………………… 
Signature        Date 
 
Note: All parties signing the Consent Form must date their own signature. 
 
 
